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List of Abbreviations 
 
Amino acids 
	   	   	  Ala  alanine (A) 	  	   Leu leucine (L) 
Arg  arginine (R) 	  	   Lys lysine (K) 
Asn  asparagine (N) 	  	   Met methionine (M) 
Asp aspartate (D) 	  	   Nle norleucine 
Cys cysteine (C) 	  	   Phe phenylalanine (F) 
Gln glutamine (Q) 	  	   Pro proline (P) 
Glu glutamate (E) 	  	   Ser serine (S) 
Gly glycine (G) 	  	   Thr threonine (T) 
h-Phe homo-phenylalanine 	  	   Trp tryptophane (W) 
h-Tyr homo-tyrosine 	  	   Tyr tyrosine (Y) 
His histidine (H) 	  	   Val valine (V) 
Ile isoleucine (I) 	  	  
	   	   
 
Chemicals and others 
Ac acetyl   DCM dichloromethane 
AcOH acetic acid   dd (NMR) doublet of doublets 
aq. aqueous   DIPEA diisopropylethylamine 
BCN bicyclo[6.1.0]nonyne   DMAP 4-dimethylaminopyridine  
Bn benzyl   DMF N,N-dimethylformamide 
Boc tert-butoxycarbonyl   DMSO dimethyl sulfoxide 
br  broad   dt (NMR) doublet of triplets 
Bu butyl   DTT 1,4-dithiothreitol 
calcd calculated   e.g.  exempli gratia (for example) 
cfu colony forming units   EDC 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide  
CI chemical ionization   EDTA Ethylenediaminetetraacetic acid 
CP cosmix-plexing   EI electron impact 
CRD carbohydrate recognizing domain   ELISA enzyme-linked immunosorbent assay 
d (NMR) doublet   equiv. equivalents 
Da dalton   ESI electrospray ionization 
DC-SIGN dendritic cell-specific ICAM-3-grabbing nonintegrin   Et ethyl 
DCC N,N-dicyclohexylcarbodiimide   et al. et alia (and others) 
 
EtOAc ethyl acetate   OSu hydroxysuccinimide 
GFP green-fluorescent protein   PCR polymerase chain reaction 
h hours   PDB protein data bank 
Hept heptane   PEG polyethyleneglycol 
HOBt N-hydroxybenzotriazole   pfu phage forming units 
HPLC  high performance liquid chromatography   Ph phenyl 
HRMS high resolution mass spectrometry   pNA 4-nitroaniline 
HRP horseradish peroxidase   POC point-of-care 
HTS high-throughput screening   ppm parts per million 
IR infrared   quant. quantitatively 
ITC isothermal titration calorimetry   Rf retention factor 
M molar   rt room temperature 
m (NMR) multiplet   RU response units 
m/z mass to charge ratio   s singlet (NMR) 
MALDI matrix-assisted laser desorption ionization   sat. saturated 
Me methyl   SAW surface acoustic wave 
MeCN acetonitrile   SPAAC strain-promoted azide-alkyne cycloaddition 
MeOH methanol   SPANC strain-promoted azide-nitrone cycloaddition 
min minutes   SPR surface plasmon resonance 
mp melting point   t (NMR) triplet 
MS mass spectrometry   TFA trifluoroacetic acid 
MsCl mesylchloride   THF tetrahydrofuran 
Na sodium   TLC thin layer chromatography 
NHS N-hydroxysuccinimide   TMD tetramethylbenzidine 
NMR nuclear magnetic resonance   UV ultraviolet 
 
  
 
Chapter 1 
Food Allergies and Biosensors 
 
 
 
 
 
 
 
 
 
Due to the lack of pharmaceuticals, patients suffering from food allergies need to avoid intake of the offending 
food in order to prevent an allergic response. Consequently, there is a strong need for biosensors to detect food 
allergens. Current biosensors are however prone to give erroneous results and are therefore not reliable for 
food allergen detection. The development of new biosensors with high sensitivity and selectivity for a 
particular has to overcome this problem. This Chapter introduces food allergies and a summary of current 
biosensors will be given. At the end of the Chapter an outline of the thesis is included.  
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1.1 Food Allergy 
In order to sustain life, the consumption of food is essential. Fortunately, for most individuals eating is not 
only functional, but also an enjoyable event. However, for people suffering from food allergies, eating can 
be a nightmare, since the wrong food intake can have severe consequences (Table 1.1), with symptoms 
ranging from mild discomfort (e.g. nausea or rash) to severely life-threatening effects (e.g. anaphylactic 
shock) or even death.5 The worldwide prevalence 
of food allergy is not precisely known, but in the 
US, 3–4% of the population suffers from food 
allergies. Up to now, over 180 allergenic food 
proteins have been identified. Although the 
incidence of the allergies differ from country to 
country, the major allergens are from nuts, fish, 
milk, eggs and (shell)fish.1,2,4 A study from Carroll et 
al. showed that in the US health problems caused 
by food-related anaphylaxis cost about $500 
million in 2007.6 It is obvious therefore, that food 
allergy is an important societal and public health 
concern.  
 
Table 1.1 Possible symptoms of a food allergy.1,2,5 
Organs affected Physiological response 
Gastrointestinal Nausea, vomiting, diarrhea, abdominal cramps 
Respiratory Bronchospasm, asthma, rhinitis, oedema 
Dermal Eczema, rash, angioedema, swelling 
Other Anaphylactic shock, hypotension, swelling of the tongue, 
oral allergy syndrome (OAS) 
 
1.1.1 Definition and Pathway 
Food allergy is defined as an adverse, immune-mediated reaction to food. As such, food allergy is a sub-
category of food sensitivity, which refers to all physiological responses to food, including those that don't 
involve the immune system, e.g. lactose-intolerance. While for food intolerance it is often enough to 
simply reduce the intake of offending food, in case of food allergy strict avoidance is necessary or even 
essential. Within the food allergy response there are two different pathways: the immediate 
hypersensitivity pathway, i.e. IgE antibody-mediated response, or the delayed hypersensitivity pathway, 
which is a cell-mediated food allergy, e.g. celiac disease.1,5,7,8 The IgE-mediated response is involved in 
acute and life-threatening allergic reactions, while cell-mediated food allergies almost never trigger an 
anaphylactic reaction and are therefore less severe. The IgE-mediated pathway is the most common food 
allergy and involves the generation of IgE antibodies that specifically recognize the allergen in the 
offending food. The normal function of IgE — one of the five classes of antibodies present in the human 
immune system —5,9 is the protection of the body from parasitic infections.10,11 Since every individual 
produces IgE, what then makes a person start to develop a food allergy? 
Figure 1.1 The most important food allergies.1,2 
Peanuts	  
9%	   Nuts	  
7%	  
Egg	  
3%	  
Milk	  
5%	  
Fish	  
6%	  
Shellﬁsh	  
30%	  
Diverse	  
40%	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The first time a person is exposed to an allergen will lead 
to sensitization (Figure 1.2).3,12 At that instance, the 
allergen, typically a protein, will bind to IgE antibodies that 
are present on the outside of immune cells, e.g. dendritic 
cells or mast cells. The binding interaction will trigger the 
generation of T-cells, followed by release of interleukins 
(signaling molecules) that in turn will activate B-cells. The 
activated B-cells will then produce and release specialized 
antibodies against the allergen and these will then 
transport to mast cells, which contain histamine. The 
second time a patient eats the same offending food, the 
allergen will bind to the IgE on the surface of the mast cells 
and this complex will trigger the release of inflammatory 
compounds such as histamine. The latter compounds are 
responsible for the inflammatory responses as described in 
Table 1.1.  
1.1.2 Classifying Food Allergens 
Food allergens can be divided in two major classes, 
namely plant food allergens and animal-derived food 
allergens. In this chapter only the plant food allergies will 
be discussed, since they are the focus of the research 
performed in this thesis.  
About 65% of the plant food allergens are included in the 
following protein families and super families: 1) the cupin super family, 2) the prolamin super family and 
3) the papain super family of cysteine proteases (Table 1.2).13  
The cupin super family is a diverse family of proteins possessing a common β-barrel structure.14,15 A 
number of cupins have been identified as major plant food allergens, including the so-called vicilins such 
as the 7S storage proteins of soybean, peanut and walnut and the 11S storage proteins of peanut, 
hazelnut and almond (Table 1.2). The prolamin super family can be subdivided in 2S albumin, non-specific 
lipid transfer protein (NSLTP), α-amylase/protease inhibitors and cereal prolamins.15 These classes contain 
several important allergens of nuts, fruits and vegetables. The third family, the papain-like cysteine 
proteases, contains three different groups of cysteine proteases that are distantly related: the papain 
group, the bleomycin hydrolase group and the calpain group.16 These proteases are enzymes that possess 
a cysteine in their active site that will attack and hydrolyze peptide bonds, and thereby differ from the 
previous two classes of proteins without an enzymatic activity. The known allergens of the cysteine 
protease class include papain from papaya, bromelain from pineapple and actinidin from kiwi. Because 
these proteases show great sequence homology, cross-reactivity is often observed, meaning that patients 
that are allergic to papaya are often also allergic to pineapple and kiwi.17,18 As can be seen in Figure 1.1, 
(pea)nut allergens are responsible for more than 15% of the total allergic food responses. A more detailed 
description of the peanut allergens will therefore be given here.  
 
Figure 1.2 The IgE-mediated pathway of an allergic 
response to allergen.3,4  
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Table 1.2 Allergenic cupins, prolamins and cysteine proteases.5 
Protein super family/family Representative allergenic proteins 
Cupin super family 
Vicilins (7S seed storage proteins) 
 
 
Legumins (11S seed storage proteins) 
 
Ara h 1 (peanut), alpha-subunit of beta conglycinin 
(soybean), Jug r 2 (English walnut), Len c 1 (lentil), Ana o 
1 (cashew), Ses I 3 (sesame) 
Ara h 3 and Ara h 4 (peanut), glycinin subunits 
(soybean), Cor a 9 (hazelnut), AMP (almond) 
Prolamin super family 
2S albumins 
 
 
Non-specific lipid transfer protein 
 
 
Alpha-amylase/protease inhibitors 
 
Cereal prolamins 
 
Sin a 1 (yellow mustard), Ber e 1 (Brazil nut), Jug r 1 
(English walnut), Ses I 2 (sesame), Ara h 2, Ara h 6, Ara h 
7 (peanut) 
Pru p 3 (peach), Mal d 3 (apple), Pru ar 3 (apricot), Cor a 
8 (hazelnut), Aspa o 1 (asparagus), Lac s 1 (lettuce) 
Hor v 15 (barley), Sec c 1 (rye), RAPs (rice allergenic 
proteins 
Tri a 19 (wheat) Sec c 20 (rye), Hor v 21 (barley) 
Papain super family of cysteine proteinases 
Papain-like cysteine proteases 
 
Act c 1 (kiwi), papain (papaya), bromelain (pineapple), 
P34/Gly m Bd 30K (soybean) 
 
1.1.3 Peanut Allergens 
Up to now, eight different peanut allergens have been identified.13,19,20 Until recently, Ara h 1 and Ara h 2 
were identified as the major peanut allergens, jointly responsible for 95% of the peanut allergic reactions. 
In 2013, a paper was published that redefined the major peanut allergens.21 Based on the standard 
definition, a major allergen will bind a large amount of IgE from the majority of the patients. However, 
another way to define major and minor allergens is the allergic effector activity, which is the ability of an 
allergen to bind and cross-link IgE antibodies to their receptor on the dendritic cells (Figure 1.2). Zhuang 
et al. found that Ara h 2 and Ara h 6 account for the majority of the effector activity in a crude peanut 
extract and marked these two allergens as the major peanut allergens.21 Here a brief summary of the four 
most important allergens is given, Ara h 1, 2, 3 and 6. A more 
detailed description of peanut allergens can be found in a 
range of comprehensive reviews.2,20,22,23  
 
The peanut allergen Ara h 1 is probably the best well- 
characterized allergenic vicilin. Ara h 1 is one of the main 
storage proteins and recognized by serum IgE from over 90% 
of peanut allergic patients by at least 23 IgE-binding 
epitopes.24,25 Ara h 1 is a 65 kDa glycoprotein featuring high-
mannose and complex glycans and the three cupin motifs of 
vicilin are arranged in a homotrimeric structure (Figure 1.3).26,27 
The monomers are held together by van der Waals interactions 
of hydrophobic amino acids present at the end where the Figure 1.3 Trimer formed by Ara h 1.  
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monomer interactions occur. The majority of the IgE-binding epitopes is also located in this region 
suggesting a possible protection from digestion due to the monomer-monomer contacts.20 The 
quaternary structure of Ara h 1 may play a significant role in the overall allergenicity, based on the fact that 
the trimer is highly stable, the presence of digestion-resistant fragments and finally, the strategic location 
of the IgE-binding epitopes within the monomers.28 
Ara h 2 is a glycoprotein with a molecular mass of 17-19 kDa and two isomers have been identified.29 Ara h 
2 is a member of the 2S albumin family and its tertiary structure shows great homology with other 
members of this family. Ten linear epitopes have been characterized that are responsible for the allergic 
response, all of which are exposed at the molecular surface of the tertiary structure.30  
Ara h 3 belongs to the 11S seed storage proteins and consists of polypeptides in the range of 14–45 kDa 
that together form the tertiary structure of Ara h 3.31,32 So far, four critical IgE-binding epitopes have been 
characterized, all situated in the 40 kDa subunit.33  
Ara h 6 belongs, like Ara h 2, to the 2S albumin family and is recognized by 38% of the sera of peanut 
allergic patients.34 Ara h 6 shows 60% homology to Ara h 2 and some cross-reactivity is observed. 
Although until recently, Ara h 6 was not listed as one of the major peanut allergens, Zhuang et al. have 
changed this since the appearance of the article as described above.21  
1.1.5 Prevalence and health impacts 
IgE-mediated allergic reactions can cause symptoms ranging from mild to life-threatening (Table 1.1).5 
Although the life-threatening allergic responses are the most worrisome outcome of food allergies, mild 
symptoms are much more likely to occur. Every patient suffers from different symptoms and even per 
allergic reaction the severity of the response can differ due to the amount of the offending food ingested 
and the length of time since the previous exposure. Currently, there is no cure for food allergies. Drugs 
presently on the market, such as anti-histamines or epinephrine, will only reduce allergic symptoms, 
however, to date no drugs are able to prevent the allergic reaction all together. The results from clinical 
trials with anti-IgE therapy for peanut allergy look promising, however, this therapy does not work for 
every individual and is also really expensive.35  
1.2 Biosensors 
1.2.1 Food Industry 
Due to the lack of pharmaceuticals, patients suffering from food allergies need to avoid intake of the 
offending food in order to prevent an allergic response.36 However, allergens are often important nutrient 
sources and complete exclusion is therefore not possible. Furthermore, these allergenic foods are often 
basic ingredients for the production of other foods.  
American and European laws such as the “Food Allergen Labeling & Consumer Protection Act” of 2004 
and “Directive 2007/68/EC” obligate companies to include a “contains” statement that lists the major 
allergens in products (Table 1.3).37,38 Furthermore, most companies will voluntarily add labels to state that 
their food “may contain…” or that “this product was produced in a facility that also processes…”. Not 
only does this lead to narrowing of the available food products edible for allergic patients, it still does not 
ensure that the offending allergen is not present. Moreover, falsely labeled products, due to the fact that 
allergens levels were below the detection limit of the analysis methods used by industry, will still give an 
allergic response to highly sensitive patients.39  
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Therefore, it is necessary for the food industry to have access to reliable detection methods. Since eating 
outdoors for patients is also very difficult, subsequently, there is also a call for the development of new, 
easy, cheap and reliable household use devices. 
 
Table 1.3 Annex III of Directive 2007/68/EC; the listed allergens and products thereof, which companies need to put on food 
labels 
cereals mustard peanuts 
crustaceans mollusks soybeans 
eggs lupine milk 
fish nuts sulfur dioxide and sulfites 
celery sesame  
1.2.2. Detection Methods 
In order to avoid false positive or false negative results, a food allergen detection method should be both 
specific for the target allergen and be sensitive enough to detect trace amounts of allergen. Thirdly, the 
influence of food matrices should be as minimal as possible. Recently, protocols of validation have 
become available by the European Committee for Standardization (CEN).40–42 Using these validation 
protocols, more reliable methods should enter the market.  
Current detection methods can be divided into four main classes: receptor-based methods, 
chromatographic methods, detection by mass spectrometry and finally real-time polymerase chain 
reaction (PCR). The receptor-based assays have been used widely and can be developed to detect either 
one allergen or several allergens in one go. The preferred method of choice nowadays is the enzyme-
linked immunosorbent assay (ELISA) (Figure 1.4).43 In an ELISA assay, an allergen-specific antibody is 
immobilized onto the surface of a microtiter plate. After binding of the allergen, another antibody 
(primary detection antibody) will also bind to the food allergen. The latter antibody will either be directly 
conjugated to the enzyme horseradish 
peroxidase (HRP), or a secondary 
detection antibody-HRP conjugate is 
involved that will bind the primary 
detection antibody. In either fashion, HRP 
will oxidize a subsequently added 
tetramethylbenzidine (TMB) substrate 
yielding a colored product for detection.  
ELISA is widely used since it is relatively 
cheap, easy to use and highly sensitive. 
Other receptor-based assays are optical 
biosensors such as surface plasmon 
resonance (SPR). Chromatographic 
methods can directly detect one or 
several allergenic proteins. High-
performance liquid chromatography 
(HPLC) is one of the examples published 
in literature for the detection of simple 
and complex mixtures.44–47 However, one 
Figure 1.4 Schematic representation of an ELISA assay. An allergen-specific 
antibody is immobilized on the surface of a microtiter plate. The allergen 
will bind to the immobilized antibody and is recognized by the detection 
antibody, which will in turn bind the secondary antibody containing 
horseradish peroxidase (HRP). HRP will then oxidize TMB into a colored 
product. 
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of the disadvantages is that reliable detection can be hampered by the presence of food matrix proteins. 
Co-elution with other proteins can give false positive results and the use of HPLC can be best preformed 
when coupled to a mass spectrometer (e.g. LC-MS), which makes it consequently a more laborious and 
expensive method.48 The use of mass spectrometry in food allergen analysis always starts with sample 
preparation (extraction) and purification of the sample via SDS-PAGE, 2D-PAGE or liquid chromatography 
(LC). Samples can contain either intact protein sample or proteolytically digested samples.43,48 Because 
mass spectrometry is an expensive and laborious technique and also requires highly qualified employees, 
this method is only used when other techniques are inconclusive.  
 
Although the described methods may seem straightforward, several distinct disadvantages are associated 
with either of the techniques and comparative studies on the different commercial kits have led to 
inconsistent results. First of all, there is no general consensus on the expression of reporting units of the 
amount of allergen present, which makes it difficult to really compare the different kits. In a study for 
soybean and hazelnut detection, four different commercial kits were tested and all four gave different 
results. For hazelnut detection, only one kit proved to give accurate results and three kits underestimated 
the amount of allergens present. On the contrary, one of the commercial kits for soybean highly 
overestimated the actual protein content and others underestimated the amount of soybean allergen 
present.49,50 
Furthermore, it needs no explanation that the choice of a highly selective antibody is essential. Most 
commercial kits make use of antibodies that are normally quite selective, however, within food allergen 
detection, allergens often show great homology and cross-reactivity may occur, leading to false-positive 
results. Therefore the selection of selective ligands is of utmost importance.  
1.3 Problem Definition 
1.3.1 Context Provided by Unihealth Program 
Existing techniques for food allergen detection are either laborious, need highly qualified people, or are 
prone to erroneous results. Especially the household point-of-care systems are not yet fully developed. 
Therefore, there is a need for new detection methods that fulfill the following requirements: lack of false 
positive or false negative results, easy to use (point-of-care device) and cheap to produce.  
The Unihealth project is a program financed by the European Union and provinces of the Netherlands and 
Germany (Interreg IV). The objective of the Unihealth project is to develop a simple and inexpensive 
allergen- and biomarker sensor system for everyday use and a more complex and precise system for basic 
research in the field of allergies, allergens, biomarkers and medical practices.  
The area of biosensors lies at the interface of physical, biological and chemical sciences and furthermore, 
technology development. Bridging the knowledge and know-how together will enable the development 
of this new point-of-care (POC) biosensor device.  
The IMS Fraunhofer Institute in Duisburg has been responsible for the technical development of the POC 
device. At Wageningen University, ligands for the Guillain-Barré syndrome (GBS) were developed and a 
general protocol for the biosensor surface modification has been developed.  
The last topic, the development of ligands for the detection of exotic fruit allergens and peanut allergens, 
is the subject of this thesis and the objective and chosen approach are further enlightened in the next 
section.  
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1.3.2 Outline of this Thesis 
The objective of the Unihealth project is to develop a point-of-care biosensor for the detection of allergens 
in food. Similar detection of biomarkers in patient samples, e.g. in a hospital setting, is also feasible but will 
not be further delineated here. 
The general design of a biosensor features two distinct parts: (a) the biosensor chip, which will be 
replaced after each measurement and (b) a read-out device. 
The quality of the biosensor surface and the choice of ligand on the surface are essential to construct a 
functional biosensor chip. For this thesis, two different allergies have been investigated, namely exotic 
fruit and peanut. To be able to detect these allergens, specific binding ligands were designed, synthesized 
and evaluated as summarized in the following chapters.  
In Chapter 2 and 3 different ligands for papain, the allergen from papaya fruit, are discussed. A small 
library of ligands was synthesized and tested in an enzymatic bioassay. Furthermore, in Chapter 3 
modeling studies were used to explain the results from the enzymatic bioassay.  
Chapter 4 focuses on the immobilization of ligands on a biosensor surface by means of copper-free ‘click’ 
chemistry. To this end, a new and generic platform for the immobilization of ligands, both small molecules 
and proteins, was developed.  
The last part of the thesis focuses on the development of ligands for peanut allergens. In Chapter 5, a 
biological approach was chosen. Based on phage display technology, a large library of phages displaying 
small peptides was used for the selection of efficient binders for four different peanut allergens. In Chapter 
6 a combination of molecular biology and chemical techniques was used to develop a dendrimer 
construct based on DC-SIGN proteins that can specifically bind to the glycans of peanut allergen Ara h 1.  
In Chapter 7 an overall conclusion is provided, as well as a future perspective of the research performed 
and described in this thesis.  
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Chapter 2 
Design, Synthesis and Evaluation of  
Nitrile-Containing Papain Ligands 
 
 
 
 
 
 
 
 
 
For the fast and sensitive detection of allergens, appropriate ligands are required with a handle for 
immobilization onto a biosensor surface. For such purpose, a small library of enzyme inhibitors was designed, 
containing different azide linkers for follow-up immobilization by ‘click’ chemistry. A model system to detect 
the interaction of ligands with proteins was developed based on papain, a protease from papaya, and nitrile-
containing amino acids. The small library was synthesized and a competitive enzymatic assay was performed 
to quantify the inhibitory capacity of the ligands.  
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2.1 Introduction 
Due to the lack of preventive pharmaceuticals, patients suffering from food allergies need to avoid intake 
of the offending food in order to prevent an allergic response.1 Consequently, there is a strong need for 
biosensors to detect food allergens.2,3 Unfortunately, current biosensors are prone to give erroneous 
results and are therefore not reliable for food allergen detection.4 Therefore, new biosensors need to be 
developed with ligands that are sensitive and selective for a particular target food allergen. In this Chapter, 
a new approach is described for a biosensor, based on papain (EC 3.4.22.2), a cysteine protease present in 
papaya fruit, as a model system for exotic fruit detection.  
2.1.1 Papain 
Proteases, enzymes that hydrolyze amide bonds in peptides, are categorized based on the catalytic 
mechanism and reactive amino acids in the active site.5 Six broad categories are currently recognized: 
cysteine, serine, threonine, aspartic acid, glutamic acid and metalloproteases. For example, the serine 
proteases –the largest family of proteases– constitute a serine in the active site. The protease families can 
be further subcategorized, for example, the papain superfamily is one of the three structural subfamilies 
within the cysteine proteases.6 The active site of papain consists of three amino acids, Cys-25, His-159 and 
Asn-175, which together form a catalytic triad. The catalytic triad of papain proteases is highly similar to 
that of serine proteases, with the exception that in the active site of papain, Asn-175 acts as hydrogen 
bond acceptor toward the imidazole moiety of His-159 and forms a permanent thiolate-imidazolium ion 
pair.6,7  
Schechter and Berger introduced comprehensive nomenclature to describe the interaction between a 
peptide (P), the enzyme's substrate, and the enzyme recognition subsites (S).8 This nomenclature is 
exemplified in Figure 2.1 for leupeptin, a tripeptide natural ligand for papain featuring an aldehyde 
function at the C-terminal arginine. The S1 pocket of papain is poorly defined as becomes clear from Figure 
2.1b (arginine side-chain on the far right) and the arginine from leupeptin is solvent-exposed. The S2 
pocket is a hydrophobic pocket defined by Val-133, Ala-160 and Pro-68 and the S3 binding pocket is 
formed by two aromatic groups, Tyr-61 and Tyr-67.  
 
a) b) 
 
 
Figure 2.1 a) General structure of nitrile-based peptide inhibitor and papain subpockets (S1 to S4). The active site is described 
according to Schechter and Berger.8 b) Docking of leupeptin in the active site of papain (PDB file 1POP).  
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2.1.2 Papain Ligands 
The cysteine proteases of the papain superfamily display a relatively broad substrate specificity. As a 
consequence, designing ligands that are highly selective for papain has proven to be a difficult task.9 To 
date, a variety of ligands have been developed with different binding functionalities, but mainly based on 
amino acid functionalities. Most of the ligands contain a reactive 'warhead' for reaction with the essential 
amino acid in the protease active site, such as an aldehyde, an epoxide, an α-chloroketone, an 
azapeptide,10 a chloromethyl sulfoxide or a nitrile7 (Figure 2.2).6  
 
 
Figure 2.2 Different classes of papain ligands with the reactive groups displayed in red.  
As stated above, designing a ligand that is selective for one particular protease can be a challenging task, 
since the active sites of different proteases show great homology.6 Most of the inhibitors shown in Figure 
2.2 therefore bind to both cysteine protease and serine proteases. One notable exception is formed by the 
nitrile-containing inhibitors, which display predominant specificity for cysteine proteases, while binding to 
the active site of serine proteases is weak or absent.6,7 Mechanistically, nitrile-based inhibitors react with 
the thiol in the active site of papain, as highlighted for a peptidonitrile (Figure 2.3), in the (reversible) 
formation of a covalent thioimidate complex (Figure 2.3). Based on the preferential inhibition of cysteine 
proteases over serine proteases, the nitrile moiety was elected as reactive moiety in the design of ligands 
for our research. Moreover, the reversible character of the cysteine-nitrile bond formation was considered 
advantageous for the development of a reusable biosensor surface, as delineated in chapter 4.  
 
 
Figure 2.3 Attachment of a peptidonitrile ligand with the cysteine thiol in the active site of papain (left) via reversible formation 
of a covalent thioimidate complex (right). 
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2.1.3 Library Design 
For the development of a biosensor, one of the main parameters is the production of a high quality ligand-
containing surface. Obviously, an essential element in detection of any target analyte is a selective binding 
ligand that is firmly immobilized on a surface, yet readily accessible. Conceptually, immobilization of a 
ligand to the surface of a biosensor requires the prior installment of a suitable linking moiety or handle. 
Although typically small, it must be taken into consideration that such a handle may compromise binding 
of the ligand to the analyte, for example due to steric bulk or unspecific hydrophobic interactions, which 
requires judicious choice of the handle, as well as the site of attachment on the ligand. Finally, the quality 
of a biosensor is determined by the technique of immobilization. Common established tools include non-
covalent streptavidin-biotin interaction, or covalent attachment by for example amide coupling or so-
called ‘click’ chemistry.11 One powerful example of the latter approach includes the strain-promoted 
azide–alkyne cycloaddition (SPAAC), i.e. the non-catalyzed triazole-forming reaction of an azide and a 
strained alkyne, typically cyclooctyne.12–15  
For the Unihealth biosensor, a strategy was chosen involving initial functionalization of a sensor surface 
with the strained alkyne bicyclo[6.1.0]nonyne (BCN) (Chapter 4) followed by ligand immobilization via 
strain-promoted azide–alkyne cycloaddition (SPAAC).15 Development of an azide-containing binding 
ligand was thus required.  
The rational design of a small library of papain inhibitors (Figure 2.4) was based on ligands reported earlier 
in literature.6 These ligands are based on a cross-over of leupeptin and nitrile compounds 1 and 2 in Figure 
2.4. Peptides that can be hydrolyzed by papain will normally be cleaved after an arginine or a lysine amino 
acid. As stated above for leupeptin (Figure 2.1) the S1 pocket is not really defined and the arginine is 
solvent exposed. However, from literature it is known that arginine is nevertheless important for 
interaction with the active site.6 Unfortunately, it is synthetically not straightforward to introduce an 
arginine at the P1 position of a nitrile-based ligand as seen for leupeptin. Therefore, we followed the 
reported strategy for nitrile ligands with a glycine at the P1 position.7 A hydrophobic amino acid (aliphatic 
or aromatic) was selected at the P2 position of the ligand and three different substituents were 
incorporated at the P3 position. The azide handle for immobilization was also positioned at P3, distal to the 
nitrile moiety, with the assumption that interaction of the azide or triazole in binding interaction would be 
minimized (Figure 2.4).  
 
 
Figure 2.4 Peptidonitriles 1 and 2 are examples of papain inhibitors.7 On the right: design of a small library of papain ligands 
(compounds 3–5); compound 3 a. R1 = iBu (Leu), b. R1 = n-Bu (Nle), c. R1 = Bn (Phe), d. R1 = CH2C6H4OH (Tyr), e. R1 = (CH2)2Phe (h-
Phe), f. R1 = (CH2)2C6H4OH (h-Tyr); compound 4 a. R2 = n-Bu (Leu), b. R2 = Bn (Phe), c. R2 = CH2C6H4OH (Tyr); compound 5 a. R3 = 
iBu (Leu) R4 = iBu (Leu), b. R3 = iBu (Leu) R4 = Bn (Phe) and c. R3 = Bn (Phe) R4 = Bn (Phe).  
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For the S3-binding phenyl (compounds 3a–f) and biphenyl (4a–c) groups, the azide was directly 
introduced at the aromatic moiety, while for compounds 5a–c the azide was incorporated at the N-
terminus and a hydrophobic amino acid P3 group was visualized to fit in the S3 binding pocket.  
2.2 Results and Discussion 
2.2.1 Synthesis of Papain Ligands 
Synthesis of the designed ligands started by incorporation of a nitrile-functional group by coupling of 
amino acetonitrile to an amino acid with the mixed anhydride method (Scheme 2.1). Thus, isobutyl 
chloroformate was added to an N-Boc protected amino acid, in the presence of freshly distilled 
triethylamine and THF as solvent,7 leading to compounds 7a–f in moderate to good yields. Subsequent 
Boc deprotection was performed with TFA in THF/water (1:1 v/v) to give compounds 8a–f (nearly) 
quantitatively.  
 
Scheme 2.1 Synthesis of building block 8a–f; a = Leu, b = Nle, c = Phe, d = Tyr, e = h-Phe and f = h-Tyr. 
The next step was the incorporation of an azido-containing benzoyl or 4-phenylbenzoyl moiety at the N-
terminus. The required 4-azidomethylbenzoic acid (14) could be readily obtained by a nucleophilic 
substitution on 4-bromomethylbenzoic acid, using a literature procedure (not depicted).16 The synthesis 
of biphenyl derivative 13 however, proved to be more troublesome (Scheme 2.2). Synthesis in this case 
started with a palladium-catalyzed Suzuki coupling of 4-bromobenzyl alcohol (9) with boronic acid 
derivative 10. Although a yield of only 24% was attained, enough material was obtained, so no further 
optimization of this reaction was performed. The Suzuki coupling was followed by substitution of the 
hydroxyl group by an azide via the mesylate, leading to biphenyl ester 12 in 98% yield, after which 
saponification gave the desired 4-[4-(azidomethyl)phenyl]benzoic acid derivative 13 in quantitative yield.  
 
 
Scheme 2.2 Synthesis of azidomethylated 4-phenylbenzoic acid 13. 
Coupling of 4-azidomethylbenzoic acid (14) to compounds 8a–f was performed under standard amide 
coupling conditions using EDC in the presence of HOBt (Scheme 2.3), providing the desired benzoylated 
compounds 3a–f in moderate to good yields. Introduction of biphenyl derivative 13 was performed under 
the same conditions, however, products 4a–c were obtained in low yields, due to incomplete conversions 
and solubility issues during workup and purification. Nevertheless, sufficient material was obtained to 
perform binding studies with papain.  
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Scheme 2.3 Synthesis of papain ligands 3a–f and 4a–c; 3 a = Leu, b = Nle, c = Phe, d = Tyr, e = h-Phe and f = h-Tyr; 4 a = Leu, b = 
Phe and c = Tyr.  
The synthesis of compounds 5a–c started with peptide coupling of nitrile 8a and 8c with Boc-protected 
leucine (6a) or phenylalanine (6c) to obtain compounds 15a–c in moderate yield (Scheme 2.4). Boc 
deprotection was performed as described above, yielding compound 16a–c in quantitative yield. In this 
case, the azide moiety was incorporated by acylation of nitriles 16a–c with azidoacetic acid, yielding 
azides 5a–c in acceptable yields.  
 
Scheme 2.4 Synthesis of leupeptin-based nitrile-containing papain ligands 5a–c; a = R1 = R2 = iBu (Leu); b R1 = Bn (Phe), R2 = iBu 
(Leu) and c R1 = R2 = Bn (Phe). 
2.2.2 Enzymatic Evaluation 
After successful synthesis of the library, dipeptide nitriles 3a–f, 4a–c and 5a–c were evaluated for their 
papain affinity and the influence of the azide on the inhibitory properties was investigated. As already 
described above, our library is based on known papain inhibitors, compounds 1 and 2 (Figure 2.1), and 
therefore these ligands were evaluated first in an enzymatic assay, both to validate the assay and to 
investigate the influence of N-terminal azide incorporation. In contrast to Löser et al., whom determined 
the affinity constant (Ki) of a range of compounds, our library was evaluated based on IC50 values obtained 
from a UV assay. In practice, the competitive enzymatic assay involved mixing different papain and ligand 
concentrations with a fixed amount of the chromogenic papain substrate Z-Phe-Arg-pNA. The papain 
concentration was varied to obtain maximum absorbance within the first 20 minutes, so Vini values could 
be obtained between 3 to 7 minutes. With the Vini values in hand, inhibition curves were prepared 
following standard enzyme kinetics and IC50 values of the different ligands were determined. The IC50 value 
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is not a direct indicator of affinity, however, the design of a competition inhibitory experiment is 
straightforward and the IC50 value is useful for the comparison of compounds within a library.17  
 
Benzoyl ligands 
The IC50 value for benzoyl ligand 1 was 0.36 ± 0.06 µM, which remained nearly the same for the 
azidomethylated derivative ligand 3c (Table 2.1, entry 1 and 5). As expected for benzoyl compound 3d, 
replacing phenylalanine by tyrosine had little influence on the IC50 value either (Table 2.1, entry 5 and 6). 
The homophenylalanine and homotyrosine-derived ligands 3e and 3f, showed somewhat reduced 
binding affinity (Table 2.1, entry 7 and 8), as a potential indication that the side chain of 
homophenylalanine and homotyrosine is too long to fit nicely into the S3 site of papain. Replacing the 
aromatic side chain by non-aromatic hydrophobic side chains (Table 2.1, entry 3 and 4) reduced the 
binding affinity as well, possibly due to the lack of π-π interaction between the aromatic amino acids in 
the S3 binding pocket and the aromatic side chains of ligands 3c and 3d.  
 
Phenylbenzoyl ligands 
Literature compound 2 showed an IC50 value of 0.22 ± 0.07 µM (Table 2.1, entry 1). In contrast to the 
benzoyl derivatives described earlier, in this case introduction of the azidomethyl moiety directly at the 
aromatic ring, as in ligands 4a–c, dramatically decreased the inhibitory capacity (Table 2.1, entries 9–11). 
Surprisingly, after the introduction of the azidomethyl moiety, despite its small size, the S3 binding pocket 
is no longer able to accommodate the aromatic site chain. No good explanation could be given at this 
point.  
 
Leupeptin based ligands 
For the last class of inhibitors, the ligands 5a–c (Table 2.1, entry 12–14), the azide was introduced on the 
N-terminus by azidoacetylation. The design of ligands 5a–c was inspired by the structure of leupeptin, 
which features an N-acetylated tripeptide (Leu-Leu-Arg) with a reactive C-terminal functionality 
(aldehyde). To our surprise, all three ligands 5a–c displayed IC50 values in the µM range, 10-fold reduced 
affinity for papain compared to ligand 3c. Apparently, replacement of the N-benzoyl group as in 3c is not 
counterbalanced by the addition of an additional amino acid as in 5a–c, despite the apparent larger 
similarity of the latter to leupeptin.  
 
Triazole derivatives 
In the anticipated final situation as in a biosensor, with the ligands immobilized to a surface, the azide will 
no longer exist as such, but will be converted into a triazole moiety. We therefore also evaluated the 
influence of such transformation on binding affinity by synthesis of compounds 17 and 18, by SPAAC 
modification with BCN and DIBAC, respectively (Table 2.1, entries 15 and 16). Entry 15 showed that 
whereas the triazole product resulting from reaction with BCN did not significantly influence binding 
affinity, the more bulky DIBAC-derived triazole 18 had a strong impact. Obviously, the triazole-DIBAC 
moiety is relatively large with respect to the small nitrile ligands and it was observed for the 
phenylbenzoyl ligands that the introduction of a small azide could already dramatically influence the 
binding affinity. Fortunately, the product resulting from SPAAC with BCN, also a triazole-cyclooctyne 
product but lacking the two phenyl rings, was still an excellent ligand for papain and is therefore clearly 
the cyclooctyne of choice here.  
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Table 2.1 IC50 values found for papain ligands 1–5, 17 and 18 
 
 
Entry R1 R2 Compound IC50 (µM) 
1 
  
1 0.36 ± 0.06 
2 
  
2 0.22 ± 0.07 
3 
 
 
3a 2.27 ± 0.3 
4 
 
3b 7.1 ± 3.2 
5 
 
3c 0.27 ± 0.03 
6 
 
3d 0.28 ± 0.03 
7 
 
3e 0.71 ± 0.15 
8 
 
3f 0.98 ± 0.22 
9 
 
 
4a 1.58 ± 0.44 
10 
 
4b 13.9 ± 11.3 
11 
 
4c 51.16 ± 25.6 
12 
 
 
5a 2.71 ± 0.2 
13 
 
5b 2.25 ± 0.7 
14 
  
5c 3.97 ± 0.3 
15 
 
 
17 0.35 ± 0.08 
16 
 
 
18 5.98 ± 1.9 
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2.3 Conclusions 
For the fast and sensitive detection of allergens, appropriate ligands are required with a handle for 
immobilization onto a biosensor surface. For such purpose, a small library of enzyme inhibitors was 
designed and synthesized, containing different azide linkers for follow-up immobilization by ‘click’ 
chemistry, in this particular case by copper-free, strain-promoted alkyne–azide cycloaddition (SPAAC).  
A robust and reproducible competitive UV assay was developed for evaluation of inhibitory potential of 
the prepared ligands on papain. Peptidonitrile 3c turned out to be the best inhibitor and will be used in 
further studies concerning the development of a biosensor.  
Additionally, a satisfactory explanation of the found IC50 values could not in all cases be given. To be able 
to provide a good interpretation of the found results, a docking study was initiated in order to obtain 
more insight in the found binding affinity values (Chapter 3).  
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2.5 Experimental 
General 
Reactions were followed and RF values were obtained using thin layer chromatography (TLC) on silica gel-
coated plates (Merck 60 F254) with the indicated solvent mixture. Detection was performed with UV light, 
and/or by charring at ~150 °C after dipping into a solution of either ninhydrin or Cl-TDM (bis[4-
(dimethylamino)phenyl]methane). Melting points were analyzed with a Büchi melting point  
B-545. IR spectra were recorded on an ATI Mattson Genesis Series FTIR spectrometer, or a Bruker Tensor 27 
FTIR spectrometer. NMR spectra were recorded on a Bruker DMX 300 (300 MHz), and a Varian 400 (400 
MHz) spectrometer in CDCl3 solutions (unless otherwise reported). Chemical shifts are given in parts per 
million (ppm) with respect to tetramethylsilane (TMS) as internal standard. Coupling constants are 
reported as J values in hertz. Peak assignment in 13C spectra was based on 2D gHSQC and gHMBC spectra. 
Column or flash chromatography was carried out using Acros silica gel (0.035–0.070 mm, and ca. 6 nm 
pore diameter). Optical rotations were determined with a Perkin Elmer 241 polarimeter. High-resolution 
mass spectra were recorded on a JEOL AccuTOF (ESI), or a JEOL JMS-T100GCvAccTOF (EI and CI).  
General procedure 1: Nitrile introduction 
Under nitrogen atmosphere, Boc-AA-OH (1 equiv.) was dissolved in dry THF and cooled to −25 °C. 
Subsequently, freshly distilled Et3N (1 equiv.) and isobutyl chloroformate (1 equiv.) were sequentially 
added under vigorous stirring. After 30 min, a solution of aminoacetonitrile sulfate (1.1 equiv.) in H2O (0.5 
mL), precooled on ice, and Et3N (1 equiv.) were added. The resulting mixture was allowed to warm to 
room temperature. After 2 h, THF was removed under reduced pressure and the residual aqueous mixture 
was diluted with a small volume of H2O, adjusted to pH 1 (10% KHSO4) and extracted with EtOAc. The 
combined organic layers were washed with H2O, sat. NaHCO3 and brine, dried over Na2SO4 and evaporated 
to dryness. The solid residue was recrystallized. 
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General procedure 2: Boc deprotection 
Trifluoroacetic acid (8 portions of 10 equiv.) was added to a cold solution (0 °C) of Boc-(AA)n-NHCH2CN (1 
equiv.) in H2O/THF (1:1 v/v, 0.1 M). The mixture was stirred for 2 h at room temperature, after which the 
solvent was removed under reduced pressure and the reaction mixture was lyophilized to obtain the 
product. 
General procedure 3: Amide coupling with EDC 
To a cooled solution (0 °C) of R’COOH (1.05 equiv.) and H2N-R” (1 equiv.) were added DMAP (2 equiv.), 
HOBt (1 equiv.) and EDC (1.05 equiv.). The reaction mixture was allowed to warm up to room temperature 
and stirred for 16 h, after which the mixture was washed with KHSO4, NaHCO3 and brine, dried over Na2SO4 
and concentrated in vacuo. The crude products were purified using column chromatography. 
4-(Azidomethyl)benzoyl-Leu-NHCH2CN (3a) 
General procedure 3, using H-Leu-NHCH2CN (100 mg, 591 µmol) and CH2Cl2 (3 mL). The residue was 
purified using column chromatography (MeOH/CH2Cl2 1:19) yielding the product (77 mg, 40%) as 
colorless oil. RF = 0.35 (MeOH/CH2Cl2 1:19). 1H NMR (300 MHz, CD3OD) δ = 7.89 (d, J = 8.3 Hz, 2H), 7.46 (d, J 
= 8.2 Hz, 2H), 4.64 (m, 1H), 4.45 (s, 2H), 4.17 (d, J = 1.9 Hz, 2H), 1.85 – 1.63 (m, 3H), 1.33 (t, J = 11.0 Hz, 1H), 
0.99 (dd, J = 7.8, 6.2 Hz, 6H) ppm. 13C NMR (75 MHz, CD3OD) δ = 175.34, 169.94, 141.16, 134.89, 129.32, 
128.78, 117.50, 54.99, 53.59, 41.58, 28.07, 26.15, 23.40, 21.90 ppm. FTIR = 3271, 3066, 2958, 2092, 1682, 
1634, 15341, 1242 cm–1. HRMS (ESI) calcd. for C16H21N6O2 (M+H)+ 329.1726, found 329.1745.  
4-(Azidomethyl)benzoyl-Nle-NHCH2CN (3b) 
General procedure 3, using H-Nle-NHCH2CN (100 mg, 591 µmol) and CH2Cl2 (3 mL). The residue was 
purified using column chromatography (MeOH/CH2Cl2 1:49) yielding the product as slightly yellow 
crystals (132 mg, 68%). RF = 0.35 (MeOH/CH2Cl2 1:19). 1H NMR (300 MHz, CDCl3) δ 7.87–7.79 (m, 2H), 7.40 
(dd, J = 8.5, 2.5 Hz, 2H), 6.99 (m, 1H), 4.83–4.69 (m, 1H), 4.42 (d, J = 2.8 Hz, 2H), 4.16 (dd, J = 17.7, 5.7 Hz, 
1H), 4.07 (dd, J = 7.6, 5.4 Hz, 1H), 2.10–1.92 (m, 1H), 1.92–1.71 (m, 1H), 1.42 (m, 4H), 0.92 (m, 3H) ppm. 13C 
NMR (75 MHz, CDCl3) δ 172.44, 172.31, 170.08, 167.50, 167.02, 139.85, 139.46, 133.79, 133.28, 130.77, 
128.46, 128.38, 128.24, 128.11, 127.85, 115.94, 54.38, 54.28, 53.68, 53.58, 41.40, 32.46, 27.62, 22.62 ppm. 
FTIR = 3272, 2931, 2860, 2097, 1749, 1749, 1626, 1530, 1220, 672 cm–1. HRMS (ESI) calcd. for C16H20N6NaO2 
(M+Na)+ 351.1545, found 351.1563.  
4-(Azidomethyl)benzoyl-Phe-NHCH2CN (3c) 
General procedure 3, using H-Phe-NHCH2CN (295 mg, 980 µmol) and EtOAc (10 mL). Column 
chromatography (MeOH/CH2Cl2 1:19) afforded the expected product (230 mg; 95%) as white crystals. Mp 
= 90–93 °C. RF = 0.39 (MeOH/CH2Cl2 1:19). 1H NMR (CD3CN, 400 MHz) δ = 7.81 – 7.76 (m, 1H), 7.49 – 7.43 
(m, 2H), 7.33 (m, 5H), 7.26 (m, 1H), 4.82 (m, 1H), 4.49 (s, 2H), 4.10 (dd, J = 5.9, 4.0 Hz, 2H), 3.35 (dd, J = 
14.0, 5.2 Hz, 1H), 3.09 (dd, J = 13.9, 9.4 Hz, 1H) ppm. 13C NMR (CD3CN, 75 MHz) δ = 172.65, 167.54, 140.69, 
138.51, 134.55, 131.01, 130.25, 129.41, 129.25, 128.67, 127.66, 118.31, 55.83, 54.62, 37.88, 28.22 ppm. FTIR 
= 3273, 3057, 2932, 2552, 2223, 2105, 1683, 1634, 1533, 1294, 1240 cm–1. HRMS (ESI) m/z calcd. for 
C19H19N6O2 (M+H)+: 363.1579, found 363.1570.  
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4-(Azidomethyl)benzoyl-Tyr-NHCH2CN (3d) 
General procedure 3, using H-Tyr-NHCH2CN (90 mg, 456 µmol) and DMF (2 mL). Column chromatography 
(MeOH/CH2Cl2 1:19) afforded the expected product (86 mg, 50%) as yellow oil. RF = 0.23 (MeOH/CH2Cl2 
1:19). 1H NMR (300 MHz, CD3OD) δ = 7.78 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 7.11 (d, J = 8.4 Hz, 
2H), 6.73 (d, J = 8.4 Hz, 2H), 4.74 (t, J = 7.5 Hz, 1H), 4.43 (s, 2H), 4.14 (d, J = 2.2 Hz, 2H), 3.17 (dd, J = 13.8, 
6.5 Hz, 1H), 3.08–2.92 (m, 1H), 2.85 (s, 1H) ppm. 13C NMR (75 MHz, CD3OD) δ = 174.20, 169.67, 157.36, 
141.09, 134.82, 131.32, 129.24, 128.95, 128.81, 117.31, 116.33, 56.87, 54.94, 37.90, 28.00 ppm. HRMS (ESI) 
m/z calcd. for C19H18N6O3Na (M+Na)+: 401.1338, found 401.1349.  
4-(Azidomethyl)benzoyl-h-Phe-NHCH2CN (3e) 
General procedure 3, using H-h-Phe-NHCH2CN (331 mg, 1.00 mmol) and DMF (10 mL). Column 
chromatography (MeOH/CH2Cl2 1:39) and recrystallization from EtOAc/Hept afforded the expected 
product (200 mg, 53%) as white crystals. Mp = 130–133 °C. RF = 0.35 (EtOAc/Hept 1:1). 1H NMR (400 MHz, 
CD3CN) δ = 7.86 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H), 7.39 (d, J = 7.5 Hz, NH), 7.34 (s, NH), 7.31–7.16 
(m, 5H), 4.50–4.42 (m, 3H), 4.49 (s, 2H), 4.05 (dd, J = 2.9, 5.8 Hz, 2H), 2.81–2.64 (m, 2H), 2.24–2.02 (m, 2H) 
ppm. 13C NMR (75 MHz, CD3CN) δ = 173.35, 167.96, 142.30, 140.68, 134.65, 129.47, 129.25, 128.91, 127.05, 
117.86, 54.67, 54.46, 33.88, 32.72, 28.22 ppm. FTIR = 3266, 2220, 2103, 1671, 1631, 1531, 1497, 1239 cm–1. 
HRMS (ESI) m/z calcd. for C20H21N6O2 (M+H)+: 377.1726, found 377.1731.  
4-(Azidomethyl)benzoyl-h-Tyr-NHCH2CN (3f) 
General procedure 3, using H-h-Tyr-NHCH2CN (82 mg, 236 µmol) and DMF (3 mL). Column 
chromatography (EtOAc/Hept 1:1 to 3:1) afforded the expected product (41 mg, 44%) as white crystals. 
Mp = 48–50 °C. RF = 0.45 (EtOAc/Hept 2:1). 1H NMR (400 MHz, CD3CN) δ 7.86 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 
8.6 Hz, 2H), 7.35 (d, J = 7.7 Hz, NH), 7.32 (d, J = 5.7 Hz, NH), 7.05 (d, J = 8.6 Hz, 2H), 6.72 (d, J = 8.6 Hz, 2H), 
4.48 (s, 2H), 4.44 (ddd, J = 4.8, 7.6, 9.4 Hz, 1H), 4.05 (dd, J = 2.8, 5.8 Hz, 2H), 2.72 – 2.56 (m, 2H), 2.22 – 1.99 
(m, 2H) ppm. 13C NMR (75 MHz, CD3CN) δ = 173.45, 167.95, 156.24, 140.67, 134.66, 133.20, 130.48, 129.24, 
128.89, 116.18, 54.67, 54.44, 34.13, 31.80, 28.20 ppm. FTIR = 3296, 2976, 2930, 2101, 1639, 1535, 1515, 
1244 cm–1. HRMS (ESI) m/z calcd. for C20H20NaN6O3 (M+Na)+: 415.1495, found 415.1497.  
4-(azidomethyl)biphenyl-Leu-NHCH2CN (4a) 
General procedure 3, using H-Leu-NHCH2CN (6.3 mg, 37.4 µmol), carboxylic acid 13 (10 mg, 37.4 µmol) 
and DMF (1 mL). Prep-HPLC afforded the product as white crystals in 18% yield. 1H NMR (300 MHz, CDCl3) 
δ 7.87 (d, J = 8.6 Hz, 2H), 7.76–7.52 (m, 4H), 7.41 (d, J = 8.4 Hz, 2H), 4.78 (m, 1H), 4.40 (s, 2H), 1.75 (m, 1H), 
1.61 (s, 2H), 0.99 (d, J = 4.5 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 184.93, 182.96, 174.04, 172.38, 167.26, 
158.77, 146.60, 145.29, 144.03, 140.09, 135.44, 129.39, 128.94, 127.82, 127.43, 81.19, 74.03, 68.83, 46.70, 
27.82. FTIR = 3292, 2957, 2098, 1756, 1631, 1533, 1495, 1212, 668 cm–1. 
4-(azidomethyl)biphenyl-Phe-NHCH2CN (4b) 
General procedure 3, using H-Phe-NHCH2CN (100 mg, 315 µmol), carboxylic acid 13 (90 mg, 347 µmol) 
and DMF (10 mL). Column chromatography (MeOH/CH2Cl2 1:99) afforded the product as white crystals in 
29% yield. 1H NMR (400 MHz, CD3OD) δ 7.85 (d, J = 8.7 Hz, 2H), 7.74-7.69 (m, 4H), 7.47 (dd, J = 2.0, 8.5 Hz, 
2H), 7.33-7.19 (m, 5H), 4.82 (ddd, J = 6.3, 7.8, 8.9 Hz, 1H), 4.42 (s, 2H), 4.15 (s, 2H), 3.29-3.05 (m, 2H) ppm. 
13C NMR (75 MHz, CD3OD) δ 174.08, 169.84, 145.23, 141.13, 138.34, 137.11, 133.95, 130.34, 130.06, 129.59, 
129.17, 128.52, 127.98, 127.91, 117.32, 56.62, 55.20, 38.67 ppm. FTIR = 3426, 3369, 2945, 2090, 1758, 1690, 
1640, 1533, 1198, 696 cm–1. HRMS (ESI) m/z calcd. for C25H22N6O2Na (M+Na)+: 461.1702, found 461.1693. 
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4-(azidomethyl)biphenyl-Tyr-NHCH2CN (4c) 
General procedure 3, using H-Tyr-NHCH2CN (106 mg, 318 µmol), carboxylic acid 13 (96 mg, 350 µmol) and 
DMF (10 mL). Prep-HPLC afforded the product as white crystals in 14% yield. 1H NMR (400 MHz, CD3OD) δ 
7.87 (d, J = 8.7 Hz, 2H), 7.75-7.68 (m, 4H), 7.47 (d, J = 8.4 Hz, 2H), 7.11 (d, J = 8.6 Hz, 2H), 6.72 (d, J = 8.6 Hz, 
2H), 4.73 (t, J = 5.9 Hz, 1H), 4.42 (s, 2H), 4.15 (s, 2H), 3.22-2.93 (m, 2H) ppm. 13C NMR (75 MHz, CD3OD) δ 
174.25, 157.43, 141.14, 137.10, 134.00, 131.35, 130.06, 129.17, 128.87, 128.52, 127.99, 117.32, 116.36, 
56.91, 55.20, 37.97, 30.74, 28.01 ppm. FTIR = 3295, 2928, 2450, 2108, 1663, 1621, 1519, 1438, 1256, 1205, 
1136 cm–1. HRMS (ESI) m/z calcd. for C25H22N6O3Na (M+Na)+: 477.1651, found 477.1644. 
N3CH2CO-Leu-Leu-NHCH2CN (5a) 
General procedure 3, using H‐Leu‐Leu‐NHCH2CN·TFA (30·mg, 105 µmol). The residue was purified by 
column chromatography (MeOH/CH2Cl2 1:39) yielding the product (8 mg, 21%) as a slightly yellow gum. 
RF = 0.39 (MeOH/CH2Cl2 1:19). 1H NMR (300 MHz, CD3OD) δ 4.37-4.47 (m, 2H, 2 × CHCH2) 4.42 (s, 2H, 
CH2N3), 3.91 (s, 2H, CH2CN), 1.29-1.70 (m, 6H, 2 × CH2CH(CH3)2), 0.95 (m, 12H, 2 × (CH3)2) ppm. 13C NMR 
(75 MHz, CD3OD) δ 174.89, 174.63, 170.45, 117.40, 53.35, 52.88, 52.68, 48.15, 41.70, 41.50, 27.99, 25.86, 
21.91, 20.96, 17.62, 16.55 ppm. HRMS (ESI) calcd. for C16H27N7O3 (M+H)+ 366.2254, found 366.2261. 
N3CH2CO-Leu-Phe-NHCH2CN (5b) 
General procedure 3, using H‐Leu‐Phe‐NHCH2CN·TFA (76 mg, 240 µmol). The residue was purified by 
column chromatography (MeOH/CH2Cl2 1:19). The desired product (35 mg, 37% yield) was obtained as 
white/yellow crystals. RF = 0.24 (MeOH/CH2Cl2 1:19). 1H NMR (300 MHz, CD3OD) δ 7.18-7.30 (m, 5H, Ph) 
4.56 (t, J = 6 Hz, 1H, CHCH2Ph), 4.36 (t, J = 6 Hz, 1H, CHCH2CH(CH3)2), 4.09 (s, 2H, CH2CN), 3.87 (s, 2H, 
CH2N3), 3.16 (dd, J = 9 Hz, J = 15 Hz, 1H, CHPh), 2.97 (dd, J = 9 Hz, J = 15 Hz, 1H, CHPh), 1.16-1.51 (m, 3H, 
CH2CH(CH3)2), 0.90 (m, 6H, CH(CH3)2)ppm. 13C NMR (75 MHz, CD3OD) δ 174.31, 173.57, 170.46, 138.08, 
130.35, 129.56, 127.87, 117.21, 55.90, 53.38, 52.58, 41.59, 38.41, 27.93, 25.79 ppm. HRMS (ESI) calcd. for 
C19H25N7O3 (M+H)+ 400.2097, found 400.2118.  
N3CH2CO-Phe-Phe-NHCH2CN (5c) 
General procedure 3, using H‐Phe‐Phe‐NHCH2CN (40 mg, 89 µmol). The residue was purified by 
preparative HPLC. The desired product (39 mg, 70% yield) was obtained as white crystals. RF = 0.30 
(MeOH/CH2Cl2 1:19). 1H NMR (400 MHz, CD3CN) δ 7.28-7.14 (m, 10H, Ph), 4.56-4.47 (m, 2H), 4.06-3.98 (m, 
2H), 3.85 (s, 1H), 3.77 (s, 2H), 3.16 (dd, J = 14.0, 5.3 Hz, 1H), 3.01 (dd, J = 14.0, 5.7 Hz, 1H), 2.90 (dd, J = 
14.0, 8.8 Hz, 1H), 2.82 (dd, J = 14.0, 8.5 Hz, 1H) ppm. 13C NMR (75 MHz, CD3CN) δ 172.25, 171.58, 168.88, 
138.11, 137.92, 131.47, 130.29, 129.39, 127.72, 125.25, 118.32, 117.59, 55.66, 55.18, 55.09, 52.37, 38.10, 
28.27, 28.16 ppm. FTIR = 3282, 3066, 2923, 2850, 2409, 2102, 1639, 1542, 1453, 1259, 1030, 699 cm–1. HRMS 
(ESI) calcd. for C22H24N7O3 (M+H)+ 434.1940, found 434.1961.  
Boc-Leu-NHCH2CN (7a) 
General procedure 1, using Boc-Leu-OH (1.00 g, 4.32 mmol). The solid residue was recrystallized from 
cHex/EtOAc to obtain the expected product (1.01 g, 87%) as white crystals. Mp 110–113 °C. RF = 0.48 
(MeOH/CH2Cl2 1:19). 1H NMR (300 MHz, CD3OD) δ = 4.14 (d, J = 2.9 Hz, 2H), 4.12–4.04 (m, 2H), 1.70 (dd, J 
= 13.1, 6.4 Hz, 1H), 1.58 – 1.47 (m, 2H), 1.45 (s, 9H), 0.95 (t, J = 6.7 Hz, 6H) ppm. 13C NMR (75 MHz, CD3OD) 
δ = 217.92, 199.96, 176.17, 117.49, 80.70, 42.00, 27.97, 18.07 ppm. FTIR = 3334, 3312, 2962, 2872, 1661, 
1519, 1156 cm–1. HRMS (ESI) calcd. for C13H24N3O3 (M+H)+ 270.1821, found 270.1817. 
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Boc-Nle-NHCH2CN (7b) 
General procedure 1, using Boc-norleucine-OH (500 mg, 2.20 mmol). Column chromatography 
(EtOAc/Hept 1:2 to 2:1) yielded the product (517 mg, 88%) as colorless oil. 1H NMR (400 MHz, CD3OD) δ = 
4.14 (d, J = 6.8 Hz, 2H), 4.07 (m, 1H), 1.72 (m, 1H), 1.59 (m, 1H), 1.43 (s, 9H), 1.34 (s, 4H), 0.91 (t, J = 6.4 Hz, 
3H) ppm. 13C NMR (75 Hz, CDCl3) δ = 172.77, 156.09, 115.88, 80.69, 54.10, 33.99, 28.28, 27.31, 18.86, 13.64 
ppm.  
Boc-Phe-NHCH2CN (7c) 
General procedure 1, using Boc-Phe-OH (1.33 g, 5.00 mmol). The solid residue was recrystallized from 
cHex/EtOAc to obtain the expected product (1.26 g, 83%) as white crystals. Mp = 136–138 °C. RF = 0.45 
(MeOH/CH2Cl2 1:39). 1H NMR (400 MHz, CDCl3) δ = 7.27 (m, 5H), 6.86 (s, 1H), 5.13 (d, J = 7.6 Hz, 1H), 4.37 
(s, 1H), 4.13 – 4.01 (m, 2H), 3.06 (t, J = 6.9 Hz, 2H), 1.40 (s, 9H) ppm. 13C NMR (75 Hz, CDCl3) δ = 171.84, 
155.73, 155.64, 136.01, 129.2, 128.82, 127.17, 115.51, 80.82, 55.29, 38.13, 28.22, 27.27, 27.16 ppm. HRMS 
(ESI) m/z calcd. for C16H22N3O3 (M+H)+: 304.1675, found 304.1661.  
Boc-Tyr-NHCH2CN (7d) 
General procedure 1, using Boc-Tyr-OH (1.00 g, 3.55 mmol). The obtained mixture was purified by flash 
chromatography (MeOH/CH2Cl2 1:19) to obtain the product (567 mg, 50%) as yellow oil. Mp 167–168 °C. 
RF = 0.25 (MeOH/CH2Cl2 1:19). 1H NMR (300 MHz, CD3OD) δ = 7.14 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 8.4 Hz, 
2H), 4.25 (m, 1H), 4.10 (d, J = 3.4 Hz, 2H), 3.04 (d, J = 6.0 Hz, 1H), 2.90 – 2.76 (m, 1H), 1.34 (s, 9H) ppm. 13C 
NMR (75 MHz, CD3OD) δ = 174.81, 157.37, 131.34, 128.82, 117.28, 116.26, 112.64, 80.77, 57.59, 38.36, 
28.61, 27.90 ppm. HRMS (ESI) calcd. for C16H22N3O4 (M+H)+ 320.1610, found 320.1617. 
Boc-h-Phe-NHCH2CN (7e) 
General procedure 1, using Boc-h-Phe-OH (500 mg, 1.79 mmol). The solid residue was purified using 
column chromatography (MeOH/CH2Cl2 1:39) yielding the product (396 mg, 70%). RF = 0.55 
(MeOH/CH2Cl2 1:39). 1H NMR (400 MHz, CDCl3) δ = 7. 27 – 7.22 (m, 2H), 7.15 (dd, J = 18.3, 7.1 Hz, 3H), 5.12 
(d, J = 6.9 Hz, NH), 4.10 (d, J = 5.1 Hz, 2H), 4.06 (m, 1H), 2.65 (t, J = 8.0 Hz, 2H), 2.19 – 1.85 (m, 2H), 1.43 (s, 
9H) ppm. 13C NMR (75 MHz, CDCl3) δ = 172.59, 156.20, 140.50, 128.73, 128.52, 126.45, 115.97, 81.00, 53.88, 
33.42, 31.92, 28.45, 27.49 ppm. FTIR = 3295, 2979, 2932, 1665, 1497, 1246, 1162 cm–1. HRMS (ESI) calcd. for 
C17H23NaN3O3 (M+Na)+: 340.1637, found 340.1640.  
Boc-h-Tyr-NHCH2CN (7f) 
Under nitrogen atmosphere, Boc-h-Tyr-OH⋅DCHA salt (300 mg, 629 µmol) and aminoacetonitrile sulfate 
(107 mg, 692 µmol) were dissolved in 5 mL dry CH2Cl2 and cooled to 0 °C. Subsequently, freshly distilled 
Et3N (318 mg, 3.15 mmol) was added and after 10 min, a solution of T3P in EtOAc (601 mg, 944 µmol). 
After 30 min, the resulting mixture was allowed to warm to room temperature and was stirred overnight. 
Then CH2Cl2 was removed under reduced pressure and the residual aqueous mixture was diluted with a 
small volume of H2O, adjusted to pH 1 (10% KHSO4) and extracted with EtOAc. The combined organic 
layers were washed with H2O and brine, dried over Na2SO4 and evaporated to dryness. The solid residue 
was purified using column chromatography (1% Et3N in MeOH/CH2Cl2 1:19) yielding the product (106 mg, 
51%). Mp = 42–45 °C. RF = 0.50 (MeOH/CH2Cl2 1:9). 1H NMR (400 MHz, CDCl3) δ = 7.04 (s, NH), 7.00 (d, J = 
8.4 Hz, 2H), 6.74 (d, J = 8.6 Hz, 2H), 5.96 (s, OH), 5.10 (d, J = 8.2 Hz, NH), 4.11 (dd, J = 48.8, 4.6 Hz, 2H), 4.02 
(dd, J = 8.2, 14.2 Hz, 1H), 2.60 (t, J = 7.5 Hz, 2H), 2.15 – 1.85 (m, 2H), 1.46 (s, 9H) ppm.  
13C NMR (75 Hz, CDCl3) δ = 172.59, 156.72, 154.40, 132.20, 129.70, 115.87, 115.64, 81.26, 53.52, 33.47, 
30.87, 28.46, 27.52 ppm. FTIR = 3305, 2976, 2929, 1666, 1514, 1243, 1160 cm–1. HRMS (ESI) calcd. for 
C17H23NaN3O4 (M+Na)+: 356.1586, found 356.1587.  
Chapter 2 Design, Synthesis and Evaluation of Nitrile-Containing Papain Ligands 
          
32 
H-Leu-NHCH2CN (8a) 
General procedure 2, using Boc-Leu-NHCH2CN (400 mg, 1.49 mmol). The reaction mixture was lyophilized 
to obtain the expected product (379 mg, 96%) as a yellow oil. 1H NMR (300 MHz, CD3OD) δ = 4.23 (d, J = 
1.4 Hz, 2H), 3.92 (t, J = 7.1 Hz, 1H), 1.71 (dd, J = 6.8, 2.3 Hz, 3H), 0.99 (m, 6H) ppm. 13C NMR (75 MHz, 
CD3OD) δ = 171.26, 117.16, 52.84, 41.46, 28.09, 25.36, 22.92, 22.09 ppm. HRMS (ESI) calcd. for C8H16N3O 
(M+H)+ 170.1293, found 170.1297. 
H-Nle-NHCH2CN (8b) 
General procedure 2, using Boc-Nle-NHCH2CN (500 mg, 1.85 mmol). The reaction mixture was lyophilized 
to obtain the expected product (379 mg, 96%) as yellow oil. The product was used in the next reaction 
without any further purification.  
H-Phe-NHCH2CN (8c) 
General procedure 2, using Boc-Phe-NHCH2CN (600 mg, 1.98 mmol). The reaction mixture was lyophilized 
to obtain the expected product (594 mg, quant.) as white crystals. Mp = 146–155 °C; 1H NMR (400 MHz, 
CD3OD) δ = 7.25–7.37 (m, 5H), 4.14–4.16 (d, J = 7.6, 2H), 4.08–4.12 (t, J = 7.2 Hz, 1H), 3.16-3.21 (dd, J = 
13.8, 7.2 Hz, 1H), 3.07–3.13 (dd, J = 13.8, 7.2 Hz, 1H) ppm. 13C NMR (75 MHz, DMSO-d6) δ = 168.81, 158.74, 
158.32, 134.60, 129.49, 128.60, 127.27, 116.90, 53.39, 36.82, 27.09 ppm. HRMS (ESI) m/z calcd. for 
C11H14N3O1 (M+H)+: 204.1138, found 204.1137.  
H-Tyr(OH)-NHCH2CN (8d) 
General procedure 2, using Boc-Tyr-NHCH2CN (224 mg, 598 µmol). The reaction mixture was lyophilized to 
obtain the expected product (189 mg, quant.) as yellow oil. 1H NMR (300 MHz, CD3OD) δ = 7.07 (d, J = 8.5 
Hz, 2H), 6.78 (d, J = 8.5 Hz, 2H), 4.18 (s, 2H), 3.99 (t, J = 7.2 Hz, 1H), 3.09 (dd, J = 14.0, 7.1 Hz, 1H), 2.98 (dd, 
J = 14.1, 7.4 Hz, 1H) ppm. 13C NMR (75 MHz, CD3OD) δ = 170.21, 158.30, 131.57, 125.64, 116.98, 116.88, 
55.84, 37.72, 27.96 ppm. HRMS (ESI) calcd. for C11H14N3O2 (M+H)+ 220.1086, found 220.1093. 
H-h-Phe-NHCH2CN (8e) 
General procedure 2, using Boc-h-Phe-NHCH2CN (350 mg, 1.10 mmol). The reaction mixture was 
lyophilized to obtain the expected product (400 mg, quant.) as white salt crystals. Mp = 34–35 °C. 1H NMR 
(400 MHz, CD3OD) δ = 7.33 – 7.18 (m, 5H), 4.24 (s, 2H), 3.98 (t, J = 6.3 Hz, 1H), 2.70 (ddd, J = 10.0, 6.5, 3.3 
Hz, 2H), 2.22 – 2.06 (m, 2H) ppm. 13C NMR (75 MHz, CD3OD) δ = 170.42, 141.15, 129.73, 129.26, 127.60, 
127.46, 117.24, 54.17, 34.46, 31.82, 28.10 ppm. FTIR = 3047, 2932, 1664, 1525, 1455, 1180, 1132 cm–1. HRMS 
(ESI) calcd. for C12H15NaN3O (M+Na)+: 240.1113, found 240.1112. 
H-h-Tyr-NHCH2CN (8f) 
General procedure 2, using Boc-h-Tyr-NHCH2CN (80 mg, 240 µmol). The reaction mixture was lyophilized 
to obtain the expected product (103 mg, quant.) as yellow oil. 1H NMR (400 MHz, CD3OD) δ = 7.02 (d, J = 
8.5 Hz, 2H), 6.71 (d, J = 8.5 Hz, 2H), 4.22 (s, 2H), 3.93 (t, J = 6.4 Hz, 1H), 2.60 (m, 2H), 2.08 (m, 2H) ppm. 13C 
NMR (75 MHz, CD3OD) δ = 170.45, 157.13, 131.74, 130.20, 117.25, 116.43, 54.14, 34.69, 30.97, 28.08 ppm. 
FTIR = 3233, 3067, 2952, 1665, 1497, 1246, 1162 cm–1. HRMS (ESI) calcd. for C12H15NaN3O2 (M+Na+) 
256.1062, found 256.1062.  
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HO-Biphenyl-CO2Me (11) 
To a solution of (4-bromophenyl)methanol (500 mg, 2.94 mmol) and [4-(methoxycarbonyl) 
phenyl]boronic acid (550 mg, 3.53 mmol) in DMF (20 mL) was added Pd(OAc)2 (200 mg, 735 µmol) and 
Na2CO3 (3 g in 20 mL H2O). The reaction mixture was allowed to stir at 70 °C. After 48 h, an extraction with 
EtOAc was performed; the organic layers were combined and washed with brine, dried over MgSO4, 
filtrated and concentrated in vacuo. Column chromatography (EtOAc/Hept 1:4) yielded the product (170 
mg, 24%) as white crystals. RF = 0.3 (EtOAc/Hept 1:1). 1H NMR (400 MHz, CDCl3) δ 8.15–8.06 (m, 2H), 7.70–
7.58 (m, 4H), 7.52–7.43 (m, 2H), 4.77 (d, J = 3.1 Hz, 2H), 4.07–3.67 (m, 3H), 1.75 (bs, 1H, OH) ppm. FTIR = 
3305, 3032, 1718, 1604, 1432, 1399, 1286, 1271, 1220, 1111, 765 cm–1.HRMS (EI) calcd. for C15H14O3 (M)+ 
242.0942, found 242.0919.  
Azidomethyl-biphenyl-CO2Me (12) 
To a cold solution (0 °C) of HO-biphenyl-CO2Me (100 mg, 412 µmol) in CH2Cl2 (5 mL) was added Et3N (86 
µL, 618 µmol) and MsCl (35 µL, 453 µmol). The reaction was allowed to stir at room temperature and after 
full conversion was seen on TLC (16 h), the mixture was quenched with H2O, extra CH2Cl2 was added and 
the organic layer was washed with water, brine, dried over MgSO4, filtrated and concentrated in vacuo. 
The crude product was redissolved in DMF and NaN3 (200 mg, 3.08 mmol) was added. The reaction 
mixture was stirred for 16 h, H2O was added and the mixture was extracted three times with EtOAc, dried 
over Na2SO4, filtrated and concentrated in vacuo. Column chromatography (EtOAc/Hept 1:4) yielded the 
product (108 mg, 98%) as white crystals. RF = 0.8 (EtOAc/Hept 1:1) 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 
8.6 Hz, 2H), 7.55 (dd, J = 12.9, 8.5 Hz, 4H), 7.40 (d, J = 8.4 Hz, 2H), 4.41 (s, 2H), 3.86 (s, 3H) ppm. 13C NMR 
(101 MHz, CDCl3) δ 166.89, 144.82, 140.09, 140.08, 137.39, 130.13, 129.16, 129.13, 127.60, 126.99, 77.34, 
77.02, 76.70, 52.14, 45.82, 31.87, 22.68, 14.10, 1.01 ppm. FTIR = 2958, 2843, 2105, 1719, 1608, 1432, 1397, 
1286, 1110, 768, 736 cm–1.HRMS (EI) calcd. for C15H13N3O2 (M-N3)+ 225.0915, found 225.0896.  
Azidomethyl-biphenyl-CO2H (13) 
To a solution of azidomethyl-biphenyl-CO2Me (108 mg, 404 µmol) was added THF (500 µL) and 1.5 mL 1 M 
NaOH. The mixture was allowed to stir for 16 h, extracted with EtOAc, washed with brine, dried over 
MgSO4, filtrated and concentrated in vacuo. Lyophilization afforded the product in quantitative yield as 
white crystals. 1H NMR (300 MHz, CD3OD) δ 8.22–7.93 (m, 2H), 7.83–7.50 (m, 4H), 7.35 (m, 2H), 4.36 (s, 
2H). FTIR = 2959, 2922, 2852, 2672, 2549, 2098, 1671, 1706, 1607, 1428, 1292, 737 cm–1. HRMS (ESI) calcd. 
for C14H10N3O2 (M-H)- 252.0760, found 252.0787.  
Boc-Leu-Leu-NHCH2CN (15a) 
General procedure 3, using Boc-Leu-OH (121 mg, 496 µmol) H‐Leu‐NHCH2CN·TFA (80 mg, 473 µmol). The 
residue was purified by column chromatography (EtOAc/Hept 2:3). The product (40 mg, 23%) was 
obtained as colorless oil. RF = 0.42 (MeOH/CH2Cl2 1:19). 1H NMR (300 MHz, CD3OD) δ 4.42 (t, J = 6 Hz, 1H, 
CHCH2) 4.14 (s, 2H, CH2CN), 4.08 (t, J = 6 Hz, 1H, CHCH2), 1.45 (s, 9H, C(CH3)3), 1.29-1.73 (m, 6H, 2 × 
CH2CH(CH3)2), 0.94 (m, 12H, 2 × (CH3)2) ppm. 13C NMR (75 MHz, CD3OD) δ 175.74, 174.85, 158.14, 117.37, 
80.73, 80.44, 62.08, 54.64, 53.58, 52.66, 41.78, 41.56, 36.09, 28.72, 27.98, 25.92, 25.85, 25.77, 23.83, 23.43, 
23.29, 22.00, 21.90, 21.81 ppm. HRMS (ESI) calcd. for C19H34N4O4 (M+H)+ 383.2658, found 383.2660. 
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Boc-Leu-Phe-NHCH2CN (15b) 
General procedure 3, using H‐Phe‐NHCH2CN·TFA (200 mg, 984 µmol). The product (220 mg, 54% yield) 
was isolated as white crystals. Mp 148–151°C. RF = 0.35 (MeOH/CH2Cl2 1:19). 1H NMR (300 MHz, CD3OD) δ 
7.19-7.29 (m, 5H, Ph), 4.60 (t, J = 6 Hz, 1H, CHCH2Ph), 4.09 (s, 2H, CH2CN), 3.99 (t, J = 6 Hz, 1H, 
CHCH2CH(CH3)2), 3.14 (dd, J = 6 Hz, J = 15 Hz, 1H, CHPh), 3.00 (dd, J = 9 Hz, J = 15 Hz, 1H, CHPh), 1.37-1.64 
(m, 3H, CH2CH(CH3)2),1.43 (s, 9H, C(CH3)3), 0.88 (m, 6H, CH(CH3)2) ppm. 13C NMR (75 MHz, CD3OD) δ 
175.56, 173.51, 158.19, 137.92, 130.36, 129.57, 127.88, 80.73, 55.52, 54.92, 41.87, 38.46, 28.74, 27.93, 25.77, 
23.29, 21.93. HRMS (ESI) calcd. for C22H32N4O4 (M+H)+ 417.2502, found 417.2518. 
Boc-Phe-Phe-NHCH2CN (15c) 
General procedure 3, using H‐Phe‐NHCH2CN·TFA (216 mg, 718 µmol). The product (160 mg, 50% yield) 
was isolated as white crystals. Mp = 167–169 °C. RF = 0.10 (EtOAc/Hept 3:2). 1H NMR (300 MHz, CD3OD) δ 
7.18-7.28 (m, 5H), 4.56 (t, J = 6 Hz, 1H), 4.24 (t, J = 6 Hz, 1H), 4.07 (s, 2H), 3.09 (dd, J = 9 Hz, J = 15 Hz, 1H, 
CHPh), 2.96-3.02 (m, 2H, CH2Ph), 2.75 (dd, J = 9 Hz, J = 15 Hz, 1H, CHPh), 1.32 (s, 9H, C(CH3)3) ppm. 13C 
NMR (75.48 MHz, CD3OD) δ 174.08, 173.34, 157.78, 138.40, 137.81, 130.38, 130.34, 129.61, 129.41, 127.93, 
127.71, 117.15, 80.87, 57.52, 55.64, 39.97, 38.71, 28.66, 27.91 ppm. HRMS (ESI) calcd. for C25H30N4O4Na 
(M+Na)+ 473.2165, found 473.2167. 
H-Leu-Leu-NHCH2CN (16a) 
General procedure 2 using Boc-Leu-Leu-NHCH2CN (40 mg, 105 µmol). The residue was dissolved in acetic 
acid and lyophilized yielding the product (46 mg, quant.) as yellow oil. The product was used without 
further purification.  
H-Leu-Phe-NHCH2CN (16b) 
General procedure 2, using Boc-Leu-Phe-NHCH2CN (100 mg, 240 µmol). The product (118 mg, quant. 
yield) was obtained as yellow oil. The product was used without further purification.  
H-Phe-Phe-NHCH2CN (16c) 
General procedure 2, using Boc-Phe-Phe-NHCH2CN (100 mg, 220 µmol). The product (222 mg, quant. 
yield) was obtained as white crystals. The product was used without further purification.  
Enzymatic assay 
Enzyme activities were calculated from kinetic measurements performed by spectrophotometric 
detection of the product 4-nitroaniline (pNA) at 25 °C in a 1 mm cuvette at a wavelength of 380 nm. A 4.5 
mM stock solution of the chromogenic substrate Z-Phe-Arg-pNA was prepared in DMSO; the final 
concentration was 300 µM. Stock solutions of the inhibitors were also prepared in DMSO and final 
concentrations were in a range from 10 nM to 100 µM. In the absence of inhibitor, 20 µL of DMSO was 
added to the cuvette. The final papain concentration used in the assay was 100 nM.  
For daily activation of papain, a 10 µM solution was prepared in a 0.1 M sodium phosphate buffer (pH 6.5), 
containing 2.5 mM EDTA and 15 mM DTT (activation buffer). The solution was incubated at 25 °C for 1 h 
and the activated enzyme was kept on ice. In this way stability was ensured for 6–8 h. Further dilutions 
were made in a 0.1 M sodium phosphate buffer (pH 6.5), containing 2.5 mM EDTA, 300 µM DTT and 6% 
DMSO (running buffer).  
After thermal equilibration, the reaction was initiated by addition of the enzyme and progress curves were 
monitored over 7–10 min. The initial velocities (Vini) were determined for seven different inhibitor 
concentrations in triplicate.  
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Chapter 3 
Docking of Peptidonitrile Ligands  
in the Active Site of Papain 
 
 
 
 
 
 
 
For fast and sensitive detection of allergens, appropriate ligands are required with a handle for immobilization 
onto a biosensor surface. For such purpose, a small library of enzyme inhibitors was developed and subjected 
to docking studies in order to corroborate the earlier experimentally determined IC50 values. The docking 
program Fleksy was used to provide insight at which position an azide moiety (or other immobilization 
handle) could be tolerated without affecting binding affinity. In addition a new, potentially selective papain 
ligand is proposed, based on projected binding interactions with the deep binding pocket of papain.  
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3.1 Introduction 
Biosensors, analytical devices to detect the presence of a specific biomolecule in a natural sample, have 
become an indispensable tool in medicinal, forensic and environmental analysis.1,2 In general, a biosensor 
consists of two main components, namely a recognition element and a transducer element: the 
recognition element ensures detection of the target biomolecule (analyte) by a binding event, whereas 
the transducer element signals the binding to a device for read-out. To obtain a sensitive and selective 
biosensor, it is important to construct a recognition element that provides a stable interface for interaction 
between the target biomolecules and the immobilized binding partners (ligands), which are packed with 
optimal density; the interface should furthermore be insensitive to non-specific binding interactions. An 
essential element in biosensor development therefore is an effective procedure that will allow 
immobilization of the binding ligands on the biosensor interface with a high level of control.  
For the Unihealth biosensor, a strategy was chosen involving initial functionalization of a sensor surface 
with the strained alkyne bicyclo[6.1.0]nonyne (BCN), followed by ligand immobilization via strain-
promoted azide–alkyne cycloaddition (SPAAC).3 As a complementary reactant for BCN, the binding 
ligands required modification with an azide handle. In Chapter 2, the design, synthesis and enzymatic 
evaluation of a small library of peptidonitrile containing ligands (Figure 3.1) was described. Attachment of 
the peptidonitrile ligands with Cys25 in the active site of papain occurs via reversible formation of a 
covalent thioimidate complex. Although the azide handle is small, this moiety surprisingly and 
dramatically influenced the binding affinity of the compounds in the library as described in Chapter 2 
(Table 2.1).  
 
 
 
Figure 3.1 Structure of the strained alkyne bicycl[6.1.0]nonyne (BCN), modified with a polar spacer, which is used for 
immobilization and an overview of azide-modified peptidonitrile ligands 1–5; compound 1 a. . R1 = iBu (Leu), b. R1 = n-Bu (Nle), c. 
R1 = Bn (Phe), d. R1 = CH2C6H4OH (Tyr), e. R1 = (CH2)2Phe (h-Phe), f. R1 = (CH2)2C6H4OH (h-Tyr); compound 2 a. R2 = n-Bu (Leu), b. 
R2 = Bn (Phe), c. R2 = CH2C6H4OH (Tyr); compound 3 a. R3 = iBu (Leu) R4 = iBu (Leu), b. R3 = iBu (Leu) R4 = Bn (Phe) and c. R3 = Bn 
(Phe) R4 = Bn (Phe).  
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In order to obtain insight in, and rationally explain the experimentally measured IC50 values on a molecular 
level, docking studies were performed. To this end, a crystal structure of papain with its natural inhibitor 
leupeptin was used as starting point (PDB-code 1POP) (Figure 3.2b).4 The nomenclature to describe the 
interaction between a peptide (P) and the enzyme recognition subsite (S) is exemplified in Figure 3.2a 
and will be used for describing the docking results.5  
 
a) b) 
 
 
Figure 3.2 a) Schematic representation of leupeptin side chains (P1 to P4) and subsequent papain subpockets (S1 to S4). The active 
site is described according to the concept of Schechter and Berger.5 b) Crystal structure of leupeptin in the active site of papain 
(PDB file 1POP).4  
3.2 Methods and Materials  
Small molecule preparation: With the modeling package MOE (2011.10) from CCG 3D structures of the 
inhibitors were drawn and energy minimized.  
Docking: All molecular docking studies in papain were performed using the flexible 
docking program Fleksy (1.2.3) with default settings. The crystal structure of a 
papain-leupeptin complex (PDB entry 1POP) was used for all docking studies.4 The 
docking process and protocol in Fleksy was based on FlexX technology, as explained 
in detail by Nabuurs et al.6 The docking algorithm of FlexX cuts ligands into 
fragments. One of those fragments was placed into the binding site and the rest of 
the ligand was systematically added. All steps were scored and only the best scored poses were further 
considered.  
Covalent docking with Fleksy is not directly possible. In order to simulate a covalent docking in Fleksy the 
position of the first fragment (base fragment) placed during the docking process was locked. Here, the 
base fragment was provided in form of the C-terminal amide bond of the inhibitors (Figure 3.3), red part 
of structure) to simulate a covalent docking protocol. 
 
Structural alignment: The papain structures (1BP4, 1BQI, 1CVZ, 1KHP, 1KHQ, 1PAD, 1PE6, 1PIP, 1POP, 1PPD, 
1PPN, 1PPP, 1STF, 2CIO, 2PAD, 3E1Z, 3IMA, 3LFY, 3TNX, 4PAD, 5PAD, 6PAD, 9PAP) were aligned based on 
the position of their Cα atoms in PyMol. 
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3.3 Results and Discussion 
Molecular docking is a computational technique to predict the orientation of a ligand in a protein binding 
pocket.7 The docking process consists of two steps. First the ligand is placed into the pocket to explore the 
conformational and configurational space. In a second step, called scoring, the strength of the receptor-
ligand interaction is evaluated. Based on the latter scores, a ranking of all possible conformations is 
obtained. We used the docking program Fleksy because it provides the option to treat parts of the protein 
flexible and at the same time allows induced fit adaptations of the protein upon inhibitor binding. The 
induced fit model considers the initial binding event as relatively weak, but upon binding of the ligand to 
the protein, the protein can rapidly induce conformational changes to strengthen the ligand-protein 
binding.8 The introduced inhibitors (Figure 3.1, compounds 1–5) bind covalently to Cys25 of papain, 
which provides valuable information of how the inhibitors will be oriented in the binding site and reduces 
the complexity of the docking process. Covalent docking with Fleksy is not directly possible. In order to 
simulate a covalent docking in Fleksy the position of the anchor fragment can be provided. In a first phase, 
a pre-selected base or anchor fragment of the ligand is placed into the active site independently of the 
rest of the ligand. In the second phase the remaining fragments of the ligand are added to the initially 
placed anchor fragment. As base fragment the C-terminal amide bond was chosen (Figure 3.3, red part of 
structure).  
Prior to docking we investigated different papain structures of the PDB to explore different ligand-papain 
complexes, as well as the flexibility of the protein in the area of the binding site. 
3.3.1 3D-Protein Structure Alignment 
In order to investigate the variability of the S2 and S3 
subsites among different ligand-papain complexes, a 
structural alignment was performed first, based on the α-
carbons of 23 PDB-structures of papain (Figure 3.4).9 No 
large structural differences were found and therefore 
only little flexibility in the S2 and S3 subsites can be 
expected. Two tyrosines, Tyr61 and Tyr67, that determine 
the size of the S3 pocket, appear to have some 
conformational freedom. Only the flexibility of the S2 and 
S3 subsite were examined, since at the P1 position of all 
ligands a glycine is present and the S4 pocket will not be 
occupied by our designed ligands.   
Figure 3.4 Structure alignment of 23 papain PBD 
structures.9 
3.3.2 Docking 
In order to evaluate the effect of an azide at different positions of the known inhibitors, one representative 
inhibitor of the three different ligand subclasses (Figure 3.1, compounds 1c, 2b and 3c) was docked into 
the papain crystal structure PDB-code 1POP first. The best-scored pose of each docked inhibitor is shown 
in Figure 3.5. 
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The covalent binding of the inhibitor to papain was mimicked during the docking process by fixing the 
position of the C-terminal amide bond as anchor fragment (Figure 3.3). With this approach, the number of 
possible inhibitor orientations in the binding site was reduced, at the same time increasing the likelihood 
that the chosen docking poses are representative for the native binding mode. Besides the covalent 
nitrile-cysteine bond, all inhibitors depicted in Figure 3.1 are predicted to form three hydrogen bonds 
between their backbone and the backbone of the protein (Gly66 and Asp156), as already observed in the 
papain−leupeptin complex. 
Since the side chains of the amino acids of papain were treated to be flexible during the docking process, 
the final position of the side chains after docking can differ from the ones found in the crystal structure. In 
Figure 3.5, the changes of the side chains upon docking are shown for the amino acids that constitute the 
S2 and S3 binding site of papain. For example in Figure 3.5d the side chains of Tyr61 and Tyr67 have moved 
outward to open up the S3 binding site and allow entry and binding of the ligand. 
For each ligand subclass, the influence of the azide moiety will be separately discussed below, based on 
the docking results. 
 
Figure 3.5 (a) Surface representation of PDB-code 1POP (C gray, O red, N blue, S yellow). The ligand leupeptin is covalently 
bound to Cys25 and forms three hydrogen bonds to the protein backbone of Gly66 and Asp156 (orange dashes). The 
hydrophobic S2 binding site is formed by Val133 and Val157, while Tyr61 and Tyr67 form the S3 binding site. Docking orientation 
of (b) benzoyl ligand 4 (yellow), (c) phenylalanine ligand 1c (blue), (d) phenylbenzoyl ligand 5 (orange), (e) azidomethylated 4-
phenylbenzoyl ligand 2b (cyan) and (f) leupeptin-based ligand 3c (pink), all superposed onto papain in complex with leupeptin 
(PDB code 1POP)(gray). For leupeptin, hydrogen bonds are shown (orange dashes). 
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3.3.3 Benzoyl Ligands 
The first approach to introduce an azide handle for immobilization (as in compounds 1a–f) involved para-
substitution at the benzoyl moiety with an azidomethylene group in the known ligand 4. As established 
by the enzymatic assay, the introduction of the p-azidomethyl group did not significantly change the 
binding affinity (Chapter 2, Table 2.1). In Figure 3.5b, the best-scored docking orientation of benzoyl 
compound 4 was superposed to the papain–leupeptin complex. The introduction of the azide linker (as in 
inhibitor 1c Figure 3.5c) at this position seemed to lead to negligible interference with the binding mode 
of the inhibitor. 
Replacing the phenylalanine in position P2 by an amino acid with another side chain was found to induce 
changes in binding affinity (Chapter 2). With respect to the docking results it can be concluded that the 
best fit of the S2 pocket is a phenylalanine. A minor reduction in binding affinity was observed for a 
tyrosine (ligand 1d) and a large decrease in binding affinity was found for aliphatic moieties (ligands 1a, 
1b). 
Two non-natural amino acids, homo-phenylalanine and homo-tyrosine, were introduced at the P2 position 
as well (ligands 1e and 1f). Based on the IC50 results, the affinity towards papain dropped by a factor of 
three. These amino acids bear an extra CH2 compared to phenylalanine and tyrosine. As a consequence of 
the longer side chain, the P2 group is less optimal for binding into the S2 subsite. This leads to the 
conclusion that the hydrophobic subpocket formed by Val133 and Val157 most comfortably 
accommodates the 4-azidomethylbenzoyl ligand 1c. 
 
 
Figure 3.6 Azidomethyl-benzoylated compounds 1 a = Leu, b = Nle, c = Phe, d = Tyr, e = h-Phe and f = h-Tyr and literature 
compound 4.10 
3.3.4 Phenylbenzoyl Ligands 
As described by Löser et al. inhibitors featuring a biphenyl moiety, such as 5 (figure 3.7) were found to 
display better affinity than the similar benzoylated ligand 4.10 However, as described in Chapter 2, in our 
experimental binding studies, inhibitors containing a biphenyl group that was 4'-substituted with an 
azidomethyl moiety, surprisingly displayed a dramatic decrease in binding affinity.  
 
 
Figure 3.7 Biphenylcarbonyl compounds 2 a = Leu, b = Phe and c = Tyr and literature compound 5.10  
As depicted in Figure 3.5d and Figure 3.5e, Tyr67 moves away to open up the binding site and to be able 
to fit the S3 phenylbenzoyl group (5 and 2b). These docking poses do not provide an explanation for the 
loss in binding affinity after introduction of the azide moiety. It seems that the poses predicted by Fleksy 
allow too much flexibility in the S3 pocket. From literature it is known that an alternative binding 
conformation can occur as well. Kim et al. showed a crystal structure for papain where the P2 and P3 
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residues are swapped and the P3 group is now locked by the S2 subsite.11 This would give a better 
explanation for the fact that ligand 5 is a good binder and after introduction of the azide at the aromatic 
group, the binding affinity drops, because S2 pocket is not large enough to bear the extra azide linker.  
3.3.5 Leupeptin-Based Ligands 
The third class of ligands that was evaluated are the leupeptin-based inhibitors 3a–c (Figure 3.8). The 
experimentally determined IC50 values for these ligands were higher than for leupeptin or e.g. ligand 1c 
(Chapter 2, Table 2.1). The IC50 value of leupeptin was determined in the low nanomolar range (data not 
shown here). The leupeptin-based ligands did not contain the arginine of leupeptin at the P1 position. 
With respect to the crystal structure 1POP the arginine group does not form additional hydrogen bonds to 
papain and therefore the impact on the binding affinity may be relatively small. Furthermore, the P2 and P3 
groups are the same as for leupeptin or contain a phenylalanine, which outperformed other residues in 
terms of binding affinity in our other ligand series. Most likely the introduced azide moiety for ligands 3a-c 
is not complementary in terms of interactions at the upper top of the S2 subpocket (Tyr67), which would 
explain the significant loss in binding affinity.  
 
Figure 3.8 Leupeptin-based ligands 3 a = R2 = R3 = iBu (Leu); b R2 = iBu (Leu), R3 = Bn (Phe) and c R2 = R3 = Bn (Phe). 
3.3.6 Proposal for High-Affinity Papain Ligands 
Docking studies showed that ligands having a phenylalanine at the P2 position could occupy the S2 subsite 
best. Furthermore, the leupeptin-based ligands 3a–c were not as good as was expected. Lastly the 
benzoyl ligands 1b and 1c proved to be good ligands. Based on these finding, docking studies were next 
employed to propose new papain ligands.  
Active sites are often deep and narrow pockets, however the one of papain is an open cleft. As a 
consequence, it is difficult to develop selective ligands for papain, considering the multiple binding 
modes and lack of specific interaction for some of the ligands. On the other hand, the large S2 subsite 
contains a deep hydrophobic shaft, which could possibly facilitate binding interactions of certain ligands 
but has so far not been addressed (Figure 3.9).  
 
 
Figure 3.9 View of the extended S2 subsite of papain. The leupeptin–papain interaction is shown including the hydrogen bonds 
with orange dashes. Tryp69, Ser131 and Ser203 are depicted in the figure as sticks. 
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Further investigation of the extended S2 pocket revealed the presence of a hydrophobic region 
surrounded by hydrogen bond acceptors and donors (indole nitrogen of Trp69, hydroxyl group of Ser131 
and Ser203). 
In our search towards selective papain ligands, first, the P2 phenylalanine was replaced by homologated 
chains with 2 or 3 methylene groups. In addition a carbonyl group was modeled on the phenyl para-
position to enable hydrogen bond formation with the indole nitrogen of Trp69. Of the compounds 
investigated, ligand 6 was predicted to optimally fit into the deep pocket and bind to Trp69 (Figure 3.10 
and Figure 3.11).  
 
 
Figure 3.10 Structure of potential high affinity papain ligand 6.  
 
  
Figure 3.11 Highest scored docking result with ligand 6. Hydrogen bonds are represented by yellow dashes. Left) upside view; 
right) view into a longitudinal section of the deep pocket.  
Compound 6 contains a ketone functional group for hydrogen bond formation with Trp69 and an amide 
moiety for hydrogen bond interaction with Ser131 in the deep pocket. 
Based on the in silico prediction of compound 6 as a potential high affinity binding ligand, a retrosynthetic 
analysis for the synthesis of ligand 6 was designed (Scheme 3.1). It was envisaged that the 
azidomethylbenzoyl moiety would be attached to compound 7 via Boc deprotection/acylation at the α-
amino group and amidation of the remote methyl ester. Introduction of the epsilon-ketohexanoic ester 
side chain of 7 was envisaged to proceed via a Fukuyama coupling reaction of thiol ester 8 and 
homotyrosine derivative 9.12,13 Finally, the aminonitrile moiety in 9 can be readily introduced on 
homotyrosine building block 10 as described in Chapter 2.  
Unfortunately, lack of time did not allow the in-depth investigation of the feasibility of the proposed 
approach. Some steps were undertaken with partial success, but insufficient for publication at this stage.  
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Scheme 3.1 Retrosynthesis of second-generation papain ligand 6. 
3.4 Conclusion 
A small library of papain peptidonitrile ligands was subjected to docking studies, in order to corroborate 
the earlier experimentally determined IC50 values (Chapter 2). The docking program Fleksy was used based 
on an induced fit model and the position of a base fragment of the ligands simulated a covalent bond. 
Fleksy was used to provide insight at which position an azide moiety or small immobilization handle could 
be introduced to a ligand without significantly influencing binding affinity. 
As was concluded in Chapter 2, 4-azidomethylbenzoyl ligand 1c showed the best IC50 value for all ligands 
bearing the azide immobilization handle. Docking studies showed that ligands having a phenylalanine at 
the P2 position can occupy the S2 subsite best and this could explain the better IC50 value compared to the 
other ligands. For phenylbenzoyl ligands 2a–c and 5, Fleksy proposed a pose where Tyr61 and Tyr67 move 
to the side to open up the S3 subside and allowing the phenylbenzoyl moiety to fit. Based on the IC50 value 
found for ligands 2a–c, this docking pose could not be correct, since a dramatic decrease in binding 
affinity was observed and this can not explained with these docking poses. As was found in literature, an 
alternative binding conformation could be possible for the ligand−papain complex.11 Taking these two 
points in account, it was concluded that flexible docking overestimated the induced fit and a swapped 
binding mode will probably occur where the P2 aromatic group will bind into the S3 subpocket and the P3 
phenylbenzoyl group will be locked by the S2 subpocket.  
For the leupeptin-based ligands, the IC50 values showed a decrease in binding affinity. Based on the 
docking results, the introduced azide moiety for ligands 3a–c is not complementary in terms of 
interactions at the upper top of the S2 subpocket (Tyr67), which would explain the significant loss in 
binding affinity. 
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After providing an explanation of the IC50 values found of the ligands designed and synthesized in Chapter 
2, docking studies were also used to propose a new, and hopefully, selective papain ligand 6. After 
synthesis and enzymatic evaluation of ligand 6, the effectiveness of deep pocket binding for better affinity 
and selectivity can be corroborated. 
At this point however, 4-azidomethyl ligand 1c appears to be the best option for a biosensor device, since 
it has the highest binding affinity of all ligands containing the immobilization handle. This will be further 
investigated in Chapter 4, where ligand 1c will be used in a biosensor system. 
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Chapter 4 
Site-Specific Peptide and Protein Immobilization on 
Surface Plasmon Resonance Chips via  
Strain-Promoted Cycloaddition  
 
 
 
Surface plasmon resonance (SPR) is a powerful label-free diagnostic tool to study biomolecular interactions. 
However, one of the drawbacks of SPR is the lack of controlled immobilization of ligands on the sensor surface. 
A modular platform was developed for the fast, reagent-free and site-specific immobilization of azide-
containing ligands by strain-promoted cycloaddition onto a cyclooctyne-modified SPR sensor surface. The 
usefulness of the concept was shown in a study with a peptide-based papain binding model system, and up to 
150 SPR experiments were performed without loss of surface quality. Furthermore, azide-containing green 
fluorescent protein (GFP) was also effectively immobilized. Taken together, cyclooctyne-modified SPR chips 
enable smooth and site-selective immobilization of ligands and prove to be more robust than traditionally 
functionalized systems.  
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4.1 Introduction 
Surface plasmon resonance (SPR) has been widely used as an optical tool for real-time and label-free 
analysis of biomolecular interactions with small quantities of material.1,2 With SPR, the strength and 
kinetics of biomolecular interactions can be studied and quantified, or new potential binding partners for 
a particular ligand can be screened and identified. Several review articles have described the principles of 
SPR detection in more detail.3–8  
Plasmons can be described as an oscillation of free electron density with respect to the fixed positive ions 
in a metal (Figure 4.1). At the metal surface, or an interface with oppositely charged dielectric constants, 
the free electrons of the metal can interact with light waves. The electrons can collectively oscillate in 
resonance with the incoming light wave and essentially trap the light wave at the surface. These coherent 
electron oscillations are called surface plasmons (SPs). SPs can be excited by irradiating the metal with a 
laser of a wavelength that fulfills the resonance condition and this is called surface plasmon resonance 
(SPR). The oscillations of the SPs are very sensitive to dielectric changes (refractive index changes) of the 
close surroundings, as this changes the resonance frequency. Furthermore, the oscillations decay 
exponentially in both materials creating an evanescent electromagnetic field that extends over ~250 nm 
(depending on the wavelength of the light). Thus detection can be done up to this distance.  
In practice the change in oscillation is measured by directing plane-polarized light to the interface via a 
glass prism and detection of the reflected light intensity. At a certain angle the light can couple to the 
oscillations of the SPs and a dip in the reflected light is observed. When the binding of an analyte to the 
ligand occurs, the local environment changes, resulting in a change in the resonance frequency, and 
coupling will occur at a different angle. The angle shift can be observed in real-time by a charge-couple 
diode (CCD) array and is proportional to the mass bound to the surface. The resonance shift can be shown 
in m° or in response units (RU), where one RU corresponds to an angular shift of 0.1 m°.  
 
In summary, binding of a biomolecule to the surface, for example the molecular interaction of an allergen 
with an immobilized ligand, will lead to a change in refractive index of the surroundings. Consequently, 
the frequency of the surface plasmons will also change and the dip in the intensity of reflected light will 
shift towards a different SPR angle that can then be detected and plotted in a real-time graph.  
Although detection of the biomolecular interaction is label-free, i.e. labeling with a reporter molecule such 
as a fluorophore is not required; the ligand itself obviously requires immobilization on the sensor surface 
prior to (non-covalent) binding of the analyte. Not surprisingly, controlled covalent attachment of ligands 
is a critical step, since the amount and orientation of ligand immobilized on the surface of the SPR chip is 
closely related to its performance and, consequently, to the quality of the data retrieved.6 For long-lasting 
SPR chip activity, the surface has to be packed with optimal density and should be stable under 
regeneration conditions, an essential step for re-use.  
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Figure 4.1 Schematic representation of the principles of SPR detection. Binding of a biomolecule to the ligand will change the 
refractive index of the surroundings and thereby changing the SPR angle.  
There are various ways to immobilize a ligand on the sensor surface. The most commonly used chip 
surface comprises a hydrophilic dextran layer displaying carboxylic end groups that are activated as N-
hydroxysuccinimide (NHS) ester, thereby enabling ligand immobilization by amide bond formation. As it 
appears, such carboxy-terminated chips are used in approximately 90% of SPR applications.6,9 Despite its 
popularity, however, the presence of multiple amines in the ligand, e.g. a peptide or a protein, will hamper 
site-specific modification, which will affect the binding process.10 In addition, reaction of other 
nucleophilic groups with activated esters may lead to further uncontrolled immobilization on the surface, 
while the hydrolytic sensitivity of the activated esters makes them only suitable for immobilization 
procedures that proceed fast.  
To avoid a coupling approach based on amino groups in the ligand, other immobilization methods have 
been developed, e.g. based on the streptavidin-biotin interaction.11,12 However, such alternative methods 
possess other disadvantages, such as long-term reversibility or non-specific binding events leading to a 
change of the affinity profile for the biomolecular interaction.6 It is clear, therefore, that a more generally 
applicable immobilization strategy is desirable. Ideally, such immobilization is fast, selective, compatible 
with water and fully orthogonal to biomolecular functionality. Given these conditions, we embarked on 
the development of a new immobilization strategy employing strain-promoted ‘click’ chemistry between 
cyclooctynes and azides (Figure 4.2).13–21 
 
Figure 4.2 Schematic representation of the surface functionalization by 1,3-dipolar cycloaddition. 
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Cyclooctynes are well known to undergo efficient (3+2) cycloaddition with a variety of 1,3-dipoles, such as 
azides (SPAAC),13,15–17 nitrones (SPANC)19,20 or nitrile oxides (SPANOC).18,21 The incorporation of such a 
dipole into a protein or a small molecule can be easily achieved by either chemical22 or enzymatic 
means.23,24 Most recently, extremely fast (4+2) cycloaddition of cyclooctynes with tetrazines has also been 
reported, which further broadens the application of strain-promoted chemistry.25  
In this chapter the application of cycloaddition chemistry for the modification of SPR chips will be 
described. The approach is based on initial functionalization of the chip surface with bicyclo[6.1.0]nonyne 
(BCN), followed by ligand immobilization by strain-promoted azide–alkyne cycloaddition (SPAAC).17 BCN-
functionalized SPR chips are modular in nature and can be smoothly functionalized in reagent-free fashion 
with azide-containing compounds. The efficacy of the method was proven by immobilization of small 
molecule inhibitors of papain, which allowed rapid and quantitative protein detection.26 The power of the 
approach was further demonstrated by attachment of a whole protein, i.e. azide-functionalized green 
fluorescent protein (Anl-GFP).  
4.2 Results and Discussion 
In order to perform a strain-promoted cycloaddition to functionalize an SPR chip, one of the reaction 
partners i.e. azide or strained alkyne needs to be immobilized to the surface first. Because azides are in 
general more easily introduced in bio(macro)molecules, a strained alkyne is the preferred functionality for 
attachment to the surface. To this end, bicyclononyne (BCN), was selected as the preferred cyclooctyne 
due to its beneficial balance between accessibility, reactivity and relatively low lipophilicity.17 Thus, a BCN-
functionalized SPR chip was first prepared by attachment of the commercially available amino-derivative 
of BCN according to the standard coupling protocol of a CM5 chip based on EDC/NHS chemistry.10 
The usefulness of the BCN-based immobilization platform was evaluated with two model systems, one 
involving attachment of azide-containing small organic molecules, and one involving attachment of a 
whole protein charged with an azido group (Figure 4.3).  
4.2.1 Papain Model System 
For the small molecule ligand, a peptide-based enzyme inhibitor from an in-house screening program was 
chosen to study binding interactions with papain, a cysteine protease from papaya fruit (Chapter 2).26-30 
After preparation of the BCN surface, a reaction with azide-containing ligand 1 was performed, leading to 
the desired ligand-containing SPR surface (Figure 4.3, left). Loading of the SPR surface was corroborated 
by treatment of each individual chip with a 1 µM papain solution, leading to a clear response (200 m° at 
equilibrium) by comparison with papain treatment of a reference cell, i.e. created by a SPAAC reaction of 
2-azidoethanol with the cyclooctyne surface. The successful SPR experiment was a first indication of the 
usefulness of SPAAC for biosensor chip functionalization. As a control, a direct ligand-functionalization of 
the surface was also executed from the carboxy-terminated chip via the amine immobilization protocol, 
leading to similar response in comparison to the reference chip. 
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Figure 4.3 Immobilization of (left) the small nitrile ligand that was used in a study with papain; (right) azido-containing GFP.  
To more closely examine and compare the surfaces obtained by the different immobilization methods, an 
assay with papain was set up to accurately determine binding constants. Firstly, the binding constant for 
the interaction at the SPR sensor chip (KC) was determined by addition of different papain concentrations 
and fitting of the equilibrium signal to a Langmuir binding isotherm (Figure 4.4). Next, competition 
experiments were performed to obtain the binding constant for binding in solution (KS).31 While the 
binding constant KS is in theory independent from effects at the sensor surface and should be comparable 
to KC, in practice differences have been observed.6  
The first experiment performed on each chip was the Langmuir binding assay and the equilibrium signals 
were used to obtain KC. As can been seen in Figure 4.4, after 60 seconds of baseline stabilization, the 
analyte papain was added to the surface for an association time of three minutes, followed by 60 seconds 
dissociation and finally regeneration of the surface with 25 mM NaOH.  
 
 
Figure 4.4 (a) SPR signals for the Langmuir binding experiment (per 
chip performed in duplicate; in total per experiment two chips were 
used) and (b) Langmuir binding graph. For ligand 1, KC = 360 ± 30 nM 
was found.  
Table 4.1 KC values obtained for ligand 1 via Langmuir 
binding experiments using either an amide or SPAAC 
immobilization procedure (experiments performed in 
duplo and on two different chips).  
 
Amide coupling SPAAC coupling 
360 ± 50 nM 360 ± 30 nM 
240 ± 30 nM 360 ± 30 nM 
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Figure 4.5 (a) SPR signals for the competition experiments (performed 
in duplo); (b) SPR competition experiments in the presence of 500 nM 
papain and various concentrations of competing ligand 1 or 3. Data are 
fitted with a competition model yielding the affinity in solution (KS) as 
described by de Mol et al.31 
Table 4.2 KS (nM) obtained in the presence of 500 nM 
papain and different ligand concentrations 
((experiments performed in duplo and on two 
different chips). 
Compound 
SPAAC 
coupling 
Amide 
coupling 
1 
500 ± 100  
500 ± 50 
1200 ± 300 
1200 ± 150 
3 
600 ± 100 
700 ± 100 
1700 ± 400 
1600 ± 400 
 
Different concentrations of papain were added to the surface in a 
range from 50 to 2000 nM leading to good, reproducible SPR signals 
(Figure 4.4a). We were pleased to find that similar KC-values were 
determined, irrespective of whether the route of immobilization of the 
ligand proceeded via SPAAC or via direct amide coupling (Figure 4.4b 
and Table 4.1). Finally, binding constants obtained in this way 
compared well with the binding constant determined with isothermal 
titration calorimetry (ITC) and a UV assay (Chapter 2). Competition 
experiments were performed to observe the influence of the 
cyclooctyne-derived triazole moiety on the affinity between ligands 1 or 3 and papain (Figure 4.5, Figure 
4.6 and Table 4.2). These experiments showed that the influence of the BCN moiety is minimal, which is 
consistent with results from a UV assay (Chapter 2). The papain experiments showed that a cyclooctyne-
modified surface could be effectively applied for the reagent-free attachment of an azido-containing 
ligand and that binding to the analyte is warranted. It was established that up to 150 experiments could 
be performed without detectable loss of quality of the surface (Figure 4.7). 
 
a)     b) 
  
Figure 4.7 (a) SPR signals after 100 measurements on the CM5 chip modified via SPAAC. Papain concentrations from 100 to 2000 
nM were added to the surface; (b) Langmuir binding on the same chip after 20 and 100 measurements. Although the Bmax is lower, 
the KC is for both measurements 350 ± 50 nM. 
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4.2.2 GFP Model System 
In order to further broaden the scope of ligand 
immobilization by SPAAC, attachment of an azide-
containing protein was next explored. To this end, an 
engineered green fluorescent protein (GFP), containing a 
single azide functionality, an N-terminal His-tag and a C-
terminal FLAG-tag, was prepared.32  
To introduce an azide into GFP, an azidonorleucine residue 
(Anl) was incorporated into GFP by employing residue-
specific non-canonical amino acid incorporation to 
produce Anl-GFP.32 Here, Anl was used as a methionine (Met) analogue and to reduce the number of 
azides in the protein, an engineered GFP gene with only one methionine codon (start codon) was used. 
The GFP was also equipped with an N-terminal histidine and a C-terminal FLAG-tag for purification and 
detection (Figure 4.8). Because Anl is not a substrate for wild-type methionyl-tRNA synthetase (MetRS), a 
mutant MetRS (L13N, Y260L, H301L; NLL-MetRS), which is able to efficiently activate Anl, was used for the 
expression of the engineered GFP in methionine auxotrophic E. coli.33 
The expression was carried out as described by Tirrell et al.33 After expression of Anl-GFP and Met-GFP 
(control protein) the proteins were purified via affinity chromatography with a Ni2+NTA column. The purity 
was verified by SDS-PAGE (Figure 4.9a) and the exact mass was determined by mass spectrometry (Figure 
4.9b). The deconvoluted masses corresponded to the theoretical masses (Anl-GFP = 29018.4 Da and Met-
GFP = 28995.4 Da). The absorbance spectrum of Anl-GFP was measured (Figure 4.9c) and a yield of 10–25 
mg/L of culture was determined for Anl-GFP using the molar extinction coefficient.  
a) 
 
b)  
 
c)
 
d)  
 
Figure 4.9 Coomassie-stained SDS-PAGE (a) and mass spectra multiply charged ion series (left) and deconvoluted total mass 
spectrum (right) of purified Anl-GFP (b) and Met-GFP (d). The absorbance spectrum of Anl-GFP (c). 
 
 
Figure 4.8 Graphical representation of Anl-GFP 
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a) 
 
 
b) 
 
  
Figure 4.10 Analysis of reaction of purified Anl-GFP (solid lines) and Met-GFP (dashed lines) with BCN-functional 
lissamine rhodamine (LisRhoB, 4) by Coomassie-stained and fluorescent SDS-PAGE (a) and by SEC (b). The green lines 
correspond to the GFP absorbance at 490 nm and the red lines correspond to the LisRhoB absorbance at 570 nm. 
 
 
 
Figure 4.11 BCN-PEG3-NH-lissamine rhodamine B conjugate 4 
 
To demonstrate the reactivity of the azide in Anl-GFP, a conjugation reaction with BCN-PEG3-NH-lissamine 
rhodamine B conjugate (BCN-LisRhoB (4), Figure 4.11) was performed. The product was then analyzed by 
SDS-PAGE (Figure 4.10a) and size exclusion chromatography (SEC) on a Superdex 75 3.2/30 column 
(Figure 4.10b). In the fluorescence analysis of the SDS-PAGE a fluorescent band corresponding to the 
labelled product was observed for Anl-GFP, while no reaction was observed for the control protein. The 
same result was found in the SEC analysis. GFP eluted from the column at a volume of 1.2 mL and only in 
the case of Anl-GFP coelution of 4 was observed, showing that 4 is attached to Anl-GFP. 
 
Having obtained the azide-functionalized GFP, the cyclooctyne surface was prepared using the same 
protocol as for the papain experiments, only in this case a PBS measuring buffer was used. To this end, a 
protein solution was prepared in 10 mM formic acid buffer (pH 4) and SPAAC reaction was performed for 
20 minutes to ensure effective attachment. A Langmuir binding study with different antibodies 
corroborated the fact that GFP was effectively immobilized. Two different anti-GFP, an anti-His and an 
anti-FLAG antibody were used (Table 4.3). For all four antibodies good to excellent KD values were found 
in the low nanomolar range. The same control experiment as for the papain experiments was performed, 
in which GFP without an azide (Met-GFP) was immobilized following the amine immobilization protocol. 
Similar KD constants were found as for our new SPAAC strategy. However, one important difference 
observed was that GFP immobilized by the EDC/NHS strategy led to a significantly enhanced loss of 
material (50%) from the surface after 50 measurements, compared to a loss of only about 20% for the 
SPAAC strategy (Figure 4.12). It can thus be concluded that the SPAAC strategy leads to a more stable and 
robust surface for both peptide and protein-based ligands.  
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Table 4.3 KC (nM) values obtained of different antibodies for Anl-
GFP and Met-GFP 
Antibody Anl-GFP Met-GFP 
Anti-His 32.2 ± 4.8 23.8 ± 2.5 
Anti-GFP (1) 61.7 ± 8.5 71.0 ± 8.7 
Anti-GFP (2) 39.7 ± 3.7 27.0 ± 2.5 
Anti-FLAG 33.9 ± 6.2 29.8 ± 4.7 
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Figure 4.12 Stability check of SPR surfaces for both immobilization strategies. For Met-GFP, which was immobilized via EDC/NHS 
coupling, more material is lost after 50 measurements, than with Anl-GFP, which was immobilized via SPAAC.  
4.3 Conclusions 
We have successfully demonstrated that functionalization of SPR sensor surfaces via strain-promoted 
cycloaddition leads to a versatile, modular system for the efficient and reagent-free attachment of ligands. 
A synthetic azidopeptide ligand was effectively immobilized to the SPR chip, leading to a highly robust 
platform that could be applied for the repeated determination of affinity for papain by standard protocols. 
An azide-containing protein was immobilized in similar fashion and effectively detected and quantified by 
binding of a range of antibodies. These experiments demonstrate the value of SPAAC-based strategies for 
the immobilization of different types of azide-containing ligands, including those that do not contain an 
amine for attachment via amide bond formation or, more commonly, feature multiple amino functions 
like in the case of proteins and the majority of peptides. In such cases, it must be noted that several 
strategies were recently developed for the selective introduction of an azide into a protein, either by 
chemical modification34 or by enzymatic, metabolic or genetic means.24 In this respect, the here presented 
methodology also compares favorably to an analogous procedure recently reported, based on the strain-
promoted reaction of trans-cyclooctenes (TCO) with tetrazines,35 because the site-specific introduction of 
either of these components into peptides or proteins is more cumbersome (or impossible). Although the 
latter TCO-tetrazine cycloaddition is in principle much faster than the cyclooctyne–azide reaction, the 
reaction rate for immobilization is not a limiting factor, while our system has the distinct advantage of 
easier accessibility and stability of both BCN (commercially available or readily prepared) and azide. 
Moreover, we recently demonstrated that (4+2) cycloaddition between BCN and tetrazines takes place 
with near similar reaction kinetics as TCO-tetrazine cycloaddition,25 thereby further enhancing the 
potential usefulness of BCN-modified SPR surfaces.  
In conclusion, the BCN-modified SPR chips described here are simple and stable modular systems that 
may find broad applications for reagent-free immobilization of azide-containing ligands. In addition, it is 
noted that strain-promoted cycloadditions with other 1,3-dipoles is also feasible, such as nitrones20 and 
nitrile oxides,21 while the recently reported cycloaddition of BCN to tetrazines by (4+2) cycloaddition may 
further extend the applicability of BCN-modified SPR chips for the controlled immobilization of peptides, 
proteins or other (bio)molecular structures.  
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4.5 Material and Methods 
General – All chemicals, enzymes and the anti-His antibody were purchased from Sigma-Aldrich, except 
BCN-POE3-NH2 and BCN-PEG3-NH-lissamine rhodamine B conjugate (SynAffix BV, The Netherlands). All 
other antibodies were purchased from Santa Cruz Biotechnology (GFP(1) = SC-5385; GFP(2) = SC-9996; 
anti-FLAG = SC-807). Aqueous solutions were prepared with pure water (18.2 MΩ.cm resistivity; Milli-Q 
station, Millipore). For SPR experiments, sensor chip CM5 (research grade) and an amino coupling kit 
composed of EDC, NHS and ethanolamine hydrochloride (pH 8.5) were purchased from GE Healthcare. 
Plasmids coding for L13N, Y260L, H301L MetRS (NLL-MetRS) and GFP were a kind gift by D.A. Tirrell.  
Protein analyte – For daily activation of papain, a 10 µM solution was prepared in a 0.1 M sodium 
phosphate buffer (pH 6.5), containing 2.5 mM EDTA and 15 mM DTT. The solution was incubated at 25 °C 
for 1 h and the activated enzyme was kept on ice. In this way stability was ensured for 6–8 h. Further 
dilutions were made in a 0.1 M sodium phosphate buffer (pH 6.5), containing 2.5 mM EDTA, 150 mM NaCl 
and 0.005% tween-20 (running buffer A).  
Monoclonal anti-polyhistidine was diluted in a PBS buffer (pH 7.0) containing 0.005% tween-20 (running 
buffer B). Working dilution samples were stored at room temperature for a maximum of 12 hours.  
Ligands – Detailed procedures for synthesis of the ligands are described in Chapter 2.  
Surface Plasmon Resonance – SPR measurements were performed on a double channel cuvette-based 
Autolab Esprit SPR instrument (Metrohm Autolab, Utrecht, The Netherlands) equipped with a CM5 sensor 
chip (GE Healthcare). All samples and buffers were degassed prior to use.  
Functionalization by amide coupling: standard EDC/NHS coupling chemistry 
was performed. For the study with papain, nitrile ligand 3 was immobilized in 
the sample cell and in the reference cell hydroxyl ligand 7 was immobilized. 
For the ligand immobilization, a 0.1 mg/mL solution in 10 mM maleic acid (pH 
6.0) was allowed to react with the activated ester surface for 10 minutes. For 
the study with Met-GFP, running buffer B was used. For the immobilization of 
Met-GFP a solution of 0.1 mg/mL in 10 mM formic acid buffer (pH 4.0) was 
used. After ligand immobilization, 1 M ethanolamine was added for 10 
minutes to the sensor surface to block remaining free ester groups, in both 
sample and reference cells.  
Functionalization by SPAAC: BCN-functionalized surface was prepared with 
BCN-POE3-NH2 8 using the same EDC/NHS protocol as described above. The 
second step involved the immobilization of the azide-containing ligands. For 
the study with papain, ligand 1 was immobilized in the sample cell, using a 
solution of 0.1 mg/mL ligand in running buffer A for 15 minutes, and 
remaining free cyclooctynes were blocked with 2-azidoethanol (0.1 mg/mL). For the reference cell, 2-
azidoethanol (0.1 mg/mL) in running buffer A was used. For the study with Anl-GFP, running buffer B was 
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used. For the immobilization of Anl-GFP a solution of 0.1 mg/mL in 10 mM formic acid buffer (pH 4.0) was 
used. Remaining free cyclooctynes were blocked with 2-azidoethanol (0.1 mg/mL). The reference cell was 
treated as described above with 2-azidoethanol.  
The net SPR signal is the difference in SPR angle between sample and reference cells, expressed in m°. SPR 
experiments were performed in duplicate at 25 °C in running buffer. Regeneration of the chips was 
achieved with a fresh 25 mM NaOH solution using a double 30 s injection. 
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Chapter 5 
Phage Display as a Tool to Select  
Peptide Ligands for Peanut Allergens  
 
 
 
 
 
 
 
 
 
Peanut allergens are responsible for highly severe cases of food allergy. For the development of a biosensor, 
binding ligands for peanut allergens need to be found. Phage Display has been used to select new, potential 
binders for four peanut allergens, Ara h 1, 2, 3 and 6. Different panning rounds were performed and 
subsequently, cosmix-plexing® provided a new library for follow-up panning rounds. Analysis of the enriched 
sublibraries was performed with phage ELISA and fishing experiments.  
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5.1 Introduction 
As described in Chapter 1, peanut allergens are responsible for highly severe cases of food allergy1-7 and a 
sensitive detection system for household use is therefore of high essence. For the purpose of 
development of a biosensor system, high-affinity and selective ligands for the four major peanut allergens 
need to be found first. Commercially available detection kits are almost exclusively based on ELISA and 
therefore require antibodies to detect specific peanut allergens. Besides sensitivity, an important 
prerequisite for the projected Unihealth biosensor is the reduction of production costs where possible. 
Therefore, the use of small peptide ligands is preferred over the use of the more expensive antibodies.  
There are various ways to find small ligands for target proteins, following both chemical and more 
biological approaches. The most common and well-established method of identifying potential ligands is 
high-throughput screening (HTS). HTS is based on the screening of large libraries of chemically 
synthesized small molecules, which are screened against various target proteins to find ligands with the 
desired mode of action.8 One of the disadvantages of HTS is the high frequency of false-negative hits, 
leading to the exclusion of promising lead ligands.9  
A well-known and extensively studied biological technique to select peptides, proteins or antibodies as 
ligands, or ligand candidates, for a target protein is phage display.10,11 Phage display is based on the 
cloning of a naive gene library of various peptides or proteins into the genome of filamentous phage, 
leading to the display of the gene products on the virus’ particle surface.11–14 From such phage libraries, an 
in vitro selection technique can extract ligands for the target protein with the desired properties. The latter 
selection is called panning and is of great importance for the successful execution of the phage display 
procedure. Before the results regarding the discovery of peptide targets for peanut allergens are 
described, first a brief overview of the phase display methodology is given, with emphasis on the applied 
panning technique.  
5.1.1 Library Design 
The generation of a phage library starts with the construction of a large number of oligonucleotides 
encoding for a wide variety of peptides.15 This gene library is fused to a gene coding for a coat protein 
from the phage particle in a phage or phagemid vector. When a phagemid vector is used, phage particle 
will only be released from E. coli after infection with a helper phage.  
Phage particles are thus formed that contain the peptide ligand phenotype (which is displayed at the 
phage surface) as well as the genotype (gene sequence of the ligand). This combination allows the 
identification of binding clones after the selection by DNA sequencing; the recovered clones can 
furthermore be re-grown to create a new and enriched library.  
From all commonly used bacteriophages, filamentous phage and in particular M13 have been used most 
often to construct a library.12,16 The phage particles consist of five coat proteins (Figure 5.1, left), a major 
coat protein (pVIII) and four minor coat proteins (pIII, pVI, pVII and pIX).17 The advantage of using M13 
phage is that the small genome and the structure of the coat proteins tolerate insertions in many regions. 
After modification of the coat proteins, in most cases retention of infectivity can be observed. The 
production of phage particles in E. coli furthermore does not lyse the bacteria (non-lytic phage), but the 
phage particles are secreted into the medium. A final advantage is the phage particle’s stability in a broad 
range of selection conditions.  
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Although in theory all five coat proteins can be used to display the ligands, the most commonly used coat 
proteins are pVIII and pIII for N-terminal display of proteins.12,18 C-terminal linkage is also possible and 
particularly desirable for display of polypeptides encoded by cDNA fragments, since inclusion of the stop 
codon at the end of the cDNA will not prevent display.17,19 For the CPL3 library, which has been applied for 
the experiments described in this chapter, the pIII coat protein is used to display the peptides. pIII has a 
broad tolerance for large gene/protein insertions, a wide availability of suitable vectors and last, it is 
compatible with monovalent display.17,20,21 The latter property is of particular importance as five copies of 
the pIII minor coat protein are found on the phage particle. In polyvalent systems, up to five ligands can 
thus be displayed on the surface (using pIII) and then avidity effects can lead to the undesired selection of 
low-affinity ligands.14 Furthermore, polyvalent systems reduce the infectivity, since pIII is required for 
attachment and propagation in E. coli. To overcome unwanted infectivity, monovalent display can be 
achieved by applying phagemid vectors with low expression levels of the gene III fusion protein,22,23 
thereby reducing the ratio of fusion protein versus the native pIII. A suitable combination of promoter and 
suppressor in the plasmid increases the probability of obtaining a single pIII peptide per phage particle. By 
fine-tuning the promotor-suppressor ratio, a Poisson distribution is obtained of phage particles, 
containing a certain percentage of single displayed ligand, a minor number of phages with two displayed 
ligands and most of the phagemids are wild-type pIII, thus display no ligand at all.17,20,21 The latter ratio 
obviously also depends on the variance in the expression of individually fusion proteins. 
  
Figure 5.1 (left) Schematic picture of a M13 filamentous phage; (right) schematic overview of panning (T4 phage is represented 
instead of the used fd phage). In the first step an incubation step of the phage library with the target protein is involved, after 
which the non-bound phage are washed away. Amplification of the eluted phage will give a new enriched library. A agar plate for 
single colonies of bacteria is prepared, in order to analyze the individual clones.12 
5.1.2 Selection Rounds 
After generation and packaging of the library, the selection/panning rounds start (Figure 5.1, right). It is 
important to take into account that the conditions of the selections should be close to the final application 
of the ligand. For example, the highest-affinity ligand identified at 4 °C is not necessarily the optimal 
ligand for binding at room temperature. The same is true for pH, salt concentrations etc. 
In most cases the panning requires pre-immobilized targets (proteins), for example adhered to a 96-well 
plate or coupled to magnetic beads. Next, the phage library will be incubated sufficiently long to allow 
binding of phage without losing for example sensitive proteins by denaturation. Non-binding phage are 
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removed by washing and the remaining phage particles can be eluted and used to re-infect E. coli to allow 
the amplification of phage clones and to result in a new and enriched library. Furthermore, individual 
colonies can be grown on an agar plate, e.g. for titration and/or single clone analysis. With the enriched 
library, another round of panning can be performed to further select the best binder.  
5.1.3 Cosmix-Plexing® 
Physical and biological constraints restrict ordinary libraries to a size not covering more than 5mer random 
peptide. Cosmix-plexing is a recombination technique to generate novel diversity in the peptides from 
binding motifs selected in a first panning round. During standard selections in most cases a few clones can 
become dominant, while many binders are lost during selection rounds with increasing stringency. To 
make an improved library that can give rise to better binders the cosmix-plexing® technique can be 
implemented (Figure 5.2).15 In short, this recombination technique enzymatically cleaves the plasmid DNA 
at a Type IIs restriction site (Figure 5.3) within the peptide gene. The design of the randomized peptide 
gene allows only directed (correct) religation and yields a randomly assorted concatamer. The 
concatemerized DNA can then be cut with a second restriction enzyme and then circularized by DNA-
ligase to yield recombinant phagemid DNA, which in turn is used to transform competent cells for the 
generation of a new library with improved sequences. The improved sequences contain combined 
structural motifs from preselected (weak) binders, thereby affording novel diversity in an optimized 
library. 
The advantage of using cosmix-plexing® compared to standard selections without further improvement of 
the peptide genes, is that already after the first selection round, towards the target protein are enriched in 
the new library, leading to recombined peptide sequences that allow the generation of new and 
potentially improved target protein binders. 
 
Figure 5.2 The cosmix-plexing® protocol presented by Collins et al.15 Recombination between variant clones is achieved through 
enzymatic cleavage and ligation steps as shown. The circles represent phagemid DNA, isolated as plasmid. The color-coding of 
the DNA represents different variant clones. The left and right fragments of the clones are recombined yielding N2 variants from 
an initial pre-selected population of N clones. The orientation of the fragments is maintained by using predetermined sets of base 
pairs at the cohesive ends generated by cleavage at the recombination. 
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Figure 5.3 The restriction sites of the CPL3 library for type IIs restriction enzymes.15  
To use the cosmix-plexing® protocol, the phage library needs to have some dedicated features. There 
must be at least one class IIs restriction site located neighboring a hypervariable sequence cassette so a 
cleavage site can be introduced between two hypervariable cassettes. To ensure correct religation, the 
sequence of the two-base pair cohesive-end generated at the abovementioned cleavage site should be 
limited to a single sequence or subset. A second restriction site should be present elsewhere, to cleave the 
concatamer (Figure 5.2). To this end, a CPL3 library was developed by Collins et al.15  
5.2 Materials and Methods 
5.2.1 Plasmids, Phage and Proteins 
Target Proteins 
Ara h 1, 2, 3 and 6 were obtained from TNO Zeist.  
 
Bacterial Strains 
E. coli strain  Genotype/Phenotype 
TG1   F’ [traD36 proAB+ lacIq lacZΔM15]supE thi-1 
Δ(lac-proAB) Δ(mcrB-hsdSM)5, (rK−mK−) 
TG1(λ)   F’ [traD36 proAB+ lacIq lacZΔM15]supE thi-1 
Δ(lac-proAB) Δ(mcrB-hsdSM)5, (rK−mK−), λ+ 
 
Bacteriophage 
Bacteriophage  Genotype/Phenotype 
M13K07 KmR-Gem (Tn903) plasmid replication origin (p15A) integrated in origin of 
replication 
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Figure 5.4 Map of M13KO7 helper phage.  
Plasmid 
Plasmid   Genotype/Phenotype 
pROCOS-CPLC  ampicillin resistance gene 
pcI857 cIts857 repressor gene, suppressor for PL promoter on pROCOS, kanamycin-
resistant 
  
Figure 5.5 Left) map of pROCOS-CPL3; right) map of pcI857. Length 4182 bp.24  
Phagemid-Displayed Peptide Library 
In the experiments the CPL3-library was used, containing about 1010 individual clones. The CPL3 peptide 
library is composed of random 15-mer hypervariable linear peptides in three recombinant cassettes, 
which can be cleaved by two different restriction enzymes (Figure 5.3). The peptides are fused to the 
phage at the N-terminal part of the major coat protein pIII.15  
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5.2.2 Chemicals/Buffers/Mediums 
General 
All chemicals were of analytical quality and purchased from Sigma-Aldrich or Carl Roth, unless stated 
otherwise. Aqueous solutions were prepared with deionized water, autoclaved and sterile filtered. Anti-
M13K07-HRP from chicken was purified with HPLC and subsequently HRP was introduced using the 
peroxidase-labeling kit from Roche. DNA loading dye was purchased from Thermo Scientific (6x orange 
DNA loading dye, R0631). 
 
Medium 
dYT-Medium (per L): yeast extract (10 g), bacto tryptone (16 g), NaCl (5 g), H2O (to 1 L, autoclaved). 
SOC-Medium pH 7.0 (per l): yeast extract (5 g), bacto tryptone (20 g), NaCl (0.5 g), 1 M KCl (2.5 mL), H2O 
(to 1 L, autoclaved). 
M9 medium (per L). All solutions were first sterile filtered and the appropriate amounts of the solutions 
were mixed at 50 °C: 2 x phosphates (Na2HPO4 1.86 g, KH2PO4 0.93 g), 1,000 x calcium chloride (CaCl2 20 
g), 100 x sulfates (NH4SO4 300 g, MgSO47H2O 20 g), 10,000 x traces (boric acid 26.8 g, MnCl2H2O 18.1 g, 
ZnSO47 H2O 2.2 g, ((NH4)2MoO4) 3.9 g, CuSO45H2O 0.79 g, Co(NO3)26H2O 0.49 g), 10,000 x FeEDTA 
(FeSO4 6 g, citric acid 6 g, Na2-EDTA 1 g), 1,000 x thiamine (thiamine (FS) 1 g), glucose 50% (w/v) 10 mL 
and H2O (to 1L).  
 
Buffers 
1 x PBS buffer (pH 7.4, 1 L): NaCl 8 g, KCl 200 mg, Na2HPO4 1.44 g, KH2PO4 240 mg and H2O (up to 1 L). 
Wash buffer: 0.05%–0.5% Tween®20 in 1 x PBS. 
Blocking buffer: 1 % ovalbumin in 1 x PBS. 
50 x TAE buffer: trisbase 200 g, acetic acid 57.1 mL, 0.5 M EDTA 100 mL, H2O (up to 1 L). 
PEG/NaCl: 200 g/L PEG 8000 + 145.25 g/L NaCl + H2O (up to 1 L). 
5.2.3 Devices  
Centrifuges: Avanti® J-26 XP, Beckman Coulter®; Biofuge primo R, Hereaus;, Micro 200 R, Hettich 
Centrifuges. Photometer: BioPhotometer, Eppendorf; spectral photometer NanoDrop ND-2000, Thermo 
Scientific. Microplate reader: infinite M200, Tecan. Incubators: circulating air incubator, Heraeus Thermo 
Scientific; incubator shaker Innovar® 40R, New Brunswick Scientific, Edison.  
5.2.4 Cultivation of Bacteria 
Bacteria were cultivated in dYT medium, if necessary supplemented with the appropriate antibiotic. 
Individual colonies of all strains were maintained by plating out the respective strain out on agar plates 
containing the suitable antibiotic. F´ factor-carrying strains were kept on M9 plates. Other strains were 
grown on dYT agar plates. The dYT agar and M9 plates were supplemented with the appropriate 
antibiotic. The agar plates were stored at 4 °C for up to 2 weeks. For prolonged storage of bacteria, 500 µL 
of a fresh overnight culture were mixed with 500 µL sterile glycerol (50%) in sterile tubes. The tubes were 
frozen in liquid nitrogen and stored at –80 °C. 
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5.2.5 Determination of Phagemid Titer 
To determine the number of infective phage particles, TG1 (pcI857) cells were infected with serially 
diluted phagemid particles. The mixture was spotted and grown on selective agar plates. The colonies 
were counted the following day and the concentration of the original phage solution could be calculated. 
dYT medium (10 mL) was inoculated with a single colony of TG1 (pcI857) and grown at 37 °C. For a 10-fold 
serial dilution, 10 µL of a phage mixture were diluted in 90 µL sterile PBS in 96-well microtiter polystyrene 
plates. 10 µL of diluted phage solution were mixed with 90 µL of a freshly grown bacterial culture (OD600 
0.4 – max. 1.0) and incubated 30–60 minutes at 37 °C to allow infection and expression of the resistance 
gene. Then the solution was mixed well and 3 µL of each dilution (at least duplicates) were spotted on dYT 
agar plates containing 200 µg/mL ampicillin. The plates were left for 5 min with open lids in the clean 
bench to ensure drying of the spots. Afterwards plates were incubated overnight at 30 °C. On the next day 
the colonies were counted and the number of colony-forming units (cfu) was determined. 
5.2.6 Affinity Selection/Panning 
5.2.6.1 Binding of Ara h 1, 2, 3 and 6 to Magnetic Beads 
For one panning round with four different Ara proteins and one control sample, Dynabeads® (Invitrogen, 
M270, carboxylated surface) were coated with the appropriate Ara proteins. Thus, 60 µL of beads were 
washed five times with 1 mL PBS buffer, activated with EDC/NHS (200 µL 0.4 M EDC, 200 µL 0.1 M NHS) for 
10 minutes, washed two times with 1 mL PBS buffer and one time with 1 mL 5 mM sodium acetate buffer 
(pH 4). Then 240 µL of sodium acetate buffer was added and the activated beads were divided into smaller 
portions. Per 10 µL protein sample (1 mg/mL concentration), 40 µL activated beads were added and this 
mixture was incubated for 45 min at rt on a rotating wheel. For the control samples, no protein was added; 
only 45 min incubation with PBS buffer was performed. After incubation, the beads were washed one time 
with 1 mL PBS and 50 µL of 0.1M ethanolamine (pH 8.5) was added and incubated for 15 minutes at rt, 
after which the beads were washed three times with PBS. The beads were further incubated using 300 µL 
1% ovalbumin solution in PBS (blocking buffer) for 1 hour at rt on a rotating wheel. Finally, the beads were 
washed five times with 1 mL PBS. The prepared beads were either used directly in a panning round, or 
stored in 200 µL PBS at 4 °C for one week maximum. 
Then, 200 µL of the phage library in blocking buffer was added to the beads and the mixture was 
incubated for 2 hours at rt on a rotating wheel. After incubation, the beads were washed five times with 
500 µL PBS and 200 µL PBS was added in the end. The bound phage were not eluted, but directly added to 
the TG1 cells (see next section).  
Two to three selection rounds were performed. In the first selection round 1 x 1012 cfu of the CPL3 library 
was used, in the following selections rounds 108 to 1010 cfu phage were used. The concentration of 
Tween®20 in the washing buffer was increased from 0% in the first round to 0.5% in the last round.  
5.2.6.2 Infection of TG1 (pcI857) Cells  
TG1 (pcI857) cells were grown in dYT at 37 °C until an OD600 between 0.5–1.0 was reached. The recovered 
phage were titered prior to amplification after every round of panning (see section 5.2.5). Then, the cells 
were incubated with phage for 20 min at 37 °C with agitation. After incubation, the solution was 
immediately poured on large dYT-agar plates containing 200 µg/mL ampicillin. After drying the plates 
under the clean bench, these were incubated overnight at 30 °C. After the overnight incubation, two 
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different protocols can be performed. One is packaging of the phagemids to obtain a new sublibrary 
(section 5.2.6.3), the other is DNA production (section 5.2.6.4).  
5.2.6.3 Packaging of Phagemids with Helper Phage 
After overnight incubation the colonies were resuspended in 25 mL dYT containing 1 x 1010 cfu/mL 
M13K07 helper phage. The cells were diluted in 25 mL dYT (200 µg/mL ampicillin and 1 x 1010 cfu/mL 
M13K07) to obtain a cell density of OD600 0.5. The cells were incubated in a baffled culture flask for 1 h at 
37 °C with agitation. Afterwards, the culture was grown for maximum 13 h at 30 °C with agitation. 
5.2.6.4 DNA Production for Cosmix-Plexing® or Sequencing 
After the first selection round with the CPL3-library, the cells were diluted in 200 mL dYT, containing 200 
µg/mL ampicillin, to obtain a cell density of OD600 0.5. The cells were incubated for 4 h at 30 °C with 
agitation. After incubation, the culture was centrifuged at 5,000 x g for 30 min at 4 °C. The supernatant was 
removed and the cell pellet was stored at –20 °C. 
5.2.6.5 Purification of Phage 
The cultures containing infected bacterial cells were centrifuged at 20,000 x g for 15 min at 4 °C to 
sediment the cells. The supernatant was added to a ¼ volume of cold PEG/NaCl solution and incubated 
for at least 1 h on ice. The phage particles were collected in a small pellet by centrifugation (30 min, 4 °C, 
20,000 x g). After removing the supernatant, the pellet was resuspended in 1 mL PBS. The solution was 
centrifuged at 20,000 x g for 10 min to remove insoluble substances. The supernatant was recovered and 
incubated with ¼ volume of PEG/NaCl solution for at least 15 min on ice. The phage were collected again 
by 30 min centrifugation at 20,000 x g, 4 °C. The remaining pellet of phage particles was resuspended in 1 
mL PBS. The titer of infective phage was determined according to section 5.2.5. The purified phage 
suspension was stored at 4 °C for several days. 
5.2.7 Single Clone Packaging 
A single colony of TG1 (pcI857) carrying the phagemid vector was picked and grown in 25 mL or 2 mL dYT 
media with 200 µg/mL ampicillin and 1010 cfu/mL M13K07 over night at 37 °C with agitation. The culture 
was centrifuged 15 min at 4 °C, 20,000 x g. The supernatant, containing the phage, was stored at 4 °C for 
several days or the phage were purified according to section 5.2.6.5. 
5.2.8 Handling of DNA — General Methods 
5.2.8.1 DNA Isolation and Purification 
DNA purification and isolation were performed with the Mini/Midi DNA and PCR purification kits 
according to the instruction of the manufacturers (ZymoResearch, Qiagen). 
5.2.8.2 Determination of DNA Concentration 
The DNA concentration was determined with a NanoDrop ND-2000 spectral photometer according to the 
manufacturer´s instruction. 
5.2.8.3 DNA Sequencing Analysis 
Sequencing of the pROCOS-CPL3 plasmid DNA was performed by GATC with primer PL1-F 
(ATAGATAACCATCTGCGGT). Vector NTI software was used to perform analysis of the DNA and protein 
sequences. 
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5.2.8.4 Agarose Gel Electrophoresis 
Plasmid DNA was separated on horizontal agarose gels. The DNA samples were separated in 0.8% agarose 
gels containing 0.5 µg/mL ethidium bromide. The sample volumes ranged from 1 to 20 µL mixed with 0.5 
vol of 2 x loading sample buffer. A suitable marker was loaded. Electrophoresis took place at 110 V, 400 
mA for 40 min. The different bands were detected on an UV transilluminator and photographed with a gel 
imager from Intas. 
5.2.9 Recombination of DNA – Cosmix-Plexing® 
5.2.9.1 Cosmix-Plexing® 
Cosmix-plexing® was performed as follows: the isolated and purified plasmid DNA of sublibraries Ara h 1 
P1, Ara h 2 P1, Ara h 3 P1 and Ara h 6 P1, gained after the first panning round on Ara h 1, 2, 3 and 6, was 
digested at 37 °C overnight with BpmI at a concentration of 0.5 u/µg DNA. The digestion resulted in 
cleavage of the hypervariable region. The restriction enzyme was inactivated by heating for 20 min at 
60 °C. To form a concatamer, the digested DNA was ligated by adding T4-DNA ligase at a concentration of 
ca. 1 u/µg DNA. A test step was performed to determine the adequate ratio of enzyme and amount of 
DNA. After incubation at 4 °C for 4 h, the enzyme was inactivated by heating for 10 min at 65 °C. A 
digestion step with Bgl I (1 u/µg DNA) followed to cleave the concatamer into single linear plasmid 
molecules. Incubation took place at 37 °C overnight. The Bgl I enzyme was inactivated for 20 min at 65 °C. 
To obtain monomeric ccDNA, the DNA was mixed with T4-ligase at a concentration of ca. 1 u/10 µL DNA 
solution. A test step was performed to determine the adequate ratio of enzyme and amount of DNA. The 
solutions were incubated over two days at 4 °C. The ligase was inactivated at 65 °C for 25 min. Each 
digestion and ligation step was verified by electrophoresis according to section 5.3.8.4. The recombined 
plasmid DNA was purified with a DNA purification kit according to Qiagen and the DNA concentration was 
determined according to section 5.2.8.2. 
5.2.9.2 Preparation of Electro-Competent Cells 
A single colony of TG1 (λ) was grown overnight in 110 mL dYT at 37 °C with agitation. 25 mL of the 
overnight bacterial culture were diluted in 475 mL of pre-warmed dYT medium. The culture in a two liter 
baffled culture flask was incubated at 37°C, with agitation until the cultures reach an OD600 of 0.6–1.0. 
Afterwards the culture was transferred to ice-cold centrifuge bottles. The cells were collected by 
centrifugation at 4,700 x g, at 4 °C for 30 min. The cell pellet was resuspended in 150 mL ice-cold 10% 
glycerol. Two subsequent washing steps with 50 mL ice-cold 10% glycerol were performed. The cell pellet 
after the second wash step was resuspended in ice-cold 10% glycerol to reach an OD600 of 1.5–3.0 x 1011 
cells/mL. The suspension was aliquoted, frozen in liquid nitrogen and stored at –80 °C. All steps were 
carried out at 4 °C. 
5.2.9.3 Electroporation 
2.2 x 1010 cells were mixed with 50 ng recombined plasmid DNA and incubated on ice. The mixture was 
transferred into an ice-cold 1 mm electroporation cuvette. Electroporation was performed with the 
following parameters: 1800 V, 25 µF and 200 Ω. The time constant ranged between 4.5 and 5.2 depending 
on the purity of the DNA (salt). The transformed solution was mixed with 450 µL SOC medium and 
transferred into a sterile vessel. For the generation of a new library, several electroporations were serially 
performed, to obtain a large library. The cell suspension was grown at 37 °C for one hour. The bacteria 
solution was plated out on large dYT agar plates containing 200 µg/mL ampicillin. Incubation took place 
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over night at 30 °C. Serial dilutions were also spread onto dYT agar plates, containing 200 µg/mL 
ampicillin, in order to estimate the transformation efficiency. 
5.2.10 Characterization of Selected Single Clones 
5.2.10.1 Phage ELISA 
To test the binding of individual clones to Ara h 1, 2, 3 or 6, phage ELISAs were performed. To this end, 500 
ng of protein was coated on Immuno™96-well plates with maxisorp™surface area from Nunc. After 
overnight incubation at rt with agitation, the wells were washed briefly three times with wash buffer. 
Afterwards the wells were blocked with 200 µL blocking buffer (1% ovalbumin in PBS) for 1.5 hours at rt 
with agitation. Phage dilutions in blocking buffer were prepared to a final amount of 109 to 1010 purified 
phage particles and the wells were incubated with 100 µL phage particle or 100 µL blocking buffer, for the 
negative control, and incubated for 1.5 hours at rt with agitation. After three wash steps with wash buffer, 
wells were incubated with 100 µL 1:1000 dilution of anti-M13KO7-HRP antibody for 1 hour at rt with 
agitation. The wells were then washed twice with washing buffer and once with PBS, after which 100 µL 
TMB substrate was added. After a 30 min incubation period in the dark, the reaction was stopped by 
adding 50 µL of 1M sulfuric acid. The absorbency was measured at 450 and 520 nm with a microplate 
reader.  
5.2.10.2 Fishing Experiments 
To test the binding of individual clones to Ara h 1, 2, 3 or 6, fishing experiments with magnetic beads 
(Dynabeads® M-280 streptavidin) were performed. A set of 50 peptides (positive hits by phage ELISA) was 
purchased by GL Biochem (Shanghai) Ltd. Per 1 µL beads, 2 pmol biotinylated peptide were immobilized 
and per fishing experiment 5 µL beads were used. The beads were washed three times with PBS buffer, 
after which they were incubated with the peptide solution for 1 hour at rt with agitation. After incubation, 
the beads were washed twice with PBS and the peptide-beads were either directly used in the fishing 
experiment or stored at 4 °C for max 1 month. To the functionalized beads 5 µL of the appropriate peanut 
protein (1 mg/mL) was added and 75 µL PBS and the mixture was incubated for 30 min at rt with 
agitation. Then the beads were washed with washing buffer (0.1% Tween®20 in PBS) and loading buffer 
for SDS-PAGE gel was added. The samples were heated for 5 min at 95 °C and subsequently loaded on a 12 
or 15% SDS-PAGE gel.  
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5.3 Results and Discussion 
5.3.1 Panning 
The first stage of selecting peptide ligands for peanut allergens involves the panning process. To this end, 
M270 magnetic beads from Invitrogen were selected as solid support for immobilization of the Ara h 1, 2, 
3 and 6 proteins, for numerous reasons. Magnetic beads have a much larger and better accessible surface 
for phage particles, a low protein binding surface and are more efficiently washed, compared to 96-well 
plates or immunotubes. In addition, phage rescue can be carried out without a second elution step of the 
phage particles by direct infection of an E. coli culture.  
Figure 5.6 gives a schematic overview of the selection experiments that have been performed with the 
CPL3 library for the four different target proteins, Ara h 1, 2, 3 and 6.  
 
Figure 5.6 Schematic overview of the panning rounds using the CPL3 library and target proteins Ara h 1, 2, 3 and 6. 
The first selection round started with the immobilization of the Ara proteins onto magnetic beads by 
standard amide bond formation chemistry (EDC/NHS). A general protocol for this immobilization was 
established (section 5.2.6.1) and the protein-coated beads were either used directly in a selection round or 
stored at 4 °C and used the same week.  
After the first selection with the naive library, the resulting preselected library (library P1) was subjected to 
two consecutive panning rounds (P2 and P3). DNA from the pre-selected phagemids was used to perform 
recombination following the cosmix-plexing® protocol and subsequent selections with the newly 
generated recombined library. 
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Panning round 2 
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Panning round 3 
(P3) 
Cosmix-plexing® 
(cp) 
Panning round 1 
after CP (CP1) 
Panning round 2 
after CP (CP2) 
Panning round 3 
after CP (CP3.0) 
Panning round 3 
after CP (CP3.1) 
Panning round 3 
after CP (CP3.2) 
Panning round 3 
after CP (CP3.3) 
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5.3.2 Cosmix-Plexing® 
To perform the cosmix-plexing® steps, DNA of the P1 library was isolated following a midi-prep protocol 
(Figure 5.2 and Figure 5.7). 
 
Figure 5.7 DNA gel of the cosmix-plexing steps for all four Ara proteins (h 1, 2, 3 and 6): 1) plasmid DNA of P1 library (DNA from 
CPL3 and M13KO7 is seen; 2) 1st restriction with BpmI; 3) concatamerization; 4) 2nd restriction with BglI; 5) circularization (crude); 
6) circularization (after purification of DNA). (Marker: GeneRulerTM 1kb DNA ladder from Fermentas). 
The plasmid DNA of the P1 libraries for Ara h 1, 2, 3 and 6 can be seen in Figure 5.7 (lanes 1.1, 2.1, 3.1 and 
6.1). The plasmid DNA was digested using the Type IIs restriction enzyme BpmI (Figure 5.7, lane 2). For 
lane 1.2 and 6.2 two bands were observed, since also M13KO7 was present in the DNA sample. The next 
step was the concatamerization using T4-DNA ligase (Figure 5.7, lanes 1.3, 2.3, 3.3 and 6.3). The 
concatamers are formed in different lengths and therefore various bands are observed. The digestion of 
the concatamer was performed with BglI (Figure 5.7, lanes 1.4, 2.4, 3.4 and 6.4). Although for Ara h 2 and 3 
the concatamer was not completely digested, it was decided to proceed with the procedure. The next step 
involved circularization with DNA ligase (Figure 5.7, lanes 1.5, 2.5, 3.5, and 6.5). The resulting DNA was 
purified by phenol extraction and subsequent ethanol precipitation (Figure 5.7, lanes 1.6, 2.6, 3.6 and 6.6). 
After DNA purification, two bands were visible on the gel. The lower band is the expected linear DNA and 
the upper one is ‘not supercoiled’ DNA, but perhaps some contamination or ‘star’ activity of the restriction 
enzymes. The latter can occur when restriction enzymes under non-standard reaction conditions can 
cleave other than the defined recognition sequences. Also in this case, the next step was performed and 
the later panning results showed that the library formed after cosmix-plexing® was good. The DNA formed 
after cosmix-plexing® was transformed by electroporation and phage particles were packaged with helper 
phage as described in section 5.2.6.3. The preselected P1 library contained between 7.4 x 106 to 2.4 x 107 
clones and the newly formed libraries contained > 1 x 108 clones. 
With the newly obtained libraries additional selection rounds were performed (cp1 till cp3). With the cp2 
library several selection attempts were performed, but some problems were observed with the phage 
rescue in the first two attempts. For the third attempt, a fresh E. coli strain was used and now the selection 
was successful.  
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5.3.3 Results Enrichment Libraries 
The progress of the panning experiments was followed by titrating the aliquots of eluted phage from each 
selection round. The enrichment of the phage libraries was calculated with Equation 1.  
 
Equation 1 Calculation of enrichment after the panning rounds.  !"#$% =    1−!"#!"(!!!"#  !"#$"#!!!"#  !"#$% ) 
 
Figure 5.8 Yield of the enrichment of phage libraries after the panning round without cosmix-plexing® as calculated according to 
Equation 1. During washing, the amount of Tween-20® was increased from 0% in P1, 0.05% in P2 to 0.1% in P3.  
 
Figure 5.9 Yield of the enrichment of phage libraries following each panning after the cosmix-plexing® round.  
In the panning rounds without cosmix-plexing®, all the libraries showed clear enrichment during each 
panning stage, with the exception of Ara h 6, where a small decrease was observed in panning 2 (Figure 
5.8). The amount of Tween-20® in the different panning rounds was increased, from 0% in panning 1, 
0.05% in panning 2 to 0.1% in panning 3. Although increase in Tween-20® normally results in a continuous 
decrease of yield, however in this case the yield still increased, which is an indication that binders are 
enriched. The enrichment yields after cosmix-plexing showed that for all peanut proteins, the yield 
increased in CP1 and CP2, however, CP3 and CP3.1 were not successful (Figure 5.9). CP3.2 gave better 
results, but no increase in yields compared to library CP2 was observed, which can be explained by the 
quantity of Tween in the third round. In panning round CP1 0.0% Tween-20® was used, in CP2 0.1% and in 
CP3.2 1%. Removal of the high concentration of Tween-20® concomitantly removed weak binders, 
because only stronger binders can survive such washing conditions.  
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5.3.4 Analysis of Individual Clones 
The analysis of the individual clones was performed in two different ways. From all different panning 
rounds, individual clones were picked and partly used to obtain DNA for sequencing, whereas the rest 
served to infect the TG1(λ) strain and grow the phage for ELISA.  
 
Individual clones were picked from panning rounds p3, cp2, cp3.0 and cp3.2, DNA was isolated and 
sequenced (Appendix A). Unfortunately, no obvious sequence similarity could be observed. One peptide 
sequence was observed several times, but most likely the result of cross-contamination because the 
peptide was found in selection rounds of all four Ara h proteins. As no motifs were found, phage particles 
from individual clones were evaluated for binding in a phage ELISA experiment. To this end, target 
proteins were immobilized on a Maxisorp™ 96-well plate and incubated with 109 to 1010 phage in blocking 
buffer. Bound phage was detected with HRP-coupled anti-M13K07 antibody. More than 200 individual 
clones were examined by phage ELISA, as exemplified in Figure 5.10.  
 
Figure 5.10 Graph of the phage ELISA for some individual clones selected for Ara h 2. The dark grey bars show the background 
signal of the individual clone, the light grey bars show the signal of binding between the individual phage and Ara h 2. In the 
background signal, no incubation with the phage was performed, only incubation with the secondary antibody and the HRP 
substrate was done.  
As can been seen from Figure 5.10, no significantly amplified signal was found, which unfortunately was 
also the case for all other ELISAs (Appendix B). One of the difficulties of the phage ELISA is that it is not 
possible to reduce background binding and secondly phage is also present, thereby interfering with 
binding between the peptide and the target protein. Therefore, it was decided to perform binding 
experiments with only the peptides. The clones with the highest signals in ELISA were sequenced and the 
peptides were ordered.  
To be able to immobilize the synthetic peptides to a streptavidin-coated magnetic bead, a biotin moiety 
was incorporated at the N-terminus. Then, a fishing experiment was performed as schematically depicted 
in Figure 5.11. In short, the peptide-charged magnetic beads were added to a solution containing the Ara 
protein. After 30 minutes of incubation, the beads were collected using a magnet, and subsequently 
heated in the presence of loading buffer to release potentially bound protein from the beads.  
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Figure 5.11 Schematic representation of the principles of the fishing experiment. The peptides were immobilized on magnetic 
particles and added to a solution containing the target protein. After 30 minutes of incubation the bound target proteins were 
collected and washed. By heating the beads together with loading sample, the proteins were released from the beads and 
analyzed by SDS PAGE.  
A total of 38 peptides were tested with the fishing assay described above and summarized in Figure 5.12 
(sequences can be found in Appendix A). For Ara h 1, nine different peptides were tested which were 
selected during different panning rounds. Some of the peptides showed binding (Figure 5.12a). The 
different intensity of the bands suggests a difference in binding affinity, however, during the washing 
steps, some of the magnet beads were washed away and thus the final amount of retrieved beads varied 
between the individual experiments. To be able to quantify the binding affinity, a different assay should 
be performed as isothermal titration calorimetry (ITC) or surface plasmon resonance (SPR).  
For Ara h 2, only two peptides showed binding (Figure 5.12b, peptides 2.07 and 2.10). The gel of Ara h 3 
(Figure 5.12c) showed the presence of protein in all lanes, however resulting exclusively from non-specific 
binding of the target protein to the peptides, because even negative controls showed the same result. 
One likely explanation is that Ara h 3 is a so-called ‘sticky’ protein, with aspecific binding to the beads. 
Finally, Ara h 6, showed unfortunately no binding at all (Figure 5.12d).  
a) b) 
 
 
c) d) 
 
 
Figure 5.12 a) sequences selected for Ara h 1 (Mw 65 kDa); b) sequences selected for Ara h 2 (Mw 17 and 19 kDa); c) sequences 
selected for Ara h 3 (Mw 14–45 kDa); d) sequences selected for Ara h 6 (Mw 15 kDa).  
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As described above, the difference in band intensity did not give information about the binding affinity. 
All peptides that showed a positive signal in the fishing experiments were therefore tested with by surface 
plasmon resonance (SPR). Since the peptides contain a biotin, streptavidin-coated Biacore chips were 
used for immobilization. After successful preparation of the surface, the binding with the different Ara 
proteins was examined. Different attempts were made, where among others the surface density was 
varied, unfortunately, no binding was observed. As a final attempt peptide 1.09 and 1.45 were tested with 
Ara h 1 in an isothermal titration calorimetry (ITC) experiment, which also failed to lead to a positive result.  
 
Since the fishing and also the SPR/ITC experiments were particularly time- and material-consuming, about 
100 individual clones from all four Ara proteins used in the phage display were selected for sequencing. 
The corresponding peptide sequences were checked with alignment software and with an especially 
created Excel spreadsheet, but no repeating sequences were identified within the analyzed set of 
peptides. Nevertheless, a couple of peptides that were rationally considered as potentially binders were 
tested in a phage ELISA. Again no positive signal was observed, so it must be concluded that no effective 
binder for one of the Ara proteins was obtained.  
5.4 Conclusions and Outlook 
The phage display technique has been used to select new, potential binders for four peanut allergens, 
Ara h 1, 2, 3 and 6. Different panning rounds were performed and subsequently, after the first panning 
round, cosmix-plexing provided a new library that was used in three more panning rounds. After each 
panning round, amplification of the selected phage was performed to obtain new, enriched sublibraries 
and furthermore, single clones were grown and analyzed either by phage ELISA or by sequencing the 
DNA, but analysis of the individual clones did not lead to potential binders.  
One of the reasons could be that the Ara proteins lack a good binding pocket, thereby complicating the 
search for high affinity peptides. It seems unlikely that immobilization of the proteins onto the magnetic 
beads was not successful, because the SPR experiments showed that Ara proteins can be effectively 
immobilized onto a carboxylated surface. However, on potential option is to optimize the ELISA in 
reduction of background binding, which would enable the analysis of more individual clones and the 
identification of more hits.  
 
For future experiments, one promising option would involve complete sequencing of a library after a 
panning round. In such case, all the phages will be sequenced and with the aid of alignment software 
already developed at Fraunhofer IZI, there is a fair chance to find motifs within the sequences. Next, based 
on these motifs, improved ligands may be developed. 
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5.7 Appendix A 
5.7.1 Ara h 1 
Number Panning round Sequence 
1.08 panning cp2 RQIVQVLCVVEAGSV 
1.09 panning cp2 SRHTYLLRQLDARLG 
1.10 panning cp2 SIVSDFRKSESTGSS 
1.44 panning cp3.0 SYILAEPHHEHTYGV 
1.45 panning cp3.0 SSFCGAFKVGSTILI 
1.47 panning cp3.0 SFVNRSSRGAVPTCT 
1.48 panning cp3.0 SLSGVLRACVLSTWC 
1.59 panning cp3.2 RRSAHVMNDQMPLVT 
1.60 panning cp3.2 RRSAHVMNDQMPLVT 
5.7.2 Ara h 2 
Number Panning round Sequence 
2.01 panning p3 SFTCHQCSQWNSVVI 
2.02 panning p3 SGVSNSGTTFRANSS 
2.03 panning p3 RASTFTPRNHFANFC 
2.05 panning p3 SLNSTHVQHRYSGGP 
2.06 panning cp2 SSEVCWGVSGQAVMV 
2.07 panning cp2 RALGWYSCWMRTVIG 
2.08 panning cp2 SFGEKLNNVRMPHKG 
2.09 panning cp2 RVVRAVLNGKSTQKV 
2.10 panning cp2 SQVTCLDQRAYATAA 
2.32 panning cp3.0 SPSNYTVHVEKSRSC 
2.34 panning cp3.0 RGAVWSRLRCEAACV 
2.44 panning cp3.0 SPCIDVMAIVTTARX 
5.7.3 Ara h 3 
Number Panning round Sequence 
3.01 panning p3 RVTRSQHDMVKAVYV 
3.06 panning cp2 SLRLKRVHYHCSLPC 
3.07 panning cp2 SGSRSMGHHESTDLV 
3.08 panning cp2 SWEGMTGVVGGAARC 
3.09 panning cp2 SSVAQAFRWRGADVN 
3.10 panning cp2 RLGNTTGNYGHALPP 
3.44 panning cp3.0 RPNIFMRRGLRTTLD 
3.48 panning cp3.0 GDFLTNAGDILSTCYC 
3.57 panning cp3.2 SPCIDVMAIVTTARG 
3.58 panning cp3.2 SKCIGPVKEERTTCF 
3.60 panning cp3.2 SKKMKVIVSQGASQH 
5.7.4 Ara h 6 
Number Panning round Sequence 
6.02 panning p3 RTLDCGPRGCFTHSL 
6.05 panning p3 RFRANSLPVVATHYS 
6.07 panning cp2 SGVTISWIGTATHAG 
6.07a    SGVTISWI 
6.07b    TATHAG 
6.32 panning cp3.0 STWQTRKTICEADGS 
6.42 panning cp3.0 SRVCDVSFLCGANFY 
6.56 panning cp3.2 SRLGGSRASSEPKTI 
6.58 panning cp3.2 RRPIIESCGKRAKAR 
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5.8 Appendix B 
 
Figure 5.13 ELISA results from individual clones CP2. 
  
  
Figure 5.14 ELISA results individual clones from CP3. 
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Figure 5.15 ELISA results individual clones from CP3.2. 
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Chapter 6 
Towards Detection of Ara h 1 with a  
Multivalent DC-SIGN Construct  
 
 
 
 
 
 
Parallel to the phage display project, a well-known carbohydrate-binding protein, DC-SIGN, was investigated 
as a candidate for interaction with peanut allergen Ara h 1. DC-SIGN is only fully active in its tetrameric 
structure and therefore it is more complicated to immobilize this protein on a biosensor surface with retention 
of activity. A strategy to immobilize a tetrameric DC-SIGN structure with full control over its orientation 
involved the development of a tetravalent dendritic structure containing at one terminus a handle for surface 
modification and at the other four termini moieties to attach the carbohydrate binding domains (CRDs). This 
Chapter describes the expression, isolation and biochemical functionalization of the CRD and the synthesis of 
the dendritic scaffold. Unfortunately, it was not yet successful to couple these two building blocks.  
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6.1 Introduction 
In Chapter 5 phage display was applied to select new ligands (peptides) for the peanut allergens Ara h 1, 
2, 3 and 6.1 Phage display is a technique with a broad screening potential and it allows the possible 
identification of ligands that are not necessarily found in natural systems.2 Besides de novo identified 
binding ligands, a biosensor can also be developed based on naturally occurring binding partners of Ara 
peanut allergens. Parallel to the phage display approach, this chapter describes the investigation of the 
well-known carbohydrate-binding protein DC-SIGN as a candidate for interaction with the Ara 
glycoprotein family. 
 
A general introduction of the peanut allergens is given in Chapter 1 and here the most important 
characteristics of Ara h 1 will be reiterated. Ara h 1 belongs to the vicilins (seed storage proteins)3 and Ara 
h 1 is a 65 kDa glycoprotein with a high-mannose N-glycan,4 that typically forms homotrimeric quaternary 
structures. The monomers contain a cupin motif, a conserved barrel domain seen within the cupin super-
family.5 The three cupin motifs of vicilin are arranged via hydrophobic interactions at the distal end of the 
monomers, where most of the IgE binding epitopes are located (Figure 6.1, left).6–8 As a consequence of 
the shielded nature of the cupin motifs, it is difficult to identify a high-affinity peptide-binding partner for 
Ara h 1 and a different approach has been followed here, based on accessibility of the typical N-glycan 
structure.  
  
Figure 6.1 Left) Homotrimeric structure of Ara h 1; right) Assigned structures of N-glycans from Ara h 1.4  
Natural carbohydrate-binding proteins are known as lectins, receptors that can be found on cell surfaces 
and that are involved in numerous biological recognition pathways.9 A specific class of lectins is formed by 
the calcium-dependent or C-type lectins, which may function as adhesion and signaling receptors and, 
when present on antigen-presenting cells, are well-known for their function as antigen-uptake 
receptors.10,11 One specific type of the C-type lectins is the human dendritic cell-specific intercellular 
adhesion molecule-3-grabbing nonintegrin (DC-SIGN). DC-SIGN is a type II transmembrane C-type lectin 
receptor present on the surface of, among others, dendritic cells.11,12 DC-SIGN is primarily known for its 
involvement in the initial stages of human immunodeficiency virus (HIV) infection.13,14 DC-SIGN binds to a 
broad spectrum of glycans, but has the highest affinity for N-linked high-mannose oligosaccharides and 
fucose-containing structures.  
The binding of Ara h 1 and DC-SIGN has been thoroughly investigated.15 In the research described here, 
the Ara h 1-DC SIGN interaction served as the basis of our continued investigations on the development of 
the peanut allergy biosensor.  
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6.1.1 Structure DC-SIGN 
DC-SIGN consists of a carbohydrate recognition domain (CRD), an extended neck region composed of 7.5 
repeating units of peptide 23-mers, and a transmembrane region followed by a cytoplasmic tail (Figure 
6.2).16,17 The hydrophobic neck oligomerizes into tetramers, which increases the binding affinity of the 
CRDs with ligands containing repetitive carbohydrate moieties. It is thought that the tetramerization has 
an enormous impact on binding affinity. The hydrophobic domains in the neck stabilize the tetramers and 
point the CRD away from the surface, thereby rendering it accessible for carbohydrate binding (Figure 
6.3).  
The number of neck region repeating units defines the tetra-, di- or monomeric structure of DC-SIGN. At 
least six repeating units are needed to form a tetrameric structure, while two or less units will provide a 
monomeric structure only.17,18 
 
Figure 6.2 Schematic structure of DC-SIGN and amino acid sequence alignment of the neck-repeating region. The repeated 
hydrophobic amino acid residues, crucial for tetramerization, are highlighted. CRD = carbohydrate recognition domain.  
 
   
Figure 6.3 DC-SIGN tetramerization through hydrophobic residues stacking in the neck-repeating domain.  
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6.1.2 Aim of Research Project 
The strategy chosen for the development of a biosensor for detection of Ara h 1, requires that DC-SIGN 
becomes immobilized on the sensor surface. As described in earlier chapters, surface modification can be 
performed in various ways. However, the immobilization technique can influence the binding affinity 
between the immobilized ligand and the food allergen. In this respect, it is essential that DC-SIGN has 
optimal binding capacity for N-linked glycans in its tetrameric form. Thus, to be able to provide a high-
affinity DC-SIGN surface, the protein should be immobilized as a tetramer. Currently, amide bond 
formation with EDC/NHS chemistry is the standard way of immobilizing DC-SIGN.19,20 One important 
disadvantageous consequence of EDC/NHS chemistry, however, is the fact that the protein is randomly 
immobilized. The CRD can thereby be oriented in the wrong way and be inaccessible for glycan binding. 
To overcome the latter problem, we opted instead for a novel approach involving the combination of 
organic chemistry and molecular biology.  
One strategy to immobilize a tetrameric DC-SIGN structure with full control over its orientation involved 
the introduction of a bioorthogonal handle at the N-terminus of the extracellular domain of DC-SIGN, for 
site-specific surface attachment. A disadvantage of such an approach, however, is that non-covalent 
assembly to the tetramer is required to take place in solution before immobilization. However, it would be 
difficult to analyze if immobilization of DC-SIGN takes place in the tetrameric or monomeric form. 
Therefore, it was decided to go for another approach in which the CRD was expressed without the neck-
repeating region, followed by covalent tetramerization of the CRD units on a dendritic scaffold (Figure 
6.4). After formation and characterization of the CRD tetramer, the complex could then be immobilized on 
the surface. Additionally, involvement of alternative dendritic structures would enable control over 
different oligomerization states and enable the examination of the binding affinity of mono-, di-, tri- and 
tetrameric DC-SIGN and even larger oligomers.  
 
Figure 6.4 Dendritic concept for linking four CRD DC-SIGN domains and immobilization onto the biosensor surface. The reactive 
moieties for SPAAC (azide and cyclooctyne) can also be incorporated the other way around, with the strained alkyne at the CRD 
and the azide at the dendrimer side. 
Based on the above argumentation, a tetravalent dendritic structure was developed containing at one 
terminus a handle for surface modification and at the other four terminal moieties to attach the CRD. For 
surface immobilization, we opted to biotinylate the dendrimer for well-established streptavidin binding 
interaction, and for the attachment of the CRD, a chemical strategy was devised based on strain-promoted 
azide–alkyne cycloaddition (SPAAC).21 The two coupling strategies are orthogonal and should therefore 
not lead to undesired cross reactivity. Furthermore, with regard to SPAAC, there is flexibility in design in 
the sense that azides can either be introduced at the dendrimer or at the CRD and vice versa for the 
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strained alkynes. Moreover, the orthogonality of the conjugation techniques would provide full flexibility 
in the selection of the order of events, i.e. first tetramerization, then immobilization or the other way 
around. Via either strategy, the CRD dendrimer should be efficiently positioned on a streptavidin-
functionalized biosensor surface in its correct orientation.  
6.2 Results and Discussion 
In order to build a dendritic construct as depicted schematically in Figure 6.4, truncated DC-SIGN was 
expressed, followed by the selective N-terminal incorporation of an azide moiety or strained alkyne. 
Furthermore, the dendrimer with terminal azides or BCN moieties needed to be synthetically prepared. 
Finally, covalent attachment of components with SPAAC chemistry was explored.  
6.2.1 Truncated DC-SIGN 
Expression and Isolation 
Truncated DC-SIGN (residues 262–404) was expressed in E. coli as described by Mitchell et al.17,18 After 
expression and isolation of the CRD, a refolding step of the protein into its biologically active 
conformation is required. Therefore, the protein was first fully unfolded in a Tris-HCl buffer containing 
guanidine and β-mercaptoethanol, and slowly refolded by dialysis with a Tris-HCl buffer containing CaCl2. 
After refolding, the purity of the protein was checked with SDS-PAGE and the exact mass was determined 
by mass spectrometry (Figure 6.5).  
 
a) 
 
b) 
 
 
 
Figure 6.5 a) Coomassie-stained SDS-PAGE after expression and isolation, but before purification; lane 1: Twice resuspended and 
lysed pellet; lane 2: Twice cleared lysate; lane 3: resuspended and lysed pellet; lane 4: cleared lysate; lane 5: insoluble fraction 
(pellet); lane 6: sample after dilution; b) Deconvoluted mass spectrum of unpurified CRD (left).  
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After confirmation that the deconvoluted mass nicely corresponded to the theoretical mass (less than 1 
Da deviation of 17793.0 kDa) (Figure 6.5b), the CRD was purified with a mannose-Sepharose affinity 
column.17,18 Upon loading of DC-SIGN on such a column, only correctly folded DC-SIGN is able to bind to 
the mannose units, while improperly folded DC-SIGN will have no affinity and directly flow through the 
column. Subsequent elution of the correctly folded DC-SIGN is then expected to lead to a pure and active 
protein sample. In our particular case, it was found that indeed the elution of the correctly folded CRD 
fragment of DC-SIGN was delayed on the column, but nevertheless eluted predominantly in the wash 
fractions, thus suggesting relative weak binding to the mannoses (Figure 6.6). As a result, the yield of 
correctly folded CRD was low and multiple purifications were requisite to obtain sufficient material for 
post-translational chemical modification.  
 
 
Figure 6.6 SDS-PAGE after mannose-Sepharose column showing presence of truncated DC-SIGN predominantly in washing 
fractions (W1–W3).  
Introduction of Azide Functionality 
The azide was introduced at the N-terminus by metal-free and pH-controlled diazotransfer with 
compound 1 as described by Schoffelen et al. (Scheme 6.1), based on the general presumption that the N-
terminal amino acid has the lowest pKa.22 Because seven lysines are present in the CRD, a pH optimization 
was performed first to selectively functionalize the N-terminus. At a first attempt pH 8.0, 8.5 and 10.5 were 
tested with a reaction time of 2 hours. At pH 8.0 and 8.5, no azide could be detected, while for pH 10.5, 
CRDs with the incorporation of one, two and three azides were found (Figure 6.7, 1a–c; Table 6.1 entries 1, 
2 and 9). The next attempt was to perform the diazotransfer at pH 8.9, 9.6 and 10.0, again with 2 hours 
reaction time (Figure 6.7, 2a–c; Table 6.1, entries 3, 7 and 8). At pH 8.9 and 9.6, only a very small amount of 
desired product was obtained, however at pH 10.0, ~30% of desired product was formed. The next 
optimization involved a longer reaction time, instead of 2 h, now the diazotransfer was performed 
overnight. At pH 9.0 and 9.2, the exclusive formation of a product with a single azide in 30% yield, besides 
starting material was found. At pH 9.4, the yield for single azide incorporation was ~50%, however, in this 
case also the product with two azides was observed (Figure 6.8a–c; Table 6.1, entries 4–6). 
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Scheme 6.1 Introduction of an azide moiety at the N-terminus of the CRD of DC-SIGN using 1 as diazotransfer reagent. 
 
1a) 
 
2a) 
 
1b) 
 
2b) 
 
1c) 
 
2c) 
 
Figure 6.7 pH scanning for diazotransfer reaction with 2 h reaction time. 1a) pH 8.0, 1b) pH 8.5, 1c) pH 10.5; 2a) pH 8.9, 2b) pH 9.6 
and 2c) pH 10.0. 
 
pH 8.0 pH 8.9 
pH 8.5 pH 9.6 
pH 10.5 pH 10.0 
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a) 
 
b) 
 
c) 
 
  
Figure 6.8 pH-optimization for overnight diazotransfer experiments. a) pH 9.0, b) pH 9.2 and c) pH 9.4. 
 
Table 6.1 pH optimization of diazotransfer at the N-terminus of the CRD of DC-SIGN. 
Entry pH Reaction time Detected mass (Da) 
1 8.0 120 min. 17793.2   
2 8.5 120 min. 17793.2   
3 8.9 120 min. 17792.9   
4 9.0 16 h 17794.3   
5 9.2 16 h 17794.1 17821.6   
6 9.4 16 h 17794.1 17820.6 17846.5  
7 9.6 120 min. 17792.9 17817.8   
8 10.0 120 min. 17792.9 17818.8  
9 10.5 120 min. 17792.9 17819.5 17845.6 17871.9 
 
To corroborate that the azide was incorporated selectively at the CRD N-terminus and not at one of the 
lysines, a tryptic digestion was performed and the fragments were analyzed with liquid chromatography – 
mass spectrometry (LC-MS). Because trypsin hydrolyzes peptide bonds at the C-terminal side of a lysine 
and arginine, the N-terminal fragment is expected to consist of the Ala-Glu-Arg (AER) sequence. The 
trypsin digestion was performed with three different samples. One sample contained non-functionalized 
CRD, the second contained functionalized CRD at pH 9.2 and the third sample contained functionalized 
CRD after SPAAC reaction with BCN-POE3-NH2 (Figure 6.9). From the LC-MS data it was clear that the azide 
was present at the N-terminus (Table 6.2, entries 1,2 and 4). After trypsin digestion, the N-terminal 
fragments were clearly seen in all three cases with the expected mass. Since with mass spectrometry it was 
found that only one azide was incorporated and with the trypsin digestion it was proven that the N-
terminal azido fragment can be detected, it is safe to conclude that only the N-terminus is functionalized 
and none of the side chains of lysines.  
After these optimization steps of the diazotransfer, the reaction was performed at a larger scale yielding 
the expected azide derivative of DC-SIGN CRD in 40% yield.  
pH 9.0 pH 9.2 
pH 9.4 
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Table 6.2 LC-MS analysis of trypsin digestion of CRD, N3-CRD and BCN-CRD. 
Entry Fragment Calc. mass Found 
1 H2N-AER-OH 374.19 [M+H]+ 375.36 
2 N3-AER-OH 401.18 [M+H]+ 401.52 
3 BCN-POE3-NH2 324.42 [M+H]+ 325.16 
4 SPAAC product 726.40 [M+H]+ 725.56 
5 fluorescein-AER-OH 1352.6 [M+2H]2+ 677.28 
 
 
Figure 6.9 Products after trypsin digestion; a) sample with unmodified CRD (Table 6.2 entry 1); b) sample with N3-CRD (Table 6.2 
entry 2); c) sample after SPAAC reaction (Table 6.2 entry 4). 
 
pH-controlled incorporation of BCN 
After successful N-terminal incorporation of a single azide, the same approach was followed for 
incorporation of a cyclooctyne moiety, in our particular case bicyclo[6.1.0]nonyne (BCN),21 because at this 
stage it was not clear which choice of protein-dendrimer functionalization would be optimal. For this 
purpose, a commercially available activated ester derivative of BCN was used (2), featuring a polyethylene 
glycol (PEG) spacer to secure accessibility to an azide-charged dendrimer (Figure 6.10). The incorporation 
of BCN was performed at pH 7.2, 7.4 and 7.6 with 1, 2 or 4 equiv. of BCN-PEG8-NHS derivative 2. At pH 7.6, 
with two equiv. of BCN-PEG8-NHS about 20% of product was formed (Figure 6.11). A model SPAAC 
reaction with fluorescein-N3 was performed to yield the expected triazole product in 50% yield. A trypsin 
digestion was performed to give insight if the BCN was introduced at the N-terminal position, and after 
LC-MS analysis it was concluded that selective BCN functionalization at the N-terminus was indeed 
successful (Table 6.2, entries 1 and 5).  
 
 
 
Figure 6.10 Structure of BCN-PEG8-NHS (2). Figure 6.11 Mass spectrum of CRD-BCN, about 20% of the CRD 
was functionalized with BCN moiety 2. 
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6.2.2 Design and Synthesis of the “Clickable” Dendrimer 
Two different “clickable” dendrimers were developed, one with terminal azides (3) and the other with 
terminal BCN moieties (4) (Scheme 6.2). A biotin moiety was incorporated at the core of these dendrimers 
for final immobilization onto a streptavidin biosensor surface. Both 3 and 4 could be prepared from 
dendrimer 5 which can be assembled by the Cu-catalyzed azide-alkyne cycloaddition (CuAAC) reaction23,24 
between alkyne 6 and azide 7 and these two compounds were easily prepared, starting from 
commercially available tetra ethylene glycol (8) and alcohol 9.  
 
Scheme 6.2 Retrosynthesis of the two dendrimers synthesized; R can either be an azide (3) or a BCN moiety (4). 
The synthesis of dendrimer 3 and 4 started with the ditosylation of commercially available tetra ethylene 
glycol (8). One tosyl group was then directly converted into an azide moiety via a substitution reaction 
with NaN3 yielding monoazide 10 in 40% yield over two steps (Scheme 6.3). Triol 11 was protected with 
an ketal moiety by a reaction with p-TSA and acetone and yielded alcohol 9 in 71%. A substitution reaction 
between tosyl 10 and alcohol 9 yielded compound 12 in 61% yield after hydrolysis of the acetonide.  
 
 
Scheme 6.3 i) p-TsCl, KOH, DCM, 0 °C, 4 h; ii) NaN3, DMF, rt, 22 h, 40% (over 2 steps); iii) p-TSA, acetone, rt, 16 h, 71%; iv) NaH, 
DMF, 0 °C-rt, 24 h; v) p-TSA, MeOH, rt, 36 h, 61%.  
Dialkyne 13 could be synthesized in 76% yield from diol 12 via a nucleophilic substitution reaction using 
NaH and propargyl bromide. Dialkyne 13 slowly polymerizes when stored as a concentrated oil and was 
therefore stored in a DCM solution to prevent cycloaddition. Staudinger reduction of the azide into the 
amine and subsequent protection with Boc anhydride yielded alkyne 6 in 78% yield over 2 steps (Scheme 
6.4).  
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Scheme 6.4 i) NaH, DMF, propargyl bromide 0 °C-rt, 17 h, 76%; ii) PPh3, THF, H2O, rt, 20 h; iii) Boc2O, DCM, 0 °C, 3 h, 78% (over 2 
steps).  
From diol 12 dimesylate 7 was obtained by reaction with mesylchloride, and the expected product (7) was 
obtained in 87% yield (Scheme 6.5).  
 
Scheme 6.5 i) MsCl, Et3N, DCM, 0 °C, 15 min, 87%.  
The core building block 6 and corona building block 7 were connected via a CuAAC reaction affording 
dendrimer 5 in 98% yield (Scheme 6.6).23,24 After successful synthesis of mesylate 5, the mesyl groups were 
converted into azide 14 via a substitution reaction with NaN3 yielding the product in 78%. Finally, the Boc-
protected amine was deprotected with TFA and subsequent reaction of the free amine with biotin-OSu 
yielded azide-functionalized dendrimer 3 in 69%.  
 
 
Scheme 6.6 i) TBTA, DiPEA, CuI, THF, rt, 17 h, 98%; ii) NaN3, DMF, 100 °C, 80 h, 78%; iii) TFA, DCM, rt, 2 h; iv) biotin-OSu, Et3N, 
DMF, 0 °C, 4 h, 69%.  
After successful synthesis of the azide dendrimer (3), synthesis of the BCN dendrimer 4 was investigated. 
First, the azides were reduced to the corresponding amines via a Staudinger reduction using 
triphenylphosphine immobilized on polystyrene. The reaction was followed with LCMS and after full 
conversion was seen, the next step, BCN incorporation, was performed. BCN 2 was introduced via the 
activated NHS ester, but unfortunately, no product was formed. LCMS showed a reduction in starting 
material which was consumed completely over time, however, the mass of the newly formed LC peak did 
not correspond to the expected mass. Also other mass spectrometry techniques such as AccuTof (ESI) did 
not give the expected mass. The obtained mass could not be assigned to any side product or degraded 
fragments of azide 3.  
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Scheme 6.7 i) PPh3, THF, H2O, rt, 20 h; ii) BCN-PEG8-OSu (1), Et3N, DMF, rt, 24 h.  
Since azide dendrimer 3 was successfully synthesized and both azido-functionalized DC-SIGN and BCN-
functionalized DC-SIGN were obtained, it was decided to use the azide dendrimer (3) in further 
experiments.  
6.2.3 Dendritic DC-SIGN 
After successful synthesis of BCN-containing DC-SIGN and azido-dendrimer 3, oligomerization by SPAAC 
was investigated. Because it was difficult to obtain large amounts of correctly folded, truncated DC-SIGN, a 
first attempt with the SPAAC reaction was made with truncated DC-SIGN BCN-CRD sample obtained after 
expression and isolated, but without purification on the mannose-Sepharose column. Four different 
amounts of BCN-CRDs were tested, namely 4, 8, 16 and 32 equivalents with respect to dendrimer 3, at a 20 
µM concentration of DC-SIGN. Unfortunately, no dendritic product was formed at all conditions evaluated 
(Figure 6.12).  
 
Figure 6.12 SDS-PAGE gel of SPAAC reaction of BCN-CRD and dendrimer 3. Lane 1: CRD-BCN, lane 2: CRD, lane 3: 4 equiv. BCN 2, 
lane 4: 8 equiv. BCN 2, lane 5: 16 equiv. BCN 2 and lane 6: 32 equiv. BCN 2.  
It is known from other experiments that performing the SPAAC reaction at high concentration has a major 
effect on the reaction rate. Unfortunately it was not possible to increase the concentration of dendrimer 3 
further due to solubility issues in the DMSO/phosphate buffer used. Another complicating aspect for 
performing the reaction at high concentration is the amount of CRD needed for these reaction conditions. 
Obtaining high amounts of BCN-CRD proved to be cumbersome and consequently it will be difficult to 
obtain the desired high concentrations in our coupling reaction.  
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6.3 Conclusion and Outlook 
The aim of this research was to develop a suitable ligand for Ara h 1 binding based on the C-lectin DC-
SIGN. Importantly, DC-SIGN forms tetramers to obtain optimal binding capacity towards N-linked glycans 
and the carbohydrate recognition domains CRDs should be accessible for the glycans to bind effectively. It 
is therefore more complicated to immobilize this protein on a biosensor surface with retention of activity. 
A strategy to immobilize a tetrameric DC-SIGN structure with full control over its orientation involved the 
development of a tetravalent dendritic structure containing at one terminus a handle for surface 
modification and at the other four termini moieties to attach the carbohydrate binding domains (CRDs). 
The CRDs were attached to the dendrimer via strain-promoted azide-alkyne cycloaddition.  
Expression and isolation of CRD was successful, although the yield of correctly folded CRD was low. Both 
the azide and BCN functionality could be easily and selectively introduced into the CRD by a pH and time-
controlled incorporation method. Synthesis of the azide-containing dendrimer proved to be 
straightforward, but the synthesis of BCN-dendrimer was not successful. Unfortunately, model SPAAC 
conjugation of the azido-dendrimer and BCN-DC SIGN CRD did not lead to detectable formation of any 
product.  
 
In the end, no dendritic structure was obtained and no binding experiments could be performed to 
analyze the binding between Ara h 1 and a dendritic DC-SIGN containing construct. Because the amount 
of CRD was a limiting factor in this respect, optimization of CRD purification is required to obtain sufficient 
material. In addition, one alternative strategy would involve tetramerization based on strain-promoted 
inverse electron demand Diels–Alder cycloaddition (SPIEDAC) between BCN and tetrazine, which is known 
to display significantly increased reaction rate constants over SPAAC (factor >1000). 
The expression, isolation and purification of the extracellular domain (ED-CRD) of DC-SIGN proved to give 
higher yields (data not shown here). Therefore, although it was considered at the beginning of the project 
not to be the most optimal approach for selective immobilization of active DC-SIGN, in light of the 
difficulties encountered, it is still an option to further explore the immobilization of ED-CRD. ED-CRD forms 
tetramers in solution and one possibility is to cross-link the protein subunits, thereby fixating the 
tetrameric structure, which can then be immobilized. To control the orientation of the protein during 
immobilization, N-terminal diazotransfer could be used, after which the SPAAC reaction could be 
performed on a BCN-functional biosensor surface.  
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6.5 Materials and Methods 
6.5.1 Materials 
Ara h 1 was kindly provided by TNO Zeist. The plasmids for CRD DC-SIGN and the mannose-Sepharose 
were kindly provided by dr. D. Mitchell from Warwick University.  
6.5.2 Expression, Isolation and Purification of CRD DC-SIGN 
For a typical expression, 50 mL LB medium, supplemented with kanamycin (50 mg/L), was inoculated 
with a single colony of E. coli BLR(DE3) containing pET28a-DC-SIGN-CRD and was incubated at 37°C 
overnight.17,18 This overnight culture was used to inoculate 1 L of 2xYT medium supplemented with 
kanamycin (50 mg/L). The culture was grown at 37°C and protein expression was induced during 
logarithmic growth (OD600 = 0.4–0.6) by addition of IPTG (Sigma-Aldrich) up to 0.5 mM. After 2.5 h of 
expression, the cells were harvested by centrifugation (4000 g at 4°C for 15 min) and the pellet was stored 
at –20 °C overnight.  
After thawing, the cell pellet was washed in 50 mL wash buffer (10 mM Tris·HCl, pH 7.8), centrifuged (4000 
g at 4°C for 15 min) and resuspended in 10 mL wash buffer. Subsequently, the cells were lysed by 
ultrasonic disruption (5 times 30 s, 100% duty cycle and output control 3, Branson Sonifier 250, Marius 
Instruments Nieuwegein, the Netherlands). The lysate was centrifuged (12000 g at 4°C for 15 min) to 
obtain the inclusion bodies. The pellet was solubilized in 10 mL of 6 M Guanidine·HCl, 10 mM Tris·HCl, 
0.01% β-mercaptoethanol, pH 7.0 by sonication (2 times 30 s, 100% duty cycle and output control 3) and 
10 min incubation at 4 °C. The mixture was centrifuged (15000 g at 4°C for 15 min) to remove the cellular 
debris. Then the supernatant was diluted 5-fold with loading buffer (1.25M NaCl, 25 mM CaCl2, 25 mM 
Tris·HCl, pH 7.8) by slow addition (2 h) at 4°C, while stirring. This diluted mixture was dialyzed against 10 
volumes of loading buffer at 4°C with 3 buffer changes over 3 days using a dialysis membrane 
(Spectra/Por 4 dialysis tubing, 12–14 kDa MWCO, 25 mm flat width). After dialysis the insoluble precipitate 
was removed by centrifugation (15000 g at 4°C for 15 min). 
 
Then the protein solution was loaded batch wise onto a Mannose-Sepharose column to purify the 
correctly folded DC-SIGN CRD.17,18 The flow-through was collected and the column was washed 4 times 
with 0.5 mL wash buffer. Eventually the protein was eluted with elution buffer (1.25M NaCl, 25 mM EDTA, 
25 mM Tris·HCl, pH 7.8). The protein was stored at 4°C. 
 
The refolded protein was produced with a yield of ± 2 mg/L of culture and the purity was verified by SDS-
PAGE. ESI-TOF: calculated 17794.7 Da, found 17793.0 Da.  
Amino Acid Sequence of DC-SIGN CRD: 
AERLCHPCPWEWTFFQGNCYFMSNSQRNWHDSITACKEVGAQLVVIKSAEEQNFLQLQSSRSNRFTWMGLSDLNQE
GTWQWVDGSPLLPSFKQYWNRGEPNNVGEEDCAEFSGNGWNDDKCNLAKFWICKKSAASCSRDEEQFLSPAPATPN
PPPA 
6.5.3 N-Terminal Modification of CRD DC-SIGN 
pH-controlled introduction of azide functionality 
Stock solutions of diazotransfer reagent 1 (3.6 mM), Na2CO3 (1 mg/mL) in MQ were prepared. Final 
reaction volume 30 µL (30 µM): 15 µL 60 µM CRD (dialyzed against MQ), 10 µL buffer and 5 µL 3.6 mM 
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reagent 1 (20 equiv., in buffer of MQ stock). Buffer: 100 mM DEA buffer for pH 8–9.6 and 10 mM Na2CO3 
buffer for pH > 9.6.  
 
pH-controlled introduction of BCN functionality 
At rt a solution of 600 µg CRD (dialyzed against phosphate buffer) in 27 µL phosphate buffer (pH 7.6) was 
prepared and BCN-PEG8-NHS (2) (73 µg, 3 equiv.) was added, after which the reaction was allowed to 
shake for 150 min. The mixture was analyzed with mass spectrometry.  
6.5.4 Synthesis Dendrimers 
General 
Reactions were followed and RF values were obtained using thin layer chromatography (TLC) on silica gel-
coated plates (Merck 60 F254) with the indicated solvent mixture. Detection was performed with UV-light, 
and/or by charring at ~150 °C after dipping into a solution of either ninhydrin or Cl-TDM (4,4’-
tetramethyldiamino-diphenylmethane). Melting points were analyzed with a Büchi melting point B-545. IR 
spectra were recorded on an ATI Mattson Genesis Series FTIR spectrometer, or a Bruker Tensor 27 FTIR 
spectrometer. NMR spectra were recorded on a Bruker DMX 300 (300 MHz), and a Varian 400 (400 MHz) 
spectrometer in CDCl3 solutions (unless otherwise reported). Chemical shifts are given in ppm with 
respect to tetramethylsilane (TMS) as internal standard. Coupling constants are reported as J-values in Hz. 
Peak assignment in 13C spectra was based on 2D-GHSQC and GHMBC spectra. Column or flash 
chromatography was carried out using Acros silica gel (0.035–0.070 mm, and ca. 6 nm pore diameter). 
Optical rotations were determined with a Perkin Elmer 241 polarimeter. High-resolution mass spectra were 
recorded on a JEOL AccuTOF (ESI). 
Azide-tetraethyleneglycol-tosylate (10) 
To a cold solution (0 °C) of tetra ethylene glycol (10.0 g, 52 mmol) in 110 mL DCM was added p-TsCl (20.0 
g, 104 mmol) and KOH (12.0 g, 208 mmol). The reaction was stirred at 0 °C for 4 h. The reaction was 
quenched by adding H2O, the organic layer was separated, dried over MgSO4, filtrated and concentrated in 
vacuo. The crude product was redissolved in 450 mL DMF and NaN3 (2.7 g, 42 mmol) was added. The 
reaction was stirred at rt for 22 h. H2O and EtOAc were added and the organic layer was separated, dried 
over Na2SO4, filtrated and concentrated in vacuo. Column chromatography (Hept to EtOAc/Hept 45:55) 
afforded the product (7.8 g, 21 mmol, 40%) as colourless oil. RF = 0.6 (EtOAc/Hept, 7:3). 1H NMR (500 MHz, 
CDCl3) δ 7.80 (d, 2H, CH, J = 8.05 Hz), 7.34 (d, 2H, CH, J = 8.05 Hz), 4.16 (t, 2H, CH2, J = 4.8 Hz), 3.71–3.62 
(m, 8H, CH2O), 3.60 (s, 4H, CH2O), 3.38 (t, 2H, CH2N3, J = 5.0 Hz), 2.45 (s, 3H, CH3) ppm. 13C NMR (125 MHz, 
CDCl3) δ 144.82, 133.03, 129.83, 127.99, 70.77, 70.68, 70.61, 70.05, 69.25, 68.69, 50.69, 21.65 ppm. HRMS 
(ESI) calcd. for C15H23N3O6SNa (M+Na)+ 396.12053, found 396.12117. 
Trimethyl-1,3-dioxane-methylalcohol (9) 
To a solution of 1,1,1-tris(hydroxymethyl)ethane (10.0 g, 83 mmol) in 100 mL acetone was added p-TSA 
(200 mg, 11 mmol). The resulting mixture was stirred at rt for 16 h. The reaction was quenched using Et3N, 
concentrated in vacuo and silica gel purification (Hept to EtOAc/Hept 1:1) of the residue afforded the 
product (9.5 g, 71%) as colourless oil. RF = 0.3 (EtOAc/Hept, 1:1). 1H NMR (500 MHz, CDCl3) δ 3.69 (m, 4H, 
CH2OH, CH2O), 3.61 (d, 2H, CH2O, J = 11.95 Hz), 1.44 (s, 3H, CCH3), 1.39 (s, 3H, CCH3), 0.83 (s, 3H, CCH3) 
ppm. 13C NMR (125 MHz, CDCl3) δ 97.96, 66.35, 66.01, 34.74, 27.32, 20.12, 17.58 ppm. 
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Azide-tetraethyleneglycol-diol (12) 
To a cold solution (0 °C) of compound 9 (4.0 g, 11 mmol) in 110 mL DMF was added NaH (950 mg, 24 
mmol). After 5 minutes of stirring, compound 10 (3.5 g, 22 mmol) was added. The reaction was stirred at rt 
for 24 h. H2O and EtOAc were added and the organic layer was separated, dried over Na2SO4, filtrated and 
concentrated in vacuo. The crude product was redissolved in 55 mL MeOH and p-TSA (0.64 g, 3.4 mmol) 
was added. The mixture was stirred at rt for 36 h. The reaction was quenched by adding Et3N and the 
mixture was concentrated in vacuo. Column chromatography (DCM to MeOH/DCM 1:9) afforded the 
product (2.1 g, 61%) as yellow oil. RF = 0.4 (MeOH/DCM, 1:9). 1H NMR (500 MHz, CDCl3) δ 3.72–3.58 (m, 
18H, CH2O, CH2OH), 3.53 (s, 2H, CCH2O), 3.40 (t, 2H, N3CH2, J = 4.8 Hz), 2.92 (t, 2H, CH2OH, J = 18.4 Hz), 0.79 
(s, 3H, CH3) ppm. 13C NMR (125 MHz, CDCl3) δ 75.94 (CH2), 70.68 (CH2), 70.65 (CH2), 70.62 (CH2), 70.58 
(CH2), 70.53 (CH2), 70.32 (CH2), 70.02 (CH2), 68.22 (2x CH2OH), 50.69 (N3CH2), 40.85 (C), 17.31 (CH3) ppm. 
HRMS (ESI) calcd. for C13H27N3O6Na (M+Na)+ 344.17975, found 344.17939. 
Dipropargyl-tetraethyleneglycol-azide (13) 
To a cold solution (0 °C) of compound 12 (2.0 g, 6.2 mmol) in 62 mL DMF was added NaH (1.0 g, 25 
mmol). After 5 minutes of stirring propargyl bromide (5.6 g, 37 mmol) was added. The reaction was stirred 
at rt for 17 hrs. H2O and EtOAc were added and the organic layer was separated, dried over Na2SO4, 
filtrated and concentrated in vacuo. Column chromatography (Hept to EtOAc/Hept 1:1) afforded the 
product (1.9 g, 76%) as dark brown oil. (NB = Keep product in solution to prevent polymerization) RF = 
0.65 (EtOAc/Hept, 3:2); 1H NMR (500 MHz, CDCl3) δ 4.12 (d, 2H, CH2CCH, J = 2.4 Hz), 3.72–3.65 (m, 10H, 
CH2O), 3.63 (q, 2H, CCH2O, J = 4.95 Hz), 3.58 (q, 2H, CCH2O, J = 4.6 Hz), 3.39 (m, 6 H, N3CH2, CH2O, J = 4.25 
Hz), 3.33 (s, 2H, CH2), 2.41 (t, 2H, CCH, J = 2.4 Hz), 0.96 (s, 3H, CH3) ppm. 13C NMR (125 MHz, CDCl3) δ 80.16 
(2x C), 74.01 (CH2), 73.66 (CH2), 72.82 (2x CH2), 71.09 (CH2), 70.78 (CH2), 70.73 (CH2), 70.66 (2x CH2), 70.44 
(CH2), 70.04 (CH2), 58.66 (2x CH2), 40.57 (C), 17.36 (CH3) ppm. HRMS (ESI) calcd. for C19H31N3O6Na (M+Na)+ 
420.21105, found 420.21177.  
Dipropargyl-tetraethyleneglycol-NHBoc (6) 
To a solution of compound 13 (1.8 g, 4.5 mmol) in a mixture of 41 mL THF and 4.1 mL H2O was added PPh3 
(1.8 g, 6.8 mmol). The reaction was stirred at rt for 20 h and then concentrated in vacuo. Crude product 
was redissolved in 45 mL DCM, cooled (0 °C) and Boc2O (990 mg, 4.5 mmol) was added. The reaction was 
stirred at 0 °C for 3 h. H2O was added and the organic layer was separated, dried over Na2SO4, filtrated and 
concentrated in vacuo. Column chromatography (Hept to EtOAc/Hept 2:3) afforded the product (1.7 g, 
78%) as orange oil. RF = 0.3 (EtOAc/Hept 3:2). 1H NMR (500 MHz, CDCl3) δ 4.12 (m, 4H, CH2CCH), 3.78–3.55 
(m, CH2O, 14H), 3.54 (t, 2H, CCH2O, J = 4.85 Hz), 3.39 (t, 2H, CCH2O, J = 1.5 Hz), 3.34–3.29 (m, 4H, CCH2O, 
C(=O)NHCH2), 2.43 (t, 2H, CH2CCH, J = 2.3 Hz), 1.44 (s, 9H, OCCH3), 1.01–0.79 (m, 3H, CH2CCH3) ppm. 13C 
NMR (125 MHz, CDCl3) δ 156.11, 80.11, 74.10, 73.63, 72.74, 71.03, 70.59, 70.57, 70.50, 70.45, 70.37, 70.23, 
58.61, 40.52, 40.33, 28.41, 17.34 ppm. HRMS (ESI) calcd. for C24H41NO8Na (M+Na)+ 494.27299, found 
494.27305. 
  
Chapter 6 Towards Detection of Ara h 1 with a Multivalent DC-SIGN Construct 
 
99 
Azide-tetraethyleneglycol-dimesylate (7) 
To a cold solution (0 °C) of compound 12 (510 mg, 1.6 mmol) in 16 mL DCM was added Et3N (640 mg, 6.3 
mmol) and MsCl (540 mg, 4.8 mmol). The reaction was stirred at 0 °C for 15 min. The mixture was washed 
with 1M HCl, H2O, saturated NaHCO3 and brine. The organic layer was dried over Na2SO4, filtrated and 
concentrated in vacuo. Column chromatography (0–100%, EtOAc/Hept) afforded the product (650 mg, 
87%) as yellow oil. RF = 0.4 (100% EtOAc). 1H NMR (500 MHz, CDCl3) δ 4.13 (s, 4H, CH3CCH2), 3.69–3.60 (m, 
14H, OCH2), 3.41–3.38 (m, 4H, CH3CH2, CH2N3), 3.05 (s, 6H, SCH3), 1.09 (s, 3H, CH2CCH3) ppm. 13C NMR (125 
MHz, CDCl3) δ 71.83, 70.98, 70.85, 70.62, 70.54, 70.52, 70.29, 69.94, 50.62, 39.92, 36.97, 16.55 ppm. HRMS 
(ESI) calcd. for C15H31N3O10S2Na (M+Na)+ 500.13643, found 500.13485. 
BocHN-ditriazole-tetramesylate (5) 
To a solution of compound 7 (550 mg, 1.2 mmol) and compound 6 (220 mg, 460 µmol) in 4.6 mL THF was 
added TBTA (49 mg, 93 µmol), DiPEA (360 mg, 2.8 mmol) and CuI (8.8 mg, 46 µmol). The reaction was 
stirred at rt for 17 h. The mixture was diluted with MeOH and DCM, filtered over Celite and concentrated in 
vacuo. Column chromatography (DCM to MeOH/DCM 1:15) afforded the product (650 mg, 460 µmol, 
98%) as yellow oil. RF = 0.7 (MeOH/DCM, 1:9) 1H NMR (500 MHz, CDCl3) δ 7.70 (s, 2H, NCCHN), 4.57 (s, 4H, 
OCH2CCHN), 4.54 (t, 4H, CCHNCH2CH2O, J = 5.1 Hz), 4.14 (s, 8H, CH3CCH2), 3.88 (t, 4H, CCHNCH2CH2O, J = 
5.1 Hz), 3.71–3.51 (m, 38H, CH2O), 3.38 (s, 8H, CH2O(S=O)2CH3), 3.32–3.27 (m, 4H, C(=O)NHCH2, CH3CCH2), 
3.05 (s, 12H, O(S=O)2CH3), 1.44 (s, 9H, OCCH3), 1.09 (s, 6H, SOCH2CCH3), 0.92 (s, 3H, OCH2CCH3) ppm. 13C 
NMR (125 MHz, CDCl3) δ 156.01, 145.26, 123.50, 79.06, 73.86, 73.07, 71.88, 71.00, 70.97, 70.81, 70.53, 70.52, 
70.49, 70.43, 70.31, 70.19, 69.45, 64.96, 50.09, 40.84, 40.32, 39.97, 37.05, 28.42, 17.45, 16.58 ppm. HRMS 
(ESI) calcd. for C54H103N7O28S4Na (M+Na)+ 1448.56315, found 1448.56272. 
BocHN-ditriazole-tetra-azide (14) 
To a solution of compound 5 (650 mg, 460 µmol) in 4.6 mL DMF was added NaN3 (890 mg, 14 mmol). The 
reaction was stirred at 100 °C for 80 h. EtOAc and H2O were added and the organic layer was separated, 
dried over Na2SO4, filtrated and concentrated in vacuo. Column chromatography (DCM to MeOH/DCM 
1:19) afforded the product (430 mg, 78%) as yellow oil. RF = 0.4 (MeOH/DCM, 1:9). 1H NMR (500 MHz, 
CDCl3) δ 7.72 (s, 2H, NCCHN), 4.58 (s, 4H, OCH2CCHN), 4.54 (t, 4H, CCHNCH2CH2O, J = 5.1 Hz), 3.88 (t, 4H, 
CCHNCH2CH2O, J = 5.1 Hz), 3.67–3.51 (m, 38H, CH2O, CH3CCH2), 3.37 (s, 4H, CH2CCH2N3), 3.33–3.23 (m, 
16H, C(=O)NHCH2, CH3CCH2N3, CH3CCH2), 1.44 (s, 9H, OCCH3), 0.95 (s, 6H, N3CH2CCH3), 0.92 (s, 3H, 
OCH2CCH3) ppm. 13C NMR (125 MHz, CDCl3) δ 155.98, 145.20, 123.49, 78.93, 73.75, 73.50, 72.94, 70.95, 
70.74, 70.50, 70.49, 70.44, 70.38, 70.26, 70.13, 69.41, 64.88, 55.61, 50.06, 41.00, 40.78, 40.28, 28.36, 18.37, 
17.38 ppm. HRMS (ESI) calcd. for C50H91N19O16Na (M+Na)+ 1236.67888, found 1236.67705. 
Biotin-ditriazole-tetra-azide (3) 
Compound 14 (60 mg, 49 µmol) was dissolved in a mixture of 1.6 mL DCM and 0.4 mL TFA. The reaction 
was stirred at rt for 2 h. Toluene was added and the mixture was concentrated in vacuo. The crude product 
was redissolved in 2 mL DMF, cooled (0 °C) and Et3N (15 mg, 0.15 mmol) and biotin-OSu ester (25 mg, 74 
µmol) were added. The reaction was stirred at 0 °C for 4 h. The mixture was concentrated in vacuo. Column 
chromatography (Hept to EtOAc/Hept 7:3) afforded the product (46 mg, 34 µmol, 69%) as yellow oil. RF = 
0.35 (MeOH/DCM, 1:9). 1H NMR (500 MHz, CDCl3) δ 7.70 (s, 2H, NCCHN), 4.58 (s, 4H, OCH2CCHN), 4.54 (t, 
4H, CCHNCH2CH2O, J = 5.1 Hz), 4.50 (dd, 1H, CHCH2S, J = 5.3 Hz, 7.3 Hz), 4.31 (dd, 1H, CHCHS, J = 4.8 Hz, 
7.3 Hz), 3.88 (t, 4H, CCHNCH2CH2O, J = 5.1 Hz), 3.67–3.51 (m, 38H, CH2O), 3.38 (s, 4H, CH2CCH2N3), 3.33–
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3.23 (m, 14H, CH3CCH2N3, CH3CCH2), 3.17–3.11 (m, 3H, C(=O)NHCH2, NHCHCHS), 2.89 (dd, 1H, NHCHCH2S, 
J = 4.8 Hz, 12.8 Hz), 2.74 (d, 1H, NHCHCH2S, J = 12.8 Hz), 2.22 (t, 2H, NHC(=O)CH2, J = 7.4 Hz), 1.79 (m, 4H, 
NHC(=O)CH2CH2CH2, NHCHCHCH2), 1.43 (m, 2H, NHC(=O)CH2CH2CH2), 0.95 (s, 6H, N3CH2CCH3), 0.92 (s, 3H, 
OCH2CCH3) ppm. 13C NMR (125 MHz, CDCl3) δ 173.36, 163.82, 145.28, 123.55, 73.85, 73.58, 73.07, 71.05, 
70.82, 70.60, 70.58, 70.53, 70.47, 70.35, 70.32, 70.07, 69.96, 69.49, 64.96, 61.75, 60.17, 55.70, 55.53, 50.15, 
45.61, 41.08, 40.86, 40.51, 35.84 28.16, 28.08, 25.56, 18.45, 17.45 ppm. HRMS (ESI) calcd. for C55H97N21O16S 
(M+H)+ 1340.72211, found 1340.72452. 
 
  
Chapter 6 Towards Detection of Ara h 1 with a Multivalent DC-SIGN Construct 
 
101 
6.6 References  
 
1. Burks, A. W. Lancet 2008, 371, 1538–1546. 
2. Smith, G. P.; Petrenko, V. A. Chem. Rev. 1997, 97, 391–410. 
3. Derbyshire, E.; Wright, D. J.; Boulter, D. Phytochemistry 1976, 15, 3–24. 
4. Kolarich, D.; Altmann, F. Anal. Biochem. 2000, 285, 64–75. 
5. Dunwell, J. M. Biotechnol. Genet. Eng. 1998, 15, 1–32. 
6. Barre, A.; Borges, J. P.; Rouge, P. Biochimie 2005, 87, 499–506. 
7. Chruszcz, M.; Maleki, S. J.; Majorek, K. A.; Demas, M.; Bublin, M.; Solberg, R.; Hurlburt, B. K.; Ruan, S.; 
Mattison, C. P.; Breiteneder, H.; Minor, W. J. Biol. Chem. 2011, 286, 39318–39327. 
8. Shin, D. S.; Compadre, C. M.; Maleki, S. J.; Kopper, R. A.; Sampson, H.; Huang, S. K.; Burks, A. W.; 
Bannon, G. A. J. Biol. Chem. 1998, 273, 13753–13759. 
9. Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. Molecular Biology of the Cell; 4th ed.; 
Garland Science: New York, 2002. 
10. Figdor, C. G.; van Kooyk, Y.; Adema, G. J. Nat. Rev. Immunol. 2002, 2, 377–377. 
11. Svajger, U.; Anderluh, M.; Jeras, M.; Obermajer, N. Cell. Signal. 2010, 22, 1397–1405. 
12. Geijtenbeek, T. B. H.; Engering, A.; van Kooyk, Y. J. Leukocyte Biol. 2002, 71, 921–931. 
13. Curtis, B. M.; Scharnowske, S.; Watson, A. J. Proc. Natl. Acad. Sci. USA 1992, 89, 8356–8360. 
14. Wu, L.; KewalRamani, V. N. Nat. Rev. Immunol. 2006, 6, 859–868. 
15. Shreffler, W. G.; Castro, R. R.; Kucuk, Z. Y.; Charlop-Powers, Z.; Grishina, G.; Yoo, S.; Burks, A. W.; 
Sampson, H. A. J. Immunol. 2006, 177, 3677–3685. 
16. Geijtenbeek, T. B.; Torensma, R.; van Vliet, S. J.; van Duijnhoven, G. C.; Adema, G. J.; van Kooyk, Y.; 
Figdor, C. G. Cell 2000, 100, 575–585. 
17. Mitchell, D. A.; Fadden, A. J.; Drickamer, K. J. Biol. Chem. 2001, 276, 28939–28945. 
18. Feinberg, H.; Guo, Y.; Mitchell, D. A.; Drickamer, K.; Weis, W. I. J. Biol. Chem. 2005, 280, 1327–1335. 
19. Becer, C. R.; Gibson, M. I.; Geng, J.; Ilyas, R.; Wallis, R.; Mitchell, D. A.; Haddleton, D. M. J. Am. Chem. 
Soc. 2010, 132, 15130–15132. 
20. Snyder, G. A.; Ford, J.; Torabi-Parizi, P.; Arthos, J. A.; Schuck, P.; Colonna, M.; Sun, P. D. J. Virol. 2005, 
79, 4589–4598. 
21. Dommerholt, J.; Schmidt, S.; Temming, R.; Hendriks, L. J.; Rutjes, F. P. J. T.; van Hest, J. C. M.; Lefeber, 
D. J.; Friedl, P.; van Delft, F. L. Angew. Chem. Int. Ed. 2010, 49, 9422–9425. 
22. Schoffelen, S.; van Eldijk, M. B.; Rooijakkers, B.; Raijmakers, R.; Heck, A. J. R.; van Hest, J. C. M. Chem. 
Sci. 2011, 2, 701–705. 
23. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem. Int. Ed. 2002, 41, 2596. 
24. Tornoe, C. W.; Christensen, C.; Meldal, M. J. Org. Chem. 2002, 67, 3057–3064. 
 
 
 
  102 
 
Chapter 7 
Conclusions and Perspectives 
 
 
 
 
 
 
 
 
  
Chapter 7 Conclusions and Perspectives 
 
104 
7.1 Unihealth Project 
The Unihealth project was started in 2009 with the aim to develop a specific and sensitive biosensor for 
the detection of food allergens. Besides the technological aims, other prerequisites that were set, dictated 
that such a device should be cheap and easy to use, so it would be suitable for household use by 
individuals suffering from a specific food allergy. 
The Unihealth project is a program financed by the European Union and provinces of the Netherlands and 
Germany (Interreg IV). The area of biosensors lies at the interface of physical, biological and chemical 
sciences and furthermore, technology development. Bridging the knowledge and know-how together will 
enable the development of new point-of-care (POC) biosensor devices. The IMS Fraunhofer Institute in 
Duisburg has been responsible for the technical development of the POC device. At Wageningen 
University methodologies for surface modification of a silicon nitride surface have been developed.1 A 
general protocol for surface modification of an SPR biosensor surface and the development of ligands for 
the detection of exotic fruit allergens and peanut allergens were the subjects of this thesis.  
Four years of research will be highlighted in a short summary below, and insights and possibilities are 
discussed for future prospects and directions.  
7.2 General Conclusions  
To be able to develop a biosensor system for food allergen detection, various issues must be taken into 
account. To start with a plate of food or a glass of juice and to process that into a qualitative and/or 
quantitative outcome of the presence of a particular food allergen is a complex process.  
The focus of this thesis has been on two aspects of biosensor development. First of all ligand 
immobilization onto the biosensor surface was investigated with a model system for the protease papain, 
based on known ligands. Secondly, known and new ligands for peanut allergen detection were 
extensively evaluated.  
With respect to ligand immobilization, a range of techniques are known for such purpose, with associated 
advantages and disadvantages. For the Unihealth biosensor, it was chosen to work with a newly 
developed technology, so-called strain-promoted azide–alkyne cycloaddition (SPAAC) chemistry, to 
immobilize ligands on the sensor surface. It was foreseen that by application of SPAAC technology, a 
modular surface could be produced in large numbers with low production costs. The power of such an 
approach would lie in a convenient modification of the modular surface by a straightforward ‘click’ 
method with a particular food allergen ligand. In this strategy, the sensor surface was functionalized first 
with a strained alkyne and as a consequence, an azide (or other dipole) had to be incorporated in the 
ligand. To further develop the chosen approach, first a model system was developed for the detection of 
papain, an enzyme present in papaya fruits. Based on known papain inhibitors, an azide handle was 
incorporated at various places in a range of ligands and the effect of azide incorporation on binding 
affinity was investigated. The results of the enzyme affinity assay revealed that incorporation of the azide, 
despite its small size, could dramatically influence binding affinity. Therefore, it is essential to make a 
rational and biased decision where to include an immobilization handle on a ligand. After the selection of 
an azide-containing ligand for papain, immobilization was explored by means of surface plasmon 
resonance (SPR) as a model system. SPR is a broadly applied biosensor technique for analytical detection 
of biomolecules and was therefore considered to be an ideal system for evaluation of the designed and 
synthesized ligands, before testing them on a new biosensor read-out system. With SPR experiments, 
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immobilization of the ligands onto the surface was thoroughly studied. Not only the formation of an 
optimally packed strained alkyne surface was investigated, also SPAAC on the surface was optimized. 
Eventually, a highly stable ligand-immobilized surface was developed that could be reused for up to 150 
measurements without affecting the assay outcome.  
Furthermore, a reliable biosensor should not give false-positive or false-negative results. It is therefore 
essential to select suitable ligands that are specific for a particular target protein (the food allergen). 
Unfortunately, for our papain model system it proved to be difficult to find a selective ligand, for two 
reasons: (a) the binding site of papain is an open cleft and (b) the active sites of different proteases 
display great amino acid sequence homology.  
Peanut allergy is one of the most severe allergies a patient can develop which can sometimes even lead to 
death. For this reason, it was decided to focus the second part of the thesis particularly on the 
development of selective ligands for peanut allergens. Two different approaches were followed in this 
research. First of all, phage display was used to identify 15-mer peptides as novel lead ligands for 
detection of four different peanut allergens. Several selection rounds appeared to be successful, however, 
full evaluation of the resulting sequences has not been completed yet, so no firm conclusions can be 
drawn at this stage. 
Secondly, Ara h 1, one of the most important peanut allergens, is an N-glycosylated protein. To find a 
natural binding partner for Ara h 1, the N-glycan moiety was utilized. It is known that lectins can 
specifically bind to glycosylated proteins, and more specifically, DC-SIGN (C-type lectin) is known to bind 
to Ara h 1. This protein shows optimal binding as a non-covalent tetramer complex. In order to prevent 
disassembly issues during immobilization and usage of DC-SIGN in a biosensor set-up, it was decided to 
synthesize and investigate a covalently linked tetrameric derivative of DC-SIGN.  To this end a chemically 
constructed dendrimer was developed to which four carbohydrate recognition domains (CRDs) were 
coupled. Expression and selective modification of CRDs was successfully executed, however, 
mulitmerization on a dendritic scaffold proved to be challenging and has not been achieved at this stage.   
7.3 Present and Future Challenges 
Food contains multiple and processed ingredients, shipped from all over the world. Furthermore, food 
products often share storage space and the same production lines are used for different food samples. 
Ensuring food safety and quality, food analysis has never been more complicated than today.2,3 In spite of 
the large number of analytical developments and applications seen in food analysis, there are still many 
issues that need to be improved.  
Food analysis starts with appropriate sample preparation and the method of choice for sample 
preparation is dependent on the analytical method used. Although an in-depth discussion of food 
processing is outside the scope of the thesis, it is clear that sample preparation is complicated, often time-
consuming and additionally, requires expensive equipment and/or trained technicians. Another 
complicating factor is that without proper and reliable sample preparation, false-positive and/or false-
negative outcomes are likely to occur.  
Although food processing and food matrices themselves do not influence allergenicity, they may 
significantly impair allergen detection. Therefore, this will always remain a challenge in allergen detection 
and only when all food allergens are investigated in different food matrices and treated with different 
processing conditions, one can be sure that false-positive and false-negative results will be discarded. 
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Obviously, such extensive allergen analysis will be laborious, time-consuming, expensive and 
consequently not realistic.  
Challenges remain also in the field of analysis. Currently available analytical methods often require highly 
trained people and/or are expensive.4 Separation techniques in combination with mass spectrometry, for 
example GC-MS and LC-MS, are methods that require complicated sample preparation and trained 
employees, and are therefore restricted as suitable methods to industrial/professional use. For household 
use, some tests are already on the market, almost exclusively based on ELISA, but these tests are also often 
expensive.  
For the future, to establish point-of-care analytical methods, much effort should be directed to 
miniaturization of instruments with fast response and minimal sample preparation. The design of the 
Unihealth biosensor is also based on miniaturization of an analytical technique, which is in this case a 
surface acoustic wave (SAW) sensor.5 Binding of an analyte to the surface ligands will lead to an increase in 
mass on the surface and consequently, the wave velocity will decrease. The drop in wave velocity can be 
measured by a read out device.  
In order to provide an efficient interface with the food sample, the biosensor will be integrated in a 
microfluidic capillary device (Figure 7.1). A droplet of the food sample can be put into the inlet of the 
capillary device, which will result in a flow of the sample over the biosensor. A detection device can then 
be coupled for the read-out of the test. At this moment the sensor device is still under construction. The 
design and evaluation of the capillary pumps have been performed within the Unihealth group. 
Furthermore, preliminary experiments with the acoustic wave sensor have been executed as well.  
 
 
Figure 7.1 Schematic representation of the surface acoustic wave sensor integration in the microfluidic capillary device. 
An interesting recent development which could facilitate the usage of point of care tests is the advent of 
the smart phones.6,7 These portable handheld devices are ideal as read-out stations, which will make the 
available food allergen detection tests more feasible for household use, since no additional expensive 
read-out devices are needed anymore.  
 
For real-time, label-free and in situ measurements in the liquid phase, SAW sensors are still in the shadow 
of other optical methods and specific SPR technology.5 One of the reasons is that SPR sensors are 
commercialized during the last 15 years, whereas this is not the case for SAW sensors. Furthermore, SAW 
sensors have to compete with the attention of the scientific community, which are now more focused on 
SPR sensors. For the future it is still of interest to further develop SAW sensors. Although the advantages of 
SAW sensors over alternative optical sensors have not yet been sufficiently displayed, SAW biosensors can 
have advantages over currently used sensors in the field of surface modification. Whereas the SPR sensor 
surface is limited to the use of gold as ground layer, SAW sensors can also use other metals, SiO2 or 
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polymers. Lastly, SAW sensors cannot only detect mass difference, but also e.g. pressure and temperature 
can be measured. Still, a lot of research needs to be performed, before the SAW sensor can be used in the 
field of food allergen detection. This can lead to a sensor with new features and advantages over currently 
available sensor systems with respect to read out devices, surfaces and costs.  
 
Although the future of SAW sensors is not known, this is not the case for point-of-care food detection 
devices. Food allergies are a major health risk and the medical costs to treat patients are high. Therefore, 
preventing food-based allergic reactions is not only import for patients, but also of social interest. The 
development of medical biosensors and point-of-care systems are currently of high interest and this will 
lead to more miniaturized, reliable, cheap and easy-to-use systems. In the end this will prevent 
unnecessary food-allergic responses and it will improve the quality of life for patients.  
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8.1 Summary 
In order to sustain life, consumption of food is essential. Fortunately, for most human individuals eating is 
not only a functional, but also an enjoyable event. However, for people suffering from food allergies, 
eating can be a risky activity, since intake of the “wrong” food can have severe consequences. Due to the 
lack of preventive pharmaceuticals against allergies, patients suffering from food allergies need to avoid 
intake of offending food in order to prevent an allergic response. Consequently, there is a strong need for 
biosensors to detect allergens in food before intake. Current biosensors, however, are prone to give 
erroneous results and are therefore not suitable for reliable food allergen detection. The development of 
new biosensors with high sensitivity and selectivity for a particular allergen is therefore of utmost 
importance.  
 
For the fast and sensitive detection of food allergens with a biosensor, appropriate ligands are required to 
‘trap’ the responsible allergens on a biosensor surface. These ligands should obviously be selective for the 
food allergen, and require a handle for immobilization onto a surface. In Chapter 2, a small library of 
enzyme inhibitors was designed and synthesized, containing different azide linkers for follow-up 
immobilization by copper-free ‘click chemistry’. A model system to detect the interaction of the peptide 
ligands with a protein was developed based on papain, a protease from papaya. A small library of nitrile-
containing peptides for reaction with the active site cysteine of papaya was synthesized, and a 
competitive enzymatic assay was performed to quantify the inhibitory capacity of the ligands. The results 
obtained with the enzymatic assay, were rather inconsistent and therefore docking studies were 
performed in order to get detailed insight in the molecular interaction between the ligands and papain, as 
described in Chapter 3. The docking program Fleksy was used to provide insight at which position an 
azide moiety (or other immobilization handle) should be tolerated as a synthetic modification without 
affecting binding affinity. In addition, a new and potentially selective papain ligand was proposed, based 
on predicted binding interactions within the deep binding pocket of papain.  
 
To be able to test the library of ligands in an immobilized biosensor environment, surface plasmon 
resonance (SPR) was applied as a reference technique. Surface plasmon resonance is a powerful label-free 
diagnostic tool to study biomolecular interactions, but a drawback of conventional SPR is the lack of 
controlled immobilization of ligands on the sensor surface. Chapter 4 describes the development of a 
modular platform for the fast, reagent-free and site-specific immobilization of azide-containing ligands by 
strain-promoted cycloaddition onto a cyclooctyne-modified SPR sensor surface. The usefulness of the 
concept was shown in a study with a peptide-based papain binding model system, and up to 150 SPR 
experiments were performed without loss of surface quality. Furthermore, azide-containing green 
fluorescent protein (GFP) was also effectively immobilized. Taken together, cyclooctyne-modified SPR 
chips enable smooth and site-selective immobilization of ligands and proved to be more constant than 
traditionally functionalized systems.  
 
After the exploration of peptide ligands for the specific detection of the rather exotic allergen papain, the 
next step was to develop a system for the rather common peanut allergy, which is responsible for highly 
severe cases of food allergy with potentially dramatic consequences. For the development of a biosensor, 
Chapter 5 describes the exploration of phage display for the identification of new peptide binders for four 
peanut allergens, Ara h 1, 2, 3 and 6. Different panning rounds were performed and subsequently, cosmix-
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plexing® provided a new library for follow-up panning rounds. Analysis of the enriched sublibraries was 
performed with phage ELISA and fishing experiments. Unfortunately, no potential binders were identified 
so more research is needed to complete this project. At the moment, next-generation sequencing is 
performed to analyze the complete sublibraries formed after the selection rounds.  
 
Parallel to the screening approach centered around phage display, a fully rational approach for selective 
peanut allergen detection was pursued based on DC-SIGN, a protein well-known for its binding 
interaction with the glycans on the peanut glycoprotein Ara h 1 (Chapter 6). In this particular approach, it 
was reasoned that immobilization of DC-SIGN on a biosensor surface with retention of activity would 
require mimicking of the native binding interaction in its tetrameric structure. A strategy to immobilize a 
DC-SIGN structure with full control over stoichiometry and orientation was designed, based on the 
development of a tetravalent dendritic structure containing at one terminus a handle for surface 
modification and at the other four termini a moiety to attach the carbohydrate binding domains (CRDs) of 
DC-SIGN. Expression, isolation and biochemical functionalization of the CRD is described, as well as the 
chemical synthesis of the dendritic scaffold. Unfortunately, coupling of these two building blocks, the CRD 
and the dendritic scaffold, was not successful.  
 
Finally, Chapter 7 describes some future perspectives in the food allergen detection field. Insight is 
provided into the challenges of food allergen detection with respect to food sample preparation, ligand 
immobilization and development of a surface acoustic wave sensor.  
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8.2 Samenvatting 
Om in leven te blijven is eten essentieel en gelukkig is dit voor de meeste mensen ook een prettig 
moment van de dag. Voor patiënten die een voedselallergie hebben, is eten echter veel ingewikkelder en 
daardoor minder aangenaam. Het consumeren van producten die allergenen bevatten kan leiden tot zeer 
ernstige allergische reacties en in het uiterste geval zelfs tot de dood leiden.  
Medicijnen die momenteel op de markt zijn, kunnen alleen de symptomen van de allergische reactie 
behandelen, maar kunnen deze reacties niet voorkomen. De enige manier om de allergische reactie te 
voorkomen is dan ook om dat voedsel te vermijden waarin eventuele allergenen aanwezig zijn. 
Begrijpelijk is, dat dit de kwaliteit van leven voor patiënten ernstig benadeeld. Het onderzoek dat in dit 
proefschrift beschreven is, heeft tot doel om de kwaliteit van leven voor patiënten met een voedselallergie 
te verbeteren. Het doel is om een biosensor te ontwikkelen welke allergenen in voedsel aan kan tonen, om 
zo de patiënten te behouden van het eten van allergeen-bevattend voedsel.  
 
Als een model systeem voor onze te ontwikkelen biosensor werd gekozen voor het enzym papaïne. Dit 
enzym is aanwezig in papaja fruit en is een cysteïne protease. Om dit enzym te kunnen detecteren werden 
er liganden ontwikkeld die zo specifiek mogelijk binden aan papaïne. Daarnaast moesten deze liganden 
ook een functionele groep bevatten waarmee ze op het oppervlak vastgezet konden worden. Van nitrilen 
is bekend dat deze een voorkeur hebben voor cysteïne proteases boven serine proteases en deze 
functionele groep werd dan ook bij onze liganden ingebouwd. Als immobilisatie techniek werd gekozen 
voor de zogenaamde koper-vrije ‘klik’ chemie en daarvoor werd een azide groep bij het ligand 
ingebouwd. In Hoofdstuk 2 wordt de ontwikkeling en analyse beschreven van een kleine bibliotheek 
papaïne liganden. Deze liganden werden gesynthetiseerd en onderzocht met een in huis ontwikkelde 
enzymatische assay. Sinds niet alle resultaten van de enzymatische assay logisch verklaard konden 
worden, werd besloten om deze verder te analyseren met behulp van docking studies. Deze resultaten 
zijn beschreven in Hoofdstuk 3 en geven een duidelijke verklaring waarom sommige liganden niet goed 
binden met papaïne.  
 
Als referentiebiosensor werd oppervlakte plasmonen resonantie spectroscopie (SPR) gebruikt. De binding 
wordt op een andere manier gedetecteerd dan met de sensor die binnen het project ontwikkeld wordt, 
maar het principe van binding op een oppervlak is vergelijkbaar en daarom goed te gebruiken als 
referentie meettechniek. SPR is een belangrijke diagnostische tool om biologische interacties te 
bestuderen. Echter één van de nadelen van SPR is dat gecontroleerde immobilisatie van liganden op het 
biosensor oppervlak problematisch is. Hoofdstuk 4 beschrijft de ontwikkeling van een modulair platform 
voor snelle en plaats-specifieke immobilisatie van liganden, waarbij het gebruik van toegevoegde 
chemicaliën niet nodig is. Dit werd bereikt door gebruik te maken van koper-vrije ‘klik’ chemie, waarbij de 
liganden een azide bevatten en waarbij een cyclooctyne  SPR oppervlak ontwikkeld werd.  Dit nieuwe 
systeem werd uitvoerig getest met de ontwikkelde papaïne liganden en daarnaast werd er ook succesvol 
een compleet eiwit, GFP, geïmmobiliseerd. Het nieuwe immobilisatie platform lijkt stabieler, robuuster en 
eenvoudiger dan reeds bestaande technieken en is een toegevoegde waarde voor het immobiliseren van 
biomoleculen op een biosensor oppervlak.  
 
Het laatste deel van dit proefschrift bestaat uit de ontwikkelen van de biosensor gericht op het detecteren 
van pinda allergenen. Die vier belangrijkste pinda allergenen zijn Ara h 1, 2, 3 en 6. In Hoofdstuk 5 wordt 
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een techniek genaamd ‘phage display’ gebruikt om uit een hele grote bibliotheek peptiden te selecteren 
die de pinda allergenen kunnen herkennen. Binnen het tijdsbestek van dit proefschrift is het helaas niet 
gelukt om een potentiele goede binder voor de pinda allergenen te selecteren, maar het onderzoek wordt 
momenteel nog voortgezet door middel ‘next generation sequencing’.  
Parallel aan het phage display project werd er ook via een andere benadering gezocht naar goede 
liganden voor Ara h 1. DC-SIGN is een zeer bekend suiker-bindend eiwit, komt in de Natuur voor als 
tetrameer en is ook alleen volledig actief als tetrameer. Ara h 1 bevat een suiker-keten en kan daarom een 
interactie aangaan met DC-SIGN. In Hoofdstuk 6 wordt onder andere de expressie en isolatie van het 
extracellulaire domain van DC-SIGN beschreven. De gecontroleerde immobilisatie van dit tetrameer is 
echter gecompliceerd en er werd gezocht naar een andere benadering om een actief DC-SIGN complex op 
het oppervlak te immobiliseren. Er werd een strategie onderzocht waarbij een tetravalente dendritische 
structuur ontwikkeld werd met aan de ene kant een handvat voor immobilisatie op het oppervlak en aan 
de andere kant vier keer het bindingsdomain van DC-SIGN. De expressie, isolatie en biochemische 
functionalisatie van het bindingsdomain kan ook gevonden worden in dit hoofdstuk. Helaas was het 
uiteindelijk niet mogelijk om de dendritische structuur en de vier bindingsdomeinen aan elkaar te 
koppelen. Meer onderzoek is nog nodig om dit te realiseren.  
 
In Hoofdstuk 7 wordt nog even kort ingegaan op de problemen, uitdagingen en oplossingen voor 
voedselallergenen detectie. Er wordt gekeken vanuit voedsel sample bereiding, oppervlakte 
functionalisatie en de ontwikkeling van de oppervlakte akoestische golven sensor (bij Fraunhofer IMS 
Duisburg).  
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8.3 Lekensamenvatting 
Om in leven te blijven is eten essentieel en gelukkig is dit voor de meeste mensen ook een prettig 
moment van de dag. Voor patiënten die een voedselallergie hebben, is eten echter een stuk minder 
aangenaam. Het consumeren van voedingsproducten die allergenen bevatten kan leiden tot zeer ernstige 
allergische reacties en in het uiterste geval zelfs tot de dood. Allergenen zijn stoffen die er voor zorgen dat 
een patiënt een allergische reactie krijgt.  
 
Medicijnen die momenteel op de markt zijn, kunnen alleen de symptomen van de allergische reactie 
behandelen, maar kunnen deze reacties niet voorkomen. De enige manier om de allergische reactie te 
voorkomen is dan ook om dát voedsel te vermijden waarin eventuele allergenen aanwezig zijn. 
Begrijpelijk is, dat dit de kwaliteit van leven voor patiënten ernstig benadeeld. Bij elk stukje voedsel moet 
namelijk nagedacht worden of iets sporen van allergenen kan bevatten en hoewel dit vaak op een 
verpakking beschreven staat, gaat dit nog wel eens mis. Niet alleen zijn fabrikanten erg voorzichtig en 
staat er al snel dat een product niet veilig is om te eten voor een patiënt, maar soms staat er op de 
verpakking niets vermeld over eventueel aanwezige allergenen en krijgt een patiënt toch een allergische 
reactie.  
Het onderzoek dat in dit proefschrift beschreven is, heeft tot doel om de kwaliteit van leven voor 
patiënten met een voedselallergie te verbeteren. Het doel is om een apparaatje te ontwikkelen welke 
allergenen in voedsel aan kan tonen. Dit apparaat wordt ook wel een biosensor genoemd. De bedoeling is 
om een sample van een voedingsproduct op de sensor aan te brengen waarna de sensor dan aangeeft of 
het voor de patiënt veilig is om het voedsel te consumeren of niet (Figuur 8.1).  
 
 
Figuur 8.1 Overzicht principe voedsel allergenen detectie. 
Om een bepaalde allergeen te kunnen detecteren moet er een stofje zijn dat het allergeen kan herkennen 
en vervolgens vast kan zetten op de sensor. Hierna kan de sensor een signaal uitzenden dat het allergeen 
aanwezig is in het sample. De wetenschappelijke benaming voor dit stofje is ‘Ligand’. Het sample met de 
allergenen dat we willen onderzoeken noemen wij ‘Analyte’. In Figuur 8.2 is een schematische weergave 
van de biosensor. In donkerpaars is het apparaatje zelf waarbij in zwart het oppervlak (ook wel membraan 
genoemd) van de sensor is weergegeven. Dit oppervlak staat onder spanning en trilt daardoor met een 
bepaalde frequentie. Op het moment dat er iets bindt aan het oppervlak, dan neemt de massa van het 
oppervlak toe en daardoor gaat het oppervlak met een andere frequentie trillen. Dit verschil kan door de 
detector opgemerkt wordt en deze zal dan een signaal uitzenden dat het ‘Analyte’ aanwezig is en dat het 
voor de patiënt niet veilig is om dit voedsel te consumeren.  
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Figuur 8.2 Schematische weergave van de biosensor. In roze de zogenoemde ‘analyten’. De blauwe spijkers zijn de ‘Liganden’ 
die vastzitten aan het oppervlak van de sensor.  
 
De allergieën waar ik me binnen dit proefschrift mee bezig gehouden hebben zijn exotisch fruit allergie en 
de pinda allergie. De exotisch fruit allergie is vooral gekozen om te dienen als model systeem voor de 
ontwikkeling van ons biosensor. De pinda allergie werd gekozen, omdat deze allergie het leven van veel 
patiënten beïnvloedt en zeer ernstige gevolgen kan hebben, wanneer een patiënt per ongeluk toch een 
spoor van het pinda allergeen binnen krijgt. Voor de exotisch fruit allergenen hebben we een kleine 
bibliotheek met liganden gemaakt en deze uitvoerig getest. Zowel in het lab (Hoofdstuk 2) als met 
computer simulaties (Hoofdstuk 3) om zo goed uit te kunnen vinden hoe de binding tussen het ligand en 
het analyte plaatsvindt.  
Binnen het pinda onderzoek zijn we echter niet tot een succesvol resultaat gekomen. Er werden twee 
subprojecten uitgevoerd waarbij met verschillende benaderingen gezocht werd naar goede liganden voor 
de pinda allergenen. Het eerste subproject (Hoofdstuk 5) noemen wij het ‘Phage Display project’. Stel je 
een phage voor als een knikker. Aan deze knikker hangen wij een ligand. We maken dan een grote zak met 
heel veel knikkers die allemaal een ander ligand bevatten. Daarnaast hebben wij magneetjes waaraan we 
ons allergeen binden. Deze magneetjes stoppen we dan in de zak met knikkers en schudden deze even 
door elkaar. We houden nu een grote magneet naast de zak en keren de zak om. De magneetjes met 
allergenen blijven in de zak en ook de knikkers die via hun ligand aan het allergeen gebonden zijn. Alle 
knikkers die liganden bevatten die niet aan het allergeen binden, zullen uit de zak vallen. Vervolgens 
kunnen we de knikkers die in de zak achtergebleven zijn (en dus potentiële binders voor de allergenen 
zijn) analyseren. Op deze manier selecteren we uit een hele grote bibliotheek potentiële liganden voor de 
pinda allergenen. De selectierondes zijn allemaal uitgevoerd en er is een start gemaakt met de analyse van 
de potentiële binders. Echter was er niet voldoende tijd om dit project tot een goed einde te brengen.  
Een andere benadering (Hoofdstuk 6) maakte gebruik van een van de fysieke eigenschappen van de 
pinda allergeen. Het pinda allergeen bevat namelijk een zogenoemd suikerstaartje en in de natuur komt 
er een eiwit voor dat dol is op deze suikerstaartjes. Net als met menselijk haar (dik, dun, stijl, krullend) 
heeft elk staartje zijn eigen specifieke kenmerk, waardoor dit eiwit niet aan alle suikerstaartjes kan binden, 
want dat zou leiden tot te veel vals-positieve resultaten. We zijn bezig geweest om dit eiwit te maken en 
de binding tussen dit eiwit en het pinda allergeen te analyseren. Echter ook in dit project liepen we tegen 
problemen aan die het onderzoek vertraagde en we hebben dit project niet tot een succesvol einde 
kunnen brengen.  
 
Naast de ontwikkeling van liganden voor verschillende allergenen, hebben we ook gewerkt aan een 
nieuwe techniek waarmee we deze liganden (de blauwe spijkers uit Figuur 8.2) ook gecontroleerd op het 
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oppervlak hebben kunnen plaatsen (Hoofdstuk 4). Huidige technieken voldeden niet aan al onze eisen 
en het is ons gelukt om een techniek te ontwikkelen waarmee we heel precies moleculen op een 
oppervlak kunnen plaatsen in een door ons gekozen oriëntatie. Hierbij moet gedacht worden dat als je 
bijvoorbeeld een kapstok aan de muur hangt dat je deze ook daadwerkelijk wilt kunnen gebruiken. 
Daarvoor is het dan belangrijk dat de kapstok goed bevestigd wordt en dus niet los kan laten. Tevens 
moeten de haakjes beschikbaar zijn om de jassen aan op te kunnen hangen en moeten deze bijvoorbeeld 
niet onderste boven of richting de muur gepositioneerd zijn. In ons geval willen wij dat het gedeelte van 
het ligand dat belangrijk is in de binding met het allergeen ook daadwerkelijk beschikbaar is voor binding 
en dus naar boven gericht is. Dit project hebben we tot een succesvol einde weten te brengen en is dan 
ook gepubliceerd in een vaktechnisch blad.  
 
Hoofdstuk 7 sluit dit proefschrift af met een korte blik in de toekomst. Waar liggen nog de uitdagingen, 
wat moeten we nog onderzoeken om uit eindelijk tot deze biosensor te komen. Maar ook, wat hebben we 
in de afgelopen vier jaar bereikt.  
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Thank you, Bedankt, Vielen Dank 
“Dank u wel” 
 
Daar ben je dan 
Al die jaren onderzoek gebundeld 
Netjes onderverdeeld in 8 hoofdstukken 
Kort, krachtig en bondig  
 
Und jetzt? 
 
Who do I want to thank? 
Everybody I want to thank 
Life is lovely when you can say “Thank you” 
 
 
  
118 
Curriculum Vitae 
Angelique Elisabeth Maria Wammes werd geboren op 14 november 1984 in Utrecht. Na het doorlopen 
van de lagere school, begon zij in 1997 op het Koningin Wilhelmina College in Culemborg, waar zij in 2003 
haar VWO diploma behaalde. In september 2003 startte zij aan de universiteit Utrecht met haar bachelor 
scheikunde, welke in 2007 werd behaald. Tussendoor, in het studiejaar 2005-2006, was zij secretaris van 
de Utrechtse Studenten Scheikundevereniging Proton. De master Chemistry werd in 2009 behaald aan de 
Vrije Universiteit Amsterdam met als specialisatie “Molecular Design, Synthesis and Catalysis”. Tijdens haar 
master heeft ze haar major onderzoeksstage uitgevoerd in de groep van prof. Liskamp (Medicinal 
Chemistry and Chemical Biology, Universiteit Utrecht) en haar minorstage in de groep van prof. Orru 
(Synthetic and Bio-Organic Chemistry). In september 2009 begon zij als promovendus in de groepen van 
prof. Van Hest en prof. Rutjes aan de Radboud Universiteit Nijmegen wat geleid heeft tot het tot stand 
komen van dit proefschrift.  
Momenteel is zij werkzaam als postdoc bij het Fraunhofer IZI in Leipzig in de groep Nanotechnologie 
onder leiding van dr. Dirk Kuhlmeier waar zij onder andere werkt aan de ontwikkeling van een biosensor 
voor detectie van circulerende kankercellen in bloedsamples.  
 
Publications 
• Wammes, A. E. M., Fischer, M. J. E., de Mol, N. J., van Eldijk, M. B., Rutjes, F. P. J. T., van Hest, J. C. M. and 
van Delft, F. L., Site-specific ligand immobilization on biosensors via strain-promoted cycloaddition, Lab on 
a Chip 2013, 13, 1863-1867. 
• Wammes, A. E. M., D. Löwik, van Hest, J. C. M. and van Delft, F. L., Surface plasmon resonance for 
detecting allergens in food, Handbook of food allergen detection and control, Woodhead Publishing 
(manuscript submitted). 
• Wammes, A. E. M., Ritschel, T., Hendriks, T. G., Wijdeven, M., Teeuwen, D., de Vlieg, J., Rutjes, F. P. J. T., 
van Hest, J. C. M. and van Delft, F. L., Design, synthesis and evaluation of nitrile- and azide-based 
inhibitors for papain, (manuscript in preparation). 
• van Wandelen, L.T.M., van Ameijde, J., Mady, A., Wammes, A.E.M., Bode, A., Poot, A.J., Ruijtenbeek, R., 
Liskamp, R.M.J., Directed modulation of Protein Kinase C isozyme selectivity with bisubstrate-based 
inhibitors, ChemMedChem. 2012, 7(12), 2113-2121. 
• van Ameijde, J., Poot, A.J., van Wandelen, L.T.M., Wammes, A.E.M., Ruijtenbeek, R., Rijkers, D.T.S. and 
Liskamp, R.M.J., Preparation of novel alkylated arginine derivatives suitable for click-cycloaddition 
chemistry and their incorporation into pseudosubstrate- and bisubstrate-based kinase inhibitors, Org. 
Biomol. Chem. 2010, 8(7), 1629-1639. 
 
 
